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Abstract 
Rapidly growing cells are dependent on sufficient concentrations of nucleotides to sustain 
proliferation. One enzyme essential for the de novo synthesis of pyrimidine-based nucleotides is 
dihydroorotate dehydrogenase (DHODH); a known therapeutic target for many diseases. In 
cancer, inhibition of DHODH depletes intracellular pyrimidine nucleotide concentrations and 
halts the cell cycle at S-phase. This metabolic enzyme is necessary for rapidly growing cells and 
DHODH inhibition has been demonstrated to sensitize resistant cells to current chemotherapy 
options. Therefore, we pursued a drug discovery project towards developing novel inhibitors of 
DHODH.  
A phenotypic screen was utilized to identify hit compounds that may be suitable leads for 
a drug discovery project. From this, a lead compound was discovered to inhibit cell growth (MIA 
PaCa-2, BxPC-3) but through an unknown enzyme target. The essential pharmacophore of the 
lead compound was elucidated via structure activity relationship (SAR) studies and biologically 
found to be remarkably similar to brequinar, a potent DHODH inhibitor. Cells were rescued from 
both the lead compound and brequinar by the addition of uridine, a mimic of a downstream 
byproduct, and both inhibitors have submicromolar IC50 values toward DHODH. For continued 
optimization, we sought to improve affinity for the DHODH enzyme. 
 We pursued a structure-guided approach toward the development of improved DHODH 
inhibitors with the goal of forming new interactions between DHODH and the brequinar class of 
inhibitors. Two residues, T63 and Y356, suitable for novel H-bonding interactions were 
identified in the brequinar-binding pocket. Analogues were designed to maintain the essential 
pharmacophore and form new electrostatic interactions through strategically positioned H-bond 
accepting groups. This effort led to the discovery of two potent quinoline based analogues with 
an IC50 against DHODH of 10.6 ± 1.1 nM for one and 32.9 ± 4.6 nM for the other. A co-crystal 
structure between a quinoline analogue and DHODH depicts a novel water mediated H-bond 
interaction with T63. Additional optimization led to a third 1,7-naphthyridine analogue with an 
IC50 = 53.9 ± 1.7 nM, which forms a novel H-bond with Y356. In conclusion, the data from our 
	 xiii	
SAR investigation supports further preclinical studies of our improved compounds toward 
selection of a candidate for early stage clinical development. 
 Finally, to fully understand brequinar-based DHODH inhibition, we developed novel 
brequinar-based probes. We disclose a 16-step convergent synthesis of the first brequinar-
PROTAC and a four-step synthesis to the first mitochondrial-directed brequinar probe. Both of 
these probes possess cytotoxicity that is superior to brequinar in a colony formation assay and 
are useful for further pharmacology studies.  
 The collective work described in this dissertation furthers the understanding of DHODH 
inhibition in cancer, identifies novel sites for electrostatic interaction between brequinar-class 
inhibitors and DHODH, and has resulted in the first brequinar-based probes for DHODH study. 
Additionally, this thesis depicts the limitations and effectiveness of DHODH targeted therapy for 
cancer and suggests potential solutions that may lead to the clinical efficacy. In general, this 
work provides an excellent foundation to improve brequinar-class inhibitor design and is of 
board interest to cancer drug discovery. 
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Chapter 1 
Introductiona 
 
1.1 Background 
Cancer is a disease of dysregulated cell growth and metabolism-related enzymes are 
important targets for drug development.1 In fact, targeting enzymes that potentiate a cancer cell’s 
metabolic dependencies presents one of the most successful approaches to halt cell growth. 
Drugs that target metabolic liabilities, antimetabolites (e.g. 5-fluorouracil, gemcitabine, and 
methotrexate), make up a significant portion of FDA-approved cancer therapies.2 At least 14 
different purine- and pyrimidine-based antimetabolites have been FDA-approved for cancer 
chemotherapy.3 Dihydroorotate dehydrogenase (DHODH) is a druggable enzyme that plays a 
vital role in the metabolism of cancer cells. DHODH catalyzes the oxidation of dihydroorotate to 
orotate, which is essential for the production of uridine monophosphate.4-6 Inhibition of DHODH 
induces pyrimidine depletion, thereby starving the cell of the essential nucleotides required to 
progress through S-phase.7 Extensive efforts have been made to develop inhibitors of DHODH 
for cancer therapy, however none have gained FDA approval to date.  
In this review, we present compelling evidence in support of DHODH as a vital enzyme 
for cancer cells. DHODH, and its relationship to de novo pyrimidine metabolism, will be 
discussed along with factors that influence its regulation and expression. We will show evidence 
of DHODH’s potential clinical relevance and co-expression network using data from The Cancer 
Genome Atlas (TCGA) and additional published glioma datasets. Additionally, results using 
previous DHODH inhibitors in cancer clinical trials and potential improvements for DHODH-
targeted therapy will be discussed.  
 
 																																																								a	Author	contributions:	Joseph	Madak	was	the	primary	author,	Armand	Bankhead	III	generated	bioinformatics	figures	1.4,	1.6,	1.7,	1.8,	and	1.9.	Christine	Cuthbertson	generated	data	for	bioinformatics	figures	1.4	and	1.5.	Dr.	Hollis	Showalter	and	Dr	Nouri	Neamati	are	the	corresponding	authors.		
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1.2 The de novo pyrimidine pathway and DHODH 
 The therapeutic basis of DHODH targeted therapy primarily derives from inhibition of 
the de novo pyrimidine biosynthetic pathway. Through this pathway, cancer cells generate the 
required substrates for continual DNA replication and protein synthesis without the limitations of 
nucleotide salvage pathways. Pharmacological inhibition of this pathway provides a selective 
approach to targeting cells undergoing rapid cellular growth. Cells growing at normal rates 
maintain nucleotide concentrations primarily via nucleotide salvage pathways.8, 9 Alternatively, 
cells with more rapid proliferation rates, such as cancer and immune cells, depend on de novo 
biosynthesis to fuel nucleotide demands. Hence, enzymes within de novo nucleotide pathways 
are frequently overexpressed in cancer cells to sustain growth.10 Therefore, enzymes within the 
de novo pyrimidine pathway present attractive targets to suppress cancer cell growth.  
 In the de novo pyrimidine biosynthetic pathway, DHODH catalyzes a committed step and 
thus presents a desirable target for halting pathway flux. Overall, the de novo pyrimidine 
pathway generates uridine monophosphate (UMP) from glutamine (Figure 1.1). Flux through 
this pathway begins with a large enzymatic complex known as CAD (an acronym for its 
domains) that catalyzes the first three steps of the pathway. These separate domains comprise a 
complex made up of carbamoyl phosphate synthetase, aspartate carbamoyl transferase, and 
dihydroorotase. The carbamoyl phosphate synthetase domain catalyzes the first reaction and 
generates carbamoyl phosphate from bicarbonate, ATP, and glutamine or ammonia (Figure 1.1, 
step 1).8 The second step is catalyzed by the aspartate carbamoyl transferase domain, converting 
carbamoyl phosphate into carbamoyl aspartate (Figure 1.1, step 2).8 The dihydroorotase domain 
hydrolyzes carbamoyl aspartate into dihydroorotate and generates the substrate for DHODH 
(Figure 1.1, step 3). As previously mentioned, DHODH oxidizes dihydroorotate into orotate 
(Figure 1.1, step 4) and is the only pathway enzyme located in the mitochondria. The final two 
steps in the pathway are catalyzed by another large enzyme complex known as uridine 
monophosphate synthetase. This enzyme is comprised of two domains: orotate 
phosphoribosyltransferase and orotidine 5’-phosphate decarboxylase. The orotate 
phosphoribosyltransferase domain catalyzes the transfer of a phosphoribosyl group to orotate 
(Figure 1.1, step 5). A final decarboxylation by the orotidine 5’-phosphate decarboxylase domain 
generates the uridine monophosphate nucleotide (Figure 1.1, step 6). Two enzymes that catalyze 
committed steps primarily control flux through this pathway. These are carbamoyl phosphate 
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synthase and DHODH.8, 11, 12 Inhibition of either enzyme halts flux through the de novo 
pyrimidine pathway, but carbamoyl phosphate synthetase is not expressed in all cancer cells. In 
fact, carbamoyl phosphate synthase has been observed to have low expression or is completely 
downregulated in most liver carcinomas.13, 14 Therefore, inhibition of DHODH’s catalytic 
activity presents itself as more pharmacologically relevant as an approach to treatcancer.4  
 
 
Figure 1.1: De novo pyrimidine biosynthesis pathway. Numbered steps represent the following enzymes and their 
catalyzed transformations: (1) Carbamoyl phosphate synthetase catalyzes the conversion of bicarbonate, ATP, and 
glutamine into carbamoyl phosphate; (2) aspartate carbamoyl transferase catalyzes the conversion of carbamoyl 
phosphate to carbamoyl aspartate; (3) dihydroorotase catalyzes the conversion of carbamoyl aspartate to 
dihydroorotate; (4) dihydroorotate dehydrogenase catalyzes the conversion of dihydroorotate to orotate; (5) orotate 
phosphoribosyl transferase catalyzes the conversion of orotate to orotidine monophosphate (OMP); (6) OMP 
decarboxylase catalyzes the conversion of OMP to UMP.   
 
DHODH catalyzes two redox reactions: the oxidation of dihydroorotate to orotate and 
subsequent flavin mononucleotide (FMN) regeneration (Figure 1.2). The oxidation of 
dihydroorotate is carried out via a stepwise mechanism with highly conserved residues. This first 
enzymatic reaction follows a deprotonation of dihydroorotate at the C5 position and a subsequent 
hydride transfer (from dihydororotate’s C6 position) to the FMN cofactor (Figure 1.2).4 The 
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catalytic base for the initial C5 deprotonation is likely S215 (Figure 1.3). This residue has been 
reported as the catalytic base for DHODH enzymes in other organisms.4, 15, 16 Adjacent residues 
T218 and F149 are highly conserved as well and may increase the basicity of S215 (Figure 1.3 
(C)).15 However, their precise roles have not been determined. Additional non-catalytic 
conserved residues contributing to dihydroorotate oxidation are N212, S214, P216, L221, R222, 
and Q225. These residues are located on a loop region that may be responsible for 
substrate/product exchange.15 The second redox reaction, resulting in regeneration of FMN, 
requires ubiquinone from the mitochondrial electron transport chain  (ETC) (Figure 1.2).4 FMN 
is thought to bind with DHODH’s G119 and V282, however the catalytic mechanism of FMN 
regeneration from ubiquinone is not well understood.15 FMNH2 is perceived to undergo multiple 
single-electron transfer but the exact residues that facilitate this oxidation are not known.4, 15, 17 
Nonetheless, FMN regeneration is necessary for continued DHODH catalysis. Two of the most 
well-known DHODH inhibitors, leflunomide and brequinar (both discussed later), are proposed 
to act as competitive inhibitors of ubiquinone.15 The necessity to regenerate FMN via ubiquinone 
may correspond to DHODH localization within the inner mitochondrial membrane. This 
localization increases exposure to ubiquinone from the mitochondrial ETC. 
  
Figure 1.2: DHODH couples mitochondrial respiration with de novo pyrimidine biosynthesis. FMN (Flavin-
mono-nucleotide, oxidized) FMNH2 (Flavin-mono-nucleotide, reduced), Q (ubiquinone, oxidized), QH2 
(ubiquinone, reduced). 
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Figure 1.3: Structural features of DHODH. (A) Overall structure of DHODH protein with N and C terminus 
highlighted. (B) Crystal structure of DHODH generated using PDB (1D3G) and Pymol software. The small N-
terminus domain is highlighted in blue. The larger C-terminal domain is color coded by α-helices (red), β-barrels 
(yellow), and loop regions (green). (C) Key residues within the catalytic site and their orientation towards the 
product orotate (magenta) are highlighted.  
 
A functional ETC is required for DHODH catalysis (Figure 1.2).18-20 DHODH requires 
FMN for catalysis and FMN is regenerated via the reduction of ubiquinone. Therefore, DHODH 
catalysis cannot occur without ubiquinone. This relationship makes DHODH dependent on the 
mitochondrial ETC to generate adequate concentrations of ubiquinone. In fact, cells lacking a 
fully functional mitochondrial ETC have an impaired ability to produce uridine 
monophosphate.11, 21, 22 Without a functional mitochondrial ETC, cells must be supplemented 
with pyruvate and uridine to support proliferation.21 This phenomenon is presumed to occur due 
to limited ubiquinone generation for DHODH catalysis. A cell line containing a dysfunctional 
mitochondrial ETC has been reported to be transformed with alternative ubiquinone oxidative 
enzymes. Once transformed, the cell lines were able to sustain cellular growth in uridine- and 
pyruvate-free media.23 This result suggests that cells containing a dysfunctional ETC may be 
indirectly inhibiting DHODH and depleting intracellular pyrimidine nucleotides necessary for 
growth. Previously, decreased DHODH activity has been observed with small molecule 
inhibitors of the ETC targeting cytochrome C oxidase.24 Additionally, inhibition of either 
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DHODH or mitochondrial respiration complexes have resulted in similar cellular responses. For 
example, inhibition of either target induced p53 up-regulation.25 Collectively, these studies 
highlight that DHODH catalysis is dependent on a functional ETC or the presence of ubiquinone. 
This relationship has generated interest around the possible role DHODH may play in reactive 
oxygen species (ROS) homeostasis.  
The connection between DHODH and ROS in cancer is not well understood. 
Mitochondrial ROS has been shown to be vital to cancer development and DHODH-catalyzed 
oxidation may affect mitochondrial ROS.26, 27 A previous study observed that isolated 
mitochondria were capable of generating radical species through DHODH and that radical 
production was diminished by DHODH inhibitors.28 This result implies that DHODH catalysis 
contributes to elevated ROS levels. However, knockdown of DHODH has been shown to 
increase the production of ROS and decrease the mitochondria membrane potential.29 These 
conflicting results complicate the understanding of DHODH’s role in ROS generation. It is 
possible that inhibitors of DHODH alter redox homeostasis in a context-dependent manner. A 
previous study noted that cell lines most sensitive to DHODH inhibition consistently generated 
the lowest amount of ROS.7 This data implies that an antioxidant dosed with a DHODH inhibitor 
may be synergistic or at least additive. However, a DHODH inhibitor, teriflunomide, did not 
abrogate cell growth when the antioxidant pyrrolidine dithiocarbamate was co-administered.30 
These studies highlight a correlation between ROS and DHODH catalysis, but the functional 
consequences appear to be context-dependent.  
 
1.3 Regulation of DHODH activity in cancer  
Regulation of DHODH activity occurs primarily through activation of de novo 
pyrimidine biosynthesis via the CAD complex. When cells are not preparing for growth, flux 
through the de novo pyrimidine pathway is slow and functions to generate RNA nucleotides 
primarily for protein synthesis.8, 31, 32 In this state, flux is controlled through product feedback 
inhibition as high concentrations of uridine inhibit CAD. However, when cells prepare to divide, 
phosphorylation of CAD alters its affinity for uridine to overcome feedback inhibition.33, 34 
Selective phosphorylation of CAD at specific residues regulates flux through the de novo 
pyrimidine biosynthesis pathway.35 Flux through the de novo pyrimidine pathway is increased 
when T456 of CAD is phosphorylated by mitogen-activated protein kinase (MAPK) or 
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mechanistic target of rapamycin 1 complex (mTORC1) via S6 kinase (S6K1).36-38 After 
sufficient concentrations of nucleotides are reached, protein kinase A (PKA) phosphorylates 
S1406 of CAD to down-regulate nucleotide biosynthesis.39 Overexpression of enzymes 
controlling CAD phosphorylation, such as MAPK or mTORC1, leads to increased flux through 
the pathway in cancer. For example, the breast cancer cell line MCF7 has been found to have 
higher MAPK kinase activation resulting in a nearly 4-fold increase in the rate of de novo 
pyrimidine biosynthesis.40 Overexpression of mTORC1 may also increase flux through the 
pathway, however this has not been confirmed experimentally. In addition to phosphorylation, 
CAD localization also affects the rate of flux through the de novo pyrimidine pathway. 
Hindrance of CAD nuclear import has been found to decrease the rate of pyrimidine synthesis by 
21% and decrease nucleotide concentrations by nearly 60%.41 However, it is unclear how and 
why CAD localization affects de novo synthesis. Nonetheless, CAD’s phosphorylation and 
localization play a significant role in regulating DHODH activity. 
 Beyond phosphorylation, cancer cells may alter pyrimidine biosynthesis through the 
activation of the proto-oncogenic transcription factor MYC. MYC is a master regulator of many 
different pathways and has significant influence on the expression of nucleotide metabolism 
genes. Previous studies have shown that overexpression of MYC significantly increased 
expression of nucleotide metabolism enzymes, including DHODH, which was validated as a 
direct MYC target gene.42 Additionally, shRNA knockdown of MYC decreased the expression of 
nucleotide metabolism genes and lowered the intracellular concentrations of nucleotides.43 These 
results demonstrate MYC’s control over DHODH expression. Surprisingly, inhibition of 
DHODH has been observed to affect MYC expression. Two well-known DHODH inhibitors, 
brequinar and teriflunomide, were shown to decrease the expression of MYC.44 However, this 
may be context-dependent as leflunomide (the pro-drug of teriflunomide), does not affect MYC 
expression.45 It is possible that a sufficient quantity of leflunomide was not converted to 
teriflunomide and therefore did not affect MYC expression, although this was not evaluated 
experimentally. Nonetheless, while these conflicting results complicate the understanding of 
MYC and DHODH’s relationship, it is clear that nucleotide biosynthesis is among the many 
pathways MYC activation influences to facilitate cellular proliferation. This is a unique 
relationship as other transcription factors, such as those in the E2F family, do not appear to 
increase expression of DHODH.46 It is possible that MYC and DHODH expression are linked 
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through glutamine metabolism because MYC increases the production of glutamine, the first 
substrate in de novo pyrimidine biosynthesis.47  
The connection between increased glutamine metabolism and de novo pyrimidine 
synthesis is not well understood. Low glutamine concentrations have been demonstrated to 
hinder S phase progression, presumably by limiting the starting metabolite for nucleotide 
production.48, 49 Conversely, higher glutamine concentrations may increase the rate of de novo 
nucleotide synthesis. However, it does not appear that cancer cells increase glutamine uptake to 
solely fuel de novo pathways.48, 50 In fact, a significant disparity exists between the rates of 
glutamine uptake and nucleotide biosynthesis, suggesting that glutamine is utilized by far more 
pathways than nucleotide biosynthesis alone.48 Interestingly, glutamine flux may be an indicator 
of cell sensitivity to DHODH inhibition. Cells containing a mutant PTEN tumor suppressor were 
observed to have increased glutamine metabolism and were sensitive to DHODH inhibition.51 
While more studies are needed, these results suggest that DHODH inhibitors may be useful in 
cells with mutant PTEN and possibly increased glutamine metabolism.  
 
1.4 DHODH and cellular differentiation 
 Beyond directly halting cell growth, DHODH has been implicated as a target to induce 
cellular differentiation. Previously, DHODH inhibition was shown to induced cell differentiation 
in neural crest52 and leukemic cell lines.53 In leukemic cells, DHODH inhibitors, such as 
brequinar, were observed to decrease the number of self-renewing cells in vivo.53 This finding 
significantly increased the interest in DHODH targeted therapy for cancer. Theoretically, 
DHODH inhibitors could induce differentiation of leukemic stem cells and hinder rapid growth 
of differentiated cancer cells. Further studies are needed to fully evaluate the ability of DHODH 
inhibitors to induce this effect. 
While the mechanism of DHODH-induced differentiation is not fully understood, this 
phenomenon may be caused by pyrimidine depletion. Inhibitors, such as pyrazofurin, of the de 
novo pyrimidine pathway not targeting DHODH are able to induce differentiation and suggest 
pyrimidine depletion as a potential mechanism.53 A possible link between pyrimidine depletion 
and cellular differentiation may be transcriptional elongation. The PHD-finger Phf5a protein is 
known to modulate transcriptional elongation in pluripotent cells. Through transcriptional 
elongation, this Phf5a protein is able to influence cellular differentiation.54 Transcription 
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elongation has been induced by pyrimidine depletion previously55 with DHODH inhibitors 
observed to modulate transcriptional elongation in melanoma cells.52 This proposed mechanism 
suggests that DHODH targeted therapy causes pyrimidine depletion that results in cellular 
transcriptional elongation, thereby inducing cellular differentiation. However, this mechanism 
has not been confirmed experimentally and the connection between DHODH and cellular 
differentiation is still not well understood. Despite this, considerable interest exists for DHODH 
targeted therapy as a potential option to induce cellular differentiation.  
 
1.5 Relevance of DHODH in cancer 
DHODH’s relevance in cancer was recognized nearly six decades ago when Smith et al. 
noted elevated DHODH activity in leukemic cells.56, 57 Following that discovery, several cancer 
projects focused on DHODH studies that culminated in the clinical evaluation of brequinar, a 
potent human DHODH inhibitor.58, 59 However, brequinar failed to produce objective responses 
in clinical trials (discussed in further detail below), leading to questions about the viability of 
DHODH inhibition as a therapeutic target for cancer. Recent reports have revisited the link 
between DHODH inhibition and antiproliferative effects on cells. However, no studies have 
thoroughly evaluated the clinical relevance of DHODH in cancer. Therefore, to address this gap 
in understanding, we analyzed data from several different in vitro and in vivo profiling projects 
to provide an un-biased summary of the potential significance of DHODH in cancer. 
Cell growth is suppressed when clinically relevant anticancer targets are knocked down. 
The Achilles Project60-62 evaluates large-scale cellular responses in the presence of shRNA 
across a catalogue of cancer cell lines and has been utilized to gauge the importance of DHODH 
to cancer cells. Changes in shRNA levels (log-fold) were averaged for each cell line and then 
ranked by essentiality; a negative shRNA score indicates that a cell line responded poorly (i.e., 
showed growth inhibition) to treatment with shRNA. Achilles’ project results (Figure 1.4A) 
depict a resounding negative response of cancer cell lines to shRNA knockdown of DHODH. 
The results suggest that DHODH inhibition is cytotoxic to most cancer cell lines. Cell lines that 
were most sensitive to DHODH knockdown were derived from cancers of the small and large 
intestines (highlighted in yellow, Figure 1.4A), which had a total of 17 out of 21 cell lines with 
lower than average shRNA scores (Figure 1.4B). Consistent with this finding, significantly 
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higher DHODH expression were observed in the Sabetes-Bellver colorectal dataset for adenomas 
tumor tissue versus normal samples using Oncomine (Figure 1.4C).63-66 
 
 
Figure 1.4: DHODH knockdown response from the Achilles Project. (A) Plot depicting shRNA scores in 216 
cell lines for shRNA targeting DHODH. Yellow bars indicate intestinal cancer cell lines. The dark blue horizontal 
line indicates the mean shRNA score (-0.8972). (B) Table depicting the distribution of cell lines with respect to the 
mean shRNA score. (C) DHODH is overexpressed in colon cancer, generated using the Sabetes-Bellver colorectal 
database on the Oncomine platform.  
  
Cells overexpressing DHODH may have higher sensitivity to its inhibition. Using data 
from the Cancer Cell Line Encyclopedia (CCLE), we evaluated mRNA levels of DHODH in 
various cancer cell lines (Figure 1.5).67 The mRNA expression levels of DHODH in 1,019 cancer 
cell lines were obtained and converted to Z-scores. The top four highest and lowest expressing 
cell lines are listed (Figure 1.5). Frequent overexpression of DHODH mRNA occurs in lung 
(33% of top ten) and haematopoietic/lymphoid (33% of top ten) tissue. Surprisingly, 
intestinal/colon cancer was not among the top ten tissues with high DHODH mRNA expression. 
However, this data still correlates well with the Achilles database (Figure 1.4). Both lung and 
haematopoietic/lymphoid are cell lines that frequently possess higher than average cell growth 
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inhibition when exposed to DHODH shRNA. Collectively, this data suggests that both lung and 
haematopoietic/lymphoid cell lines may be more sensitive to DHODH inhibitors.  
 
Figure 1.5: mRNA levels of DHODH in 1,019 cancer cell lines. Top four over and under expressing cell lines are 
depicted. Data generated using the CCLE.  
 
We then evaluated in vivo DHODH mRNA expression using data from The Cancer 
Genome Atlas (TCGA).68 To perform a pan-disease comparison of DHODH expression, log2 
TPM expression values were converted to z-scores calculated per patient.  Figure 1.6 shows that 
across all 34 diseases (9,726 unique patient samples) the median DHODH expression is above a 
Z-score of zero. This indicates that most patients express DHODH more than the average of all 
other genes measured.  Among these diseases, liver hepatocellular carcinoma (LIHC) patients 
tended to express DHODH the most (Figure 1.6). TCGA disease patient samples were evaluated 
for reduced survivability by comparing survival outcomes for patients with high DHODH 
expression to those with low DHODH expression. High DHODH expression was associated with 
reduced survival in low-grade glioma (LGG) and stomach adenocarcinoma (STAD) patients. 
High DHODH expression was also found to be associated with increased grade and stage in 
glioma patients from the TCGA, in the Rembrandt and Gravendeel studies (Figure 1.7).69-71 
Within glioma, stage III and IV tumors have a higher average mRNA expression of DHODH in 
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comparison to normal and stage I tumors. Therefore, in general, later stage glioma tumors have a 
higher DHODH mRNA expression level.  
 
Figure 1.6: Z-score for mRNA expression generated from The Cancer Genome Atlas database. Pan-disease 
expression of DHODH across 34 TCGA diseases.  Z-scores were calculated per patient per disease.  The majority of 
patients across all diseases show higher than average expression (z-score = 0) of DHODH.  Adrenocortical 
carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma cohort (BRCA), Cervical 
squamous cell carcinoma and endocervical adenocarcinoma (CESC), Cholangiocarcinoma (CHOL), colon 
adenocarcinoma (COAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), esophageal carcinoma 
(ESCA), glioblastoma multiforme (GBM), glioma (GBMLGG), head and neck squamous cell carcinoma (HNSC), 
kidney chromophobe (KICH), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), brain 
lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous 
cell carcinoma (LUSC), mesothelioma (MESO), ovarian serious cystadenocarcinoma (OV), pancreatic 
adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), 
rectum adenocarcinoma (READ), sarcoma (SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma 
(STAD), testicular germ cell tumors (TGCT), thymoma (THYM), uterine corpus endometrial carcinoma (UCEC), 
uterine carcinosarcoma (UCS), uveal melanoma (UVM). 
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Figure 1.7: Analysis of DHODH in glioma. Kruskal-Wallis and survival analysis statistics were calculated using 
the R statistical programming language.71 (A) Kaplan-Meier curves for DHODH in glioma. (B) mRNA expression 
of DHODH in LGG and GBM. (C) DHODH expression increases with stage in LGG patients. Shown using a 
Kruskal-Wallis evaluation.69, 70  
 
In an effort to determine genes that are correlated with DHODH expression in the TCGA 
patient population, gene set enrichment analysis (GSEA) was used to identify pathways that were 
enriched with genes that co-express with DHODH. Co-expression of DHODH in patients was 
evaluated in lower grade glioma (LGG), stomach adenocarcinoma (STAD), liver hepatocellular 
carcinoma (LIHC), colon adenocarcinoma (COAD), rectum adenocarcinoma  (READ), and 
pancreatic adenocarcinoma (PAAD) using a Pearson correlation measure (Figure 1.8).72 In each 
of these patient populations, DHODH is co-expressed with genes involved with mitochondrial 
translation, mitochondrial respiratory complex, electron transport chain, MYC targets, and 
translation elongation. These findings are consistent with our description of DHODH function.  
We also performed a correlation analysis independent of annotated gene sets to identify 
potentially novel genes that are co-expressed with DHODH.  Using the top 100 DHODH co-
expressed genes in COAD, LGG, STAD, and PAAD diseases, we identified four common genes 
across all four diseases (Figure 1.9). These genes are translation elongation mitochondrial factor 
A B 
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(TUFM), DNA polymerase delta 2 (POLD2), peter pan homolog (PPAN), and ribosomal subunit 
RNA processing 9 (RRP9). Of these genes, TUFM may be the most relevant in cancer. TUFM 
has been shown to prevent the epithelial-to-mesenchymal transition (EMT).73 Knockdown of 
TUFM induces EMT transition in lung cancer cells.73 However, TUFM appears to be 
considerably overexpressed in colon cancer and may be a potential prognostic biomarker.74 
Additionally, TUFM may play a role in the transition of normal cells into adenomas for 
colorectal cancer.75 Although co-expression does not prove DHODH is directly interacting with 
these four targets, one might hypothesize a common functional relationship or transcriptional 
regulation that is worth investigating.  
 
Figure 1.8: Common gene sets enriched for genes that are co-expressed with DHODH. Gene set enrichment 
analysis (GSEA) was used to identify enriched pathways with genes that are co-expressed with DHODH.  
GSEAv2.2.3 was used with v6 gene sets sourced from MSigDB.  10,000 gene set permutations were performed 
using weighted mode scoring and Pearson metric.72 Only genes with evidence of expression in > 50% of a disease 
patient population were considered.  Six diseases were evaluated based on association with reduced survivability 
(LGG, STAD), high expression (LIHC), or experimental evidence (COAD, READ, PAAD). 22 Gene sets were 
significantly enriched for genes positively correlated with DHODH expression using Gene Set Enrichment Analysis 
(GSEA) (A).  Heatmap coloring indicates the normalized enrichment score (NES) and all gene sets with an FWER 
adjusted p-value < 0.05 are colored with a black border.  GSEA running sum statistic visualizations are shown (B) 
for the Gene Ontology (GO) category, Mitochondrial Translation that was significantly enriched in LIHC, COAD, 
LGG, STAD, and PAAD TCGA diseases. 
 
LIHC, NES = 2.8, FWER < 0.0001 
COAD, NES = 2.3, FWER < 0.019 
LGG, NES = 3.2, FWER < 0.0001 
STAD, NES = 3.6, FWER < 0.0001 
PAAD, NES = 3.6, FWER < 0.0001 
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Figure 1.9: DHODH co-expressed genes were identified across multiple TCGA diseases. DHODH gene co-
expression was evaluated and compared across multiple diseases.  DHODH correlations were clustered using 
Euclidean distance, agglomerative hierarchical clustering and COAD, LGG, STAD, and PAAD showed the 
strongest agreement in co-expression. (A) A Chow-Ruskey weighted Venn diagram shows overlap of the top 100 
genes correlated with DHODH within COAD, LGG, PAAD, and STAD TCGA diseases.  (B) TUFM was one of the 
four top co-expressed genes (POLD2, PPAN, RRP9, TUFM) in common across all four diseases and has been 
shown to be associated with mitochondrial translation and organelle biogenesis and maintenance.   
 
STRING protein interactions have been used to highlight enzymes associated with 
DHODH (Figure 1.10).76 Using the online database for STRING analysis, all reported/predicted 
protein-protein interactions with DHODH are depicted. The reported protein-protein associations 
are primarily within the de novo nucleotide synthesis pathways (CAD, carbamoyl phosphate 
synthase 1, uridine monophosphate synthetase, and phosphoribosylglycinamide 
formyltransferase (de novo purine)).11 These edges, showing connections between proteins, are 
primarily reported in non-human organisms. Beyond de novo pathways, DHODH is reported to 
associate with the dihydropyrimidinase-like (DPYSL) family. DPYSL is also known as a 
collapsing response mediator protein (CRMP) family.77 CRMP1 has been implicated in 
metastasis and differentiation78 acting as a tumor suppressor in prostate cancer and hindering the 
epithelial-mesenchymal transition.79 Additionally, CRMP may present a potential biomarker for 
cancers. In neuroblastoma, the activation of MYC selectively decreased the expression of 
CRMP3, but not CRMP1 or CRMP2. Conversely, siRNA knockdown of MYC increased 
expression of CRMP3, suggesting a unique role for CRMP3 as a biomarker for aggressive 
A B 
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neuroblastoma.77, 80 Beyond neuroblastoma, CRMP5 is reported as a biomarker for poor 
prognosis in osteosarcoma.81 However, the complete connection between these proteins, 
DHODH, and cancer is not fully understood.  
 
 
Figure 1.10: STRING analysis of interactions with DHODH. STRING Analysis reports/predicts protein-protein 
interactions with DHODH using predicted and experimental data from online databases. CAD, carbamoyl phosphate 
synthetase 2, aspartate transcarbamylase, and dihydroorotatase; CPS1 carbamoyl phosphate synthase 1; CRMP1, 
collapsing response mediator protein 1; DPYS, dihydropyrimidinase; DPYSL2, dihydropyrimidinase-like 2; 
DPYSL3, dihydropyrimidinase-like 3; DPYSL4, dihydropyrimidinase-like 4; DPYSL5, dihydropyrimidinase-like 5; 
GART phosphoribosylglycinamide formyltransferase; UMPS, uridine monophophase synthetase.  
 
Murine knockout studies, performed by the International Mouse Phenotyping 
Consortium, identified DHODH as homozygous-lethal gene.82, 83 At least one functional allele 
copy is necessary for survival. However, even heterozygous mutations in DHODH may be 
responsible for health defects, as mutations in DHODH were implicated as a cause of Miller 
syndrome.84 At least 11 different DHODH mutations have been identified.84 Some amino acid 
changes in patients with Miller’s syndrome are R346W and G202A.84 These mutations do not 
have an impact on mitochondrial localization but were later observed to decrease protein 
stability.85 It is unclear how other mutations alter DHODH function in patients with Miller’s 
syndrome. However, there is a clear implication that DHODH function is necessary for normal 
embryonic development. In fact, DHODH inhibitors such as leflunomide are known teratogens 
and its use is avoided during pregnancy.86 In murine studies, leflunomide dosing in pregnant 
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mice caused significant malformations. These malformations did not occur when leflunomide 
was co-administered with uridine.87, 88 For embryonic development, this data suggests that 
DHODH function is necessary to generate nucleotides for continued growth.   
 Overall, the results of these bioinformatics studies suggest that DHODH is an important 
oncology target. The cellular response to DHODH shRNA highlights cancer’s dependence on de 
novo pyrimidine biosynthesis. Additionally, increased DHODH expression has been correlated 
with decreased survival in glioma patients. Collectively, this data strengthens the case to pursue 
drug discovery campaigns aimed at inhibiting DHODH for cancer therapy.  
 
1.6 Select inhibitors of DHODH 
 The importance of DHODH to cancer cells has resulted in many drug discovery 
campaigns. Various DHODH inhibitors belonging to different chemical classes have been 
reported and recently reviewed.5, 6 Only select inhibitors targeting human DHODH, which were 
not previously reviewed, are discussed with the most notable inhibitors, brequinar and 
leflunomide/teriflunomide, discussed in detail. 
Table 1.1: DHODH inhibitors evaluated in clinical trials.  
Name Structure Diseases/Status 
Brequinar 
 Cancer59 
Did not meet objective response in multiple phase 
II clinical trials for breast89, colon90, head and 
neck91, gastrointestinal92, lung93, melanoma94, and 
ovarian cancer95. 
 
Immunomodulatory96, 97 
Used in combination with cyclosporine A, observed 
to alter PK properties of brequinar97  
Did not gain FDA approval 
Leflunomide 
 
 
FDA approved for rheumatoid and psoriatic 
arthritis98 
 
 
Teriflunomide 
 
FDA approved for multiple sclerosis98 
 
 
 
F3C
N
H
O
O
N
F3C
N
H
O OH
CN
N
F
F
O OH
	 18	
Brequinar 
Brequinar is a potent DHODH inhibitor (Table 1.1, DHODH assay Ki = 27.4 ± 1.6 nM) 
with significant anticancer properties.99 DuPont Pharmaceuticals developed brequinar from a 
lead compound discovered in the National Cancer Institute’s Developmental Therapeutics 
Program.59 Initial studies with brequinar revealed promising anticancer effects. Dosing at 20-40 
mg/kg in murine xenograft models inhibited the growth of breast, lung, stomach, and colon 
tumors by > 90%.59 However, the target was not initially known until a mechanism of action 
study observed a selective depletion of uridine and cytidine triphosphate.100 This finding 
ultimately led to the discovery of DHODH as the target. Further studies of brequinar highlighted 
a schedule dependency, as cells exposed to brequinar for 1-24 hours could sustain growth once 
brequinar was removed. However, when exposed for 48 hours, cells were unable to continue 
growth. Therefore continual inhibition is necessary to maximize DHODH’s anticancer effects, 
which has been demonstrated in multiple cell lines.59, 99 Cells with a faster doubling time are 
more likely to be sensitive to brequinar.7 In fact, brequinar’s IC50 in two breast cancer cell lines 
with doubling times between 25-45 hours, T-47D and MDA-MD-231, was < 1 µM whereas in 
slower growing MDA-MB-436 and W3.006, two breast cancer cell lines with doubling times of 
75-85 hours, brequinar’s IC50  was > 100 µM.7 This data highlights the sensitivity of faster 
growing cells to DHODH inhibition. The overall impressive preclinical results of brequinar were 
sufficient to pursue clinical evaluation for treatment of cancer. 
Early clinical evaluation of brequinar gave conflicting results. First, high doses were well 
tolerated by most patients. Doses at 200-250 mg/m2 were tolerated with few dose-limiting 
toxicities (e.g., myelosuppression and nausea).58, 101-105 Second, objective responses were not 
regularly observed 104-106 in multiple studies leading to the recommendation for increasing the 
dose in phase II studies. However, the results were similar in each study with brequinar failing to 
produce an objective response in breast,89 colon,90 head and neck,91 gastrointestinal,92 lung,93 
melanoma,94 and ovarian cancers.95 These results were befuddling considering that patient-
derived samples of lymphocytes had undetectable DHODH activity for at least a week after 
treatment with brequinar had ceased.107 Furthermore, brequinar at 600 mg/m2 induced plasma 
uridine depletion (40-80%), which ranged from 6 hours to 4 days after dosing. However, a 
significant rebound of plasma uridine (160-350%) was observed 4-7 days after dosage.107 These 
results suggest that despite potent DHODH inhibition, clinically relevant uridine depletion may 
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not have continually occurred, possibly due to a sub-optimal dosing regimen. Effective brequinar 
therapy requires continuous inhibition of DHODH. With most patients in these trials dosed 
weekly at high doses,53 it is likely that alternative sources of plasma uridine overcame DHODH 
inhibition. Hence, brequinar did not meet its objective response, likely due to poorly chosen 
dosing regimens. 
Recent studies have reported on brequinar’s impact beyond cell growth inhibition. 
Brequinar induced differentiation in acute myeloid leukemia (AML) cells. Differentiation was 
observed both in vitro and in vivo suggesting a new utility for brequinar, or other DHODH 
inhibitors.108 Additionally, when dosed in neural crest stem cells, both a brequinar analogue and 
leflunomide (described below) decreased the cell’s self-renewing capabilities. This study 
suggests that DHODH inhibitors halt neural crest cell growth and limit stem cell renewal.52 
Aside from differentiation, brequinar was also observed to overcome tumor necrosis factor-
related apoptosis ligand (TRAIL) resistance. Genomic screening was used to identify potential 
enzymes that may sensitize cells to TRAIL. In this study, siRNA for DHODH was found to 
sensitize resistant cells to TRAIL. Dosing cells with brequinar and TRAIL reproduced these 
results, which validates DHODH as a viable target for these cells.109 Together these studies 
highlight a future for brequinar beyond single agent use, potentially in combination with agents 
that induce apoptosis. 
 
Leflunomide and Teriflunomide 
Leflunomide is a potent DHODH inhibitor that has gained FDA approval for the 
treatment of rheumatoid and psoriatic arthritis (Table 1.1).110 Leflunomide is a prodrug of the 
active metabolite teriflunomide, itself FDA approved for multiple sclerosis.111 The two are used 
interchangeably for this indication. Besides arthritis, leflunomide has been evaluated in multiple 
clinical trials for the treatment of ankylosing syndrome,112 Crohn’s disease,113, 114 rare 
autoimmune diseases such as Felty syndrome and granulomatosis with polyangiitis,115 Kimura’s 
disease,116 pemphigoid,117 organ transplantation,110, 118, 119 sarcoidosis,120 Still’s disease,121 
systemic lupus,122 Takayasu arteritis,123 and uvetitis.124 Despite being marketed primarily for 
autoimmune disorders, leflunomide also displays anticancer effects. Several studies report anti-
proliferative effects of leflunomide in various cell lines, including those derived from multiple 
myeloma,125 non-small cell lung carcinomas,126 neuroblastomas,127 neuroendocrine,128 and 
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cancer in medullary thyroids.129 However, the off-target effects of leflunomide therapy 
complicate attributing these responses to DHODH inhibition. 
Leflunomide has been reported to target additional enzymes beyond DHODH. One 
reported off-target effect is due to the aryl hydrocarbon receptor, which may contribute to 
leflunomide’s overall mechanism of action. In fact, melanoma cells were not rescued from 
leflunomide’s antiproliferative effects by uridine supplementation.45 DHODH inhibition effects 
are reversed by uridine supplementation and this result suggests that leflunomide may not be 
suppressing cell growth solely through DHODH inhibition. Other studies have suggested that 
leflunomide may inhibit S6 kinase (S6K1), a kinase responsible for ribosomal and CAD 
phosphorylation,130 but this has not been completely verified experimentally. Additionally, 
leflunomide modestly inhibits the EGF-receptor tyrosine kinase at high concentrations (IC50 ≈ 40 
µM).131 As a result, it is difficult to ascribe leflunomide-induced cellular responses to DHODH 
alone, due to likely contributions from off-target effects.   
Leflunomide also affects other signaling pathways beyond antiproliferation. In oral 
squamous cell carcinoma cells, leflunomide induced an upregulation of cyclin A.132 Cyclin A is 
upregulated in S phase when flux through the de novo pyrimidine pathway is abundant and 
possibly upregulated in response to pyrimidine depletion.133 In murine xenografts of Ehrlich’s 
ascites carcinoma, leflunomide decreased TNF-α and EGF protein levels and this response is 
associated with immunosuppression.134 Leflunomide has been shown to inhibit frizzled-10 
(FZD10) gene expression in renal carcinoma cells, which is a receptor protein that can initiate 
WNT/β-catenin signaling.135 Other cellular studies on leflunomide and teriflunomide have 
highlighted their chemo-preventative properties for prostate cancer.136 In fact, both inhibitors 
have progressed into clinical trials for prostate cancer.137 However, it is difficult to attribute this 
response to DHODH inhibition, as uridine rescue did not overcome antiproliferative effects in 
prostate cancer.136 Finally, p53 may be a marker of nucleotide depletion as it has been shown that 
inhibition of de novo pyrimidine biosynthesis resulted in a p53 mediated cell cycle arrest.25, 138 
Leflunomide treatment was found to increase the expression of p53,25 but it is unknown if 
functional p53 must be present to induce cell death via DHODH inhibition.  
Leflunomide and teriflunomide represent the only FDA approved DHODH inhibitors in 
clinical use. Therefore, they are commonly chosen for studies on DHODH inhibition. However, 
there are many off-target effects that complicate leflunomide-induced responses and their 
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relationship to DHODH. Nonetheless, the continued use of these inhibitors highlights the 
potential of long-term DHODH inhibition as a valid clinical strategy.  
 
Selected human DHODH inhibitors 
In general, DHODH inhibitors possess diverse scaffolds that likely vary mechanistically 
by different binding sites to the enzyme (Table 1.2). A variety of structurally distinct inhibitors 
of human DHODH have been developed for cancer,5, 6 including biphenyl indoles,139 amides like 
ML390,140 derivatives of ascochlorin,141 substituted quinolines like brequinar,59 and 
leflunomide.45, 52 There are brequinar-like quinoline-based inhibitors such as FA-613,142 
CD44,143 and compound 11.144 Leflunomide-like inhibitors have also been reported, including 
compound 4.145 In addition to brequinar and leflunomide-like inhibitors, pyrazole-based 
analogues 18d146 and 21q147 were reported for human DHODH as antivirals. A tri-substituted 
benzimidazole inhibitor (compound 8d) of DHODH, which is structurally similar to compound 
A14,149 was reported with an IC50 = 81 ± 2 nM,148 However, the rest of compounds shown in 
Table 1.2 represent unique classes of DHODH inhibitors without any obvious structural 
similarity.  
 
Table 1.2: Selected recently published DHODH inhibitors 
Name Structure Diseases/Status 
Compound 8d 
 
DHODH IC50 = 81 ± 2 nM148 
DD778 
 
Racemate* 
Antiviral150  
BEHI 
 
Anticancer cell data139 
IC50 = 20.5 µM for A549  
IC50 = 18.5 µM for 4T1  
FA-613 
 
Antiviral suggested as DHODH 
inhibitor142 
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Compound 4 
 
Antiproliferative 
IC50 = 1.04 ± 0.04 µM for Jurkat cells145 
ML390 
 
Antiproliferative 
EC50 = 1.8 ± 0.6 µM for ER-HOX-GFP 
cells140 
Compound A14 
 
DHODH IC50 = 0.178 µM149 
Compound 19 
 
DHODH IC50 = 0.032 µM151  
Compound 18d 
 
 
 
 
 
 
 
 
DHODH IC50 = 25 ± 5 nM 
Jurkat IC50 = 0.02 µM146 
Compound 21q 
 
DHODH pIC50 = 5.9 M147 
Fr1-4 
 
DHODH IC50 = 0.773 µM152 
Compound 44 
 
DHODH IC50 = 26 nM153 
Compound 11 
 
DHODH IC50 = 0.94 ± 0.06 µM 
IC50 = 5.03 µM A-375 melanoma cells.144  
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DSM338 
 
DHODH IC50 = 1.6 µM154 
Compound 1 
 
DHODH IC50 = 1.5 ± 0.2 nM155 
C44 
 
DHODH IC50 = 1 nM143 
 
Non-DHODH de novo pyrimidine biosynthesis inhibitors 
 Beyond DHODH, multiple inhibitors of the de novo pyrimidine biosynthesis pathway 
have been evaluated for anticancer activity (Figure 1.11). Carbamoyl phosphate synthetase is a 
reported target for the antitumor agent acivicin.156, 157 However, acivicin appears to target most 
enzymes containing a glutamine binding site, thus studies with this compound were not pursued 
further due to high toxicity.158 Aspartate carbamoyl transferase has been targeted by N-
phosphoacetyl-L-aspartate (PALA), a potent inhibitor with a Ki = 26 nM for the murine 
enzyme.159, 160 PALA performed well against solid murine tumors, but did not fare well in 
clinical trials.160, 161 In humans, PALA caused a meager decrease in plasma uridine 
concentrations but only one patient was a reported responder.161, 162 A metabolic resistance 
mechanism was proposed in which PALA-induced inhibition of aspartate carbamoyl transferase 
led to a significant increase in carbamoyl phosphate, the substrate. Sufficient concentrations may 
have been reached to displace PALA and continue flux through the de novo pathway.160, 163 A 
few inhibitors have been developed for dihydroorotase with the most notable being 4-mecapto-6-
oxo-1,4-azaphosphinane-2-carboxylic acid 4-oxide (MOAC). However, these inhibitors have 
shown minimal anticancer activity.160, 164, 165 Additionally, attempts have been made to target 
orotidine 5’-monophosphate decarboxylase (OMP decarboxylase) by pyrazofurin, which is 
phosphorylated in the cell to generate an active OMP decarboxylase inhibitor.166 In clinical trials, 
pyrazofurin did not fare well as limited objective responses were observed.167-169 Far more 
extensive efforts have been made to target dihydroorotate dehydrogenase for cancer. 
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Figure 1.11: Selected inhibitors of the de novo pyrimidine biosynthesis pathway.  
 
1.7 Combination approaches to increase efficacy of DHODH inhibitors 
Results from the multitude of de novo pyrimidine inhibitors in anticancer clinical trials 
depict a mixed outlook for single agent DHODH inhibition. As previously discussed, brequinar 
produced minimal objective responses in clinical trials. These results were similar for all 
inhibitors of the de novo pathway evaluated in the clinic (e.g., PALA and pyrazofurin). However, 
a significant problem with targeting de novo pyrimidine biosynthesis is the salvage pathway. 
Cells can obtain the necessary nucleotides for growth through either pathway. In theory, an 
inhibitor of DHODH may shut down de novo synthesis, but extracellular uridine can enter the 
intracellular salvage pathway to form the necessary nucleosides/nucleotides. As previously 
mentioned, supplementation of a treated cell line with uridine or other pyrimidines recapitulates 
this phenomenon. Uridine rescue has been demonstrated to work exceptionally well in the 
context of potent DHODH inhibitors such as brequinar.58, 170 Results from uridine rescue 
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experiments have led to the hypothesis that a DHODH inhibitor may require concomitant 
administration of other agents to be successful.  
The combination of brequinar and 5-fluorouracil (5-FU) has been evaluated to assess if 
brequinar-induced uridine depletion would improve 5-FU activity. In cells, 5-FU is metabolized 
into FdUMP and inhibits thymidylate synthetase, which catalyzes the formation of thymidine 
monophosphate from deoxyuridine monophosphate.171, 172 A combination of brequinar and 5-FU 
was proposed to increase generation of FdUMP by decreasing intracellular nucleotide 
concentrations. Initial evaluation of this combination utilized a low dose of brequinar to assess if 
pretreatment would improve the activity of 5-FU or 5-FU with leucovorin. The results indicated 
that brequinar did enhance the potency of 5-FU when pretreated at 24 or 48 hours, and that cells 
treated with this combination had significantly higher concentrations of FdUMP compared to 5-
FU alone.173 However, brequinar pretreatment did not significantly improve the 5-FU and 
leucovorin combination.173 A larger study evaluating 5-FU and brequinar in vivo suggested the 
combination provided a synergistic effect in colon cancer cells at low uridine concentrations. 
However, at higher concentrations, the combination did not perform well. Studies were also 
conducted in colon 26 (estimated intracellular [uridine] of 10 µM) and colon 38 (estimated 
intracellular [uridine] of 50-100 µM) cell lines.174, 175 When applied in vivo the 5-FU and 
brequinar combination significantly decreased tumor weight in colon 26, but the results in colon 
38 were not significantly different than for 5-FU alone.175 A third compound was then added to 
improve the combination in vitro. An equilibrative nucleoside transport inhibitor, dipyridamole 
(DPM), believed to hinder nucleobase/nucleoside transport across the cell membrane was 
evaluated. This three inhibitor cocktail combination inhibited cell growth at low concentrations 
of uridine, but was unable to inhibit cell growth in the presence of 50 µM uridine.175 If the 
salvage pathway rescued the cells, it may have occurred due to additional nucleoside 
transporters. Additionally, DPM may have limited the influx of 5-fluorouracil across the 
membrane. Further in vivo studies on the combination demonstrated a significant decrease in 
tumor weight when comparing brequinar as a single agent to brequinar with 5-FU.176 The 
combination was tested in a phase I study, where weekly doses as high as 600 mg/m2 brequinar 
and 600 mg/m2 of 5-FU were used in patients. However, no objective responses were observed in 
the 25 patients with refractory solid tumors.177 Brequinar doses as high as 400 mg/m2 were 
observed to decrease baseline uridine levels by more than 50%.177 Beyond combinations with 5-
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FU, brequinar has also been evaluated in combination with cisplatin. Unfortunately, the results in 
a phase I study were much the same with no objective responses.96  
Other combination therapy studies have been pursued with non-DHODH inhibitors of de 
novo biosynthesis. 5-FU and DPM have been evaluated in combinations with other de novo 
pyrimidine biosynthesis inhibitors. PALA and 5-FU were evaluated in multiple anticancer 
clinical trials, but the combination showed little advantage in comparison to 5-FU alone.178, 179 
The addition of leucovorin was not much better in in a trial against pancreatic ductal 
adenocarcinoma. From a total of 26 patients, only 3 showed partial responses to a combination of 
PALA, 5-FU, and leucovorin (12%).180 Beyond 5-FU, PALA was investigated with DPM. This 
combination progressed to a phase I clinical trial, but only 4 of 65 patients responded to the 
therapy.181 An additional phase II study evaluating PALA and DPM for soft tissue sarcoma 
concluded that the combination was not better than PALA alone, which had previously failed to 
induce objective responses in clinical trials.182 Aside from PALA, a combination of acivicin and 
DPM has been evaluated in cancer patients diagnosed with a various types of tumors. However, 
this did not result in objective responses despite achieving plasma concentrations of DPM that 
were sufficient to inhibit nucleoside transport in vitro.183, 184   
The results from these clinical studies raise an important question. Why have inhibitors of 
pyrimidine biosynthesis, and in particular DHODH, been unsuccessful in clinical trials?  The 
existence of the salvage pathway may provide an explanation. 
Extracellular uridine can be transported across the cell membrane to enter the nucleotide 
salvage pathway. For brequinar, it was shown that a colon cancer cell line, colon 26, 
supplemented with 5 µM uridine was capable of continuing growth in the presence of 1 µM 
brequinar.175 The supplemented uridine may be transported across the cell membrane by either 
the solute carrier 29 family (equilibrative nucleoside transporter, ENT1-4), solute carrier 28 
family (concentrative nucleoside transporters, CNT1-3), or select members of the solute carrier 
35 family (Figure 1.12).185, 186 Once inside the cell, the uridine may be converted into uridine 
monophosphate by uridine kinase.187 This circumvents pyrimidine depletion induced by 
DHODH inhibition. Thus, an extensive network of salvage enzymes can generate the required 
nucleotides from extracellular sources of nucleobases/nucleosides to sustain cellular growth. 
However, it is unclear why combinations of DHODH inhibitors, such as brequinar, with DPM 
have been unsuccessful. DPM halts flux of nucleobases/nucleosides across the cell membrane by 
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targeting the ENT isoforms.185 While other nucleoside transporters are present, the ENT family 
is thought to be the predominant source of uridine flux across the membrane as most ENT 
isoforms catalyze facilitative diffusion and have a higher turnover rate in comparison to CNTs 
(ENT1 200 uridine/sec vs. CNT1 10 uridine/sec).185, 188 Despite the slower rate of transport, it is 
possible that the sodium or proton coupled CNT transport may be able to sustain the required 
intracellular nucleotide concentrations.185 The role of nucleoside transporters from the SLC35 
family is unknown. Select members of the large family transport UDP analogues across 
membranes. For example, the SLC35 family member UGT catalyzes the transport of UDP-
galactose and UDP-N-acetylgalactosamine across the membrane, but requires UMP as an 
antiport exchange substrate186 It is unclear if these transporters would be active in cells with low 
UMP concentrations.  For successful combination therapy, inhibitors of both CNT and ENT with 
DHODH inhibitors might be necessary. To date, this has not been evaluated.  
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Figure 1.12: Proposed compensatory resistance mechanism to DHODH inhibition. 
 
1.8 Future of DHODH-targeted therapy 
The future of DHODH targeted therapy in cancer lies in combination therapy. Despite the 
setbacks of brequinar in clinical trials, DHODH remains a viable anticancer target. The 
pyrimidine depletion induced by DHODH inhibition may sensitize cells to better outcomes with 
current chemotherapy options. In fact, a variety of studies have previously implicated DHODH 
inhibition as key to overcoming chemotherapy resistance.109, 189, 190  
DHODH inhibition sensitizes cancer cells to conventional chemotherapy by targeting 
their metabolic dependencies. Such inhibition has been demonstrated to overcome resistance 
mechanisms. A recent publication highlighted leflunomide as a key to overcoming chemotherapy 
resistance in triple-negative breast cancer cell lines.190 Triple-negative breast cancer cell lines 
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exposed to genotoxic agents increased flux through the de novo pyrimidine pathway, resulting in 
increased nucleotide concentrations to facilitate DNA repair. This decreases sensitivity to 
genotoxic agents. Pretreatment with leflunomide induced pyrimidine depletion in triple-negative 
breast cancer cells and genotoxic agents such as doxorubicin were able to inhibit cell growth.190 
Additionally, as previously described, brequinar increased cell sensitivity to TRAIL therapy.109 
Beyond doxorubicin and TRAIL, DHODH inhibitors have been shown to sensitize cells to DNA 
substrate mimics. When leflunomide and gemcitabine were used in combination, it had a more 
significant effect than single-agent dosing. Similar to combinations of brequinar and 5-FU, 
leflunomide-induced pyrimidine depletion may have led to a higher incorporation of 
gemcitabine.189 Similar combinations were evaluated in resistant cell lines such as teriflunomide 
with 5-azacytidine in 5-azacytidine-resistant leukemic cells,191  and leflunomide with fludarabine 
in a fludarabine-resistant chronic lymphocytic leukemia cell line.192 It is unclear if these 
combinations would have a similar effect clinically as brequinar and 5-FU. However, preclinical 
data suggests that DHODH-induced pyrimidine depletion may be used to overcome certain 
acquired resistance mechanisms.  
With the recent expanse of technology to evaluate synthetic lethality, new combinations 
with DHODH inhibitors may be uncovered.193 Synthetic lethality screening with DHODH may 
soon identify genes corresponding to druggable enzyme targets. For example, a synthetic 
lethality screening of the nucleotide salvage pathway may be utilized to identify enzymes that are 
synergistic with DHODH inhibition.  
Future DHODH-targeted therapy may be improved by identifying patient populations 
that are more likely to be sensitive to DHODH inhibition. The recent decrease in the cost of 
genomic profiling makes effective personalized medicine increasingly feasible and may be used 
to develop and test biomarkers that predict DHODH sensitivity. A variety of biomarkers have 
been observed including the mTORC1 enzyme. In fludarabine-resistant cells, mTORC1 is 
overexpressed, and these cells were surprisingly sensitive to both leflunomide and other 
inhibitors of the de novo pyrimidine pathway (PALA).194 A similar response was observed with 
inhibitors of de novo purine biosynthesis suggesting a potential dependence of cells expressing 
mTORC1 on de novo nucleotide biosynthesis pathways.195 An additional biomarker may be 
PTEN. Cell lines with mutant PTEN, a known hallmark of resistant prostate and breast cancer, 
were remarkably sensitive to both brequinar and leflunomide.51, 196 While the exact mechanism is 
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not well understood, it appears that PTEN regulates glutamine entry into the de novo pathway. 
The increased flux through the pathway may increase cell sensitivity to DHODH inhibition. 
While more data is needed, DHODH-targeted therapy may be more effective in cells expressing 
mTORC1 and/or mutant PTEN. 
DHODH-targeted therapy may also be better suited for non-solid tumors. Previous 
clinical trials focused primarily on solid tumors, which was met with minimal objective 
responses. Brequinar, for example, was never clinically evaluated in acute myeloid leukemia. As 
myelosuppression was a common side effect of brequinar therapy, DHODH inhibition may be 
more efficacious in patients with leukemia.101, 102 In fact, the extent of myelosuppression was 
enough to consider brequinar as a potential immunosuppressant.197-200 DHODH inhibition is well 
known to suppress the immune system as two FDA-approved DHODH inhibitors, 
leflunomide/teriflunomide, are for autoimmune diseases, such as rheumatoid arthritis.115 
Therefore, DHODH targeted therapy more be more effective in leukemia or other cancers with 
non-solid tumors. 
 
1.9 Conclusions 
DHODH is a promising anticancer target that alters cellular nucleotide concentrations. 
Inhibition of DHODH is pharmacologically relevant for a variety of diseases, including cancer. 
However, the impact of DHODH-induced cell inhibition is still not well understood. DHODH 
inhibition induces pyrimidine depletion and halts cell cycle progression at S-phase. Despite this, 
brequinar failed to achieve an objective response in multiple cancer clinical trials. Rather than 
single agent dosing, the future of DHODH inhibitors may lie in combination therapy. Brequinar 
and leflunomide have been observed to overcome resistance mechanisms for common 
chemotherapy agents. Additionally, brequinar-induced differentiation in AML and may be used 
to target cancer stem cells. Collectively, there is considerable optimism surrounding DHODH-
targeted therapy for cancer.  
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Chapter 2 
Identification of a Novel Dihydroorotate Dehydrogenase Inhibitor From Cell-Based 
Screeningb 
 
2.1 Introduction  
There is a perpetually unmet medical need for new and effective anticancer therapeutics, 
especially for pancreatic cancer. Due to poor diagnosis, pancreatic tumors are discovered in late 
stages and therapy regimes are centered around chemotherapy.1 Chemotherapy options for 
patients with metastatic pancreatic cancer are gemcitabine or combinations such as 
FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin).1-5 However, drug 
resistance and low response rates to these treatments limit patient survival.6-8 In fact, the 5-year 
survival rate of patients diagnosed with stage IV endocrine pancreatic cancer is 1%.9 To improve 
patient survival, new therapeutics must be developed, preferably with a novel mechanism of 
action.  
Our efforts towards developing a new anticancer drug focused on utilizing phenotypic 
screening. It is well known that drug discovery projects have high attrition rates and low 
probability of achieving FDA approval. A variety of factors have been suggested as a cause, 
including the use of target-based screening.10, 11 Target-based screening focuses on enzymatic 
inhibition or affinity to a recombinant protein rather than eliciting a desired cellular response. 
Often this approach identifies potent ligands for protein inhibition but the ligands may not elicit 
the desired cellular response. In contrast, the alternative phenotypic screening evaluates the 
ability of hit compounds to induce a desired cellular phenotype. A comparison between the two 
screening methods shows that phenotypic screening has led to a higher percentage of FDA 
approved drugs with a novel mechanism of action.11 In our program to identify novel scaffolds 
eliciting a desirable response against transformed cell lines, we utilized a phenotypic screen to 
identify lead compound 1 (Figure 2.1), which is structurally similar to brequinar (2, Figure 2.2) 
																																																								b	Author contributions: Joseph Madak designed, synthesized, and characterized all compounds. Shuzo Tamura and Christine Cuthbertson 
evaluated compounds in biochemical and cellular assays. Dr. Hollis Showalter and Dr. Nouri Neamati are corresponding authors.	
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Compound 1 elicits its cell growth inhibition through an unknown cellular target. To 
reach our ultimate goal of developing an anticancer clinical candidate, 1 must be optimized to 
display better drug-like properties. In particular, the potency and solubility must be improved 
(BxPC-3 IC50 = 13.9 ± 5.8 µM, MIA PaCA-2 IC50 = 18.8 ± 12 µM, cLogP = 6.49). However, 
cell-based evaluations present significant challenges to lead optimization campaigns. For 
example, the multitude of enzymatic targets makes structure-activity-relationship (SAR) studies 
difficult to attribute a cellular response to one enzyme. Furthermore, analogues with poor cell 
permeability may generate false negatives despite potent inhibition of an enzymatic target. To 
minimize these possibilities and expedite an optimization campaign, we sought to identify the 
enzymatic target of 1.  
We postulated that lead compound 1 targets the same enzymatic target as brequinar (2), a 
structurally similar compound that inhibits dihydroorotate dehydrogenase (Figure 2.2). To 
validate this hypothesis, we sought to establish the essential pharmacophore of 1 and compare it 
directly to brequinar’s SAR. Furthermore, we sought to identify if compound 1 is susceptible to 
the same resistance mechanisms as DHODH inhibitors. Finally, we evaluated compound 1 for 
activity in a DHODH assay.  
 
2.2 Phenotypic screen 
A phenotypic screen was utilized to identify compound 1. Nearly 2 million compounds 
from commercial sources were filtered based on their adherence to “drug-like” properties to 
generate the Neamati library.12, 13 Compounds in the Neamati library were evaluated for 
physiochemical properties, which included cLogP < 7, the presence of pan-interfering structures 
(PAINS), and adherence to a modified version of Lipinski’s rules.12, 13 Compounds (20,000) 
from the Neamati library were selected at random and evaluated for their ability to inhibit cancer 
cell growth in a panel of three cell lines: MIA PaCa-2 (pancreatic), BxPC-3 (pancreatic), and 
HFF-1 (non-transformed) (Figure 2.1). Initial analysis focused on cell growth inhibition in the 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and active 
compounds were further tested in a colony formation assay (CFA). Compounds with consistent 
activity in both the MTT and CFA assay were progressed further for evaluation of purity and the 
presence of structural alerts (primarily metabolic liabilities).14, 15 Only compound 1 met the 
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selection criteria. Due to the use of phenotypic screening, the enzymatic target of 1 was unknown 
and thus SAR studies had to be conducted to elucidate its primary pharmacophore.  
 
Figure 2.1: Flow diagram and criteria leading to compound 1 
 
2.3 Structural similarity  
Compound 1 contains a quinoline ring with an aryl-lipophilic attachment at the C2 
position and a carboxylic acid at the C4 position (Figure 2.2). Other known inhibitors with 
potential anticancer properties incorporate this core including brequinar (2)16, a P-selectin 
inhibitor (3)17, and a geminin-CDT complex inhibitor (4) (unpublished ChEMBL result).18 
These quinoline inhibitors possess distinct SAR trends that were previously published 
and may be useful toward assessing target similarity with 1 (Figure 2.2).  The potent 
dihydroorotate dehydrogenase (DHODH) inhibitor, brequinar (DHODH assay Ki = 27.4 ± 1.6 
nM), has a strict requirement for the C4 carboxylic acid to form an interaction with Arg136.19, 20 
In fact, the ethyl ester analogue is significantly less potent than brequinar (DHODH assay Ki = 
MTT Assay 
CFA Assay 
Purity Analysis 
20,000 Compounds 
IC50 < 30 µM 
IC50 < 30 µM  
> 95% purity 
Lead Compound (1) 
BxPC-3 IC50 = 13.9 ± 5.8 µM 
MIA PaCa-2 IC50 = 18.8 ± 12 µM 
MW = 331.42 
cLogP = 6.49 
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74,800 ± 10,800 µM).19 Additionally, only large lipophilic functional groups were tolerated at 
the C2 position, primarily 1,4 biaryl attachments. In contrast, the P-selectin inhibitor 3 (Cell-flow 
assay IC50  = 4.5 µM, DHODH assay IC50 = 26 µM) does not tolerate large biaryl attachments at 
the C2 position.17 However, a dependence upon the carboxylic acid was also observed. While the 
authors did not evaluate anticancer activity for 3, we were aware of previous studies that suggest 
P-selectin as an anticancer target.21 Additionally, an unpublished ChEMBL finding reported 4 as 
an inhibitor of the geminin-CDT complex. Compound 4 possesses a quinoline core similar to 1 
but incorporates an amide moiety. While SAR trends were not disclosed, geminin is a known 
anticancer target.22 A collective comparison of the SAR trends for compound 1 and these related 
scaffolds may reveal if 1 targets any of these enzymes.  
 
 
Figure 2.2: Structurally similar quinolines and their SAR trends. Molecular weight and cLogP predicted using 
Chemdraw Professional 16.0 software.  
 
2.4 Synthesis   
To explore the basic pharmacophore of 1 through robust SAR, it was necessary to 
develop a novel synthetic route to access a library of derivatives. As compound 1 is primarily 
aromatic and contains few heteroatoms, palladium catalysis was utilized to introduce diversity 
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through carbon-carbon bond coupling. Towards this aim, a halogenated starting material must be 
synthesized in large quantities as a suitable coupling partner. Initial efforts focused on 
chlorination of the 2-hydroxyl of commercially available 2-hydroxyquinoline-4-carboxylic acid 
(38, Scheme 2.1), which would provide a suitable starting material for Suzuki coupling to 
quickly introduce diversity. However, initial approaches to generate the halogenated C2 position 
resulted in low yields, presumably due to the presence of the carboxylic acid. A Fischer 
esterification protocol, similar to Yang et al., was utilized to install a methyl ester-protecting 
group at the C4 position, giving 39 in 88%.23 With the ester in hand, a modified version of 
Donohoe et al.’s Vilsmeier chlorination protocol was utilized to generate the chlorinated 
intermediate 40 in a 91% yield.24 The adjacent nitrogen improved the reactivity of the C2 
chlorine for Suzuki coupling, which was accomplished in yields ranging from 22-91%. Once the 
diverse substituents had been installed, the methyl ester was readily hydrolyzed with NaOH (6- 
78%). While this synthetic scheme worked well, the limited commercial availability of phenyl 
substituted boronic acids diminished its usefulness toward installing diverse chemical moieties. 
To explore a greater range of chemical diversity, a new protocol was developed.  
 
Scheme 2.1: Synthesis of R1 substituted quinolines.  
 
To cover additional chemical space, a new synthetic route was pursued that focused on 
the generation of a quinoline scaffold (43) with a p-bromo phenyl substituent off the C2 position 
(Scheme 2.2). This allows for a Suzuki coupling with a variety of commercially available 
boronic acids (Scheme 2.2, i.e. 26, 33, 35). This route incorporates the phenyl ring early on and 
expands the possible chemical space around its para-position. However, working out full details 
of the route presented significant challenges. Direct Suzuki coupling between chloroquinoline 40 
and 4-bromobenzene boronic acid was unsuccessful and produced many side products. The 
hypothesized problem was deemed to be the order of reactivity, as palladium inserts better into 
carbon-bromide bonds than carbon-chloride bonds.25 The lower chloro reactivity of 40 presented 
a significant hurdle that a variety of palladium catalysts, bases, and solvent conditions could not 
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overcome. An alternate solution to this problem focused on generating a C2 triflate of 39 for 
direct Suzuki coupling with 4-bromobenzene boronic acid. This was unsuccessful, directing our 
attention towards utilizing a Vilsmeier-bromination protocol. With this, intermediate 41 was 
reproducibly generated in high yields (80%). The nitrogen adjacent to the C2-bromine bond on 
41 decreases the activation energy for palladium insertion and presents a better coupling partner 
for selective reaction onto the boron-bearing carbon of 4-bromobenzene boronic acid. Under 
precise temperature control 43 was generated in high yields. With this in hand, a variety of 
commercially available boronic acids were coupled to yield ester intermediates, which were 
readily hydrolyzed to generate acid analogues.  
 
Scheme 2.2: Improved synthesis of R1 substituted quinolines. 
 
 In addition to analogues derived from Suzuki couplings, analogues derived via 
Buchwald-Hartwig coupling were evaluated. Such an attempt to make 26 was unsuccessful 
(Scheme 2.3). An alternative approach to derive amine-substituted analogues focused on first 
generating the quinoline ring using the Pfitzinger reactions in which the desired R1 substituent 
would be incorporated into the acetophenone coupling partner (Scheme 2.4). This route yielded 
carboxylic acid analogues directly and eliminated the need for ester hydrolysis. However, this 
approach is limited to reagents that can tolerate the harsh basic conditions and high temperatures. 
Furthermore, our carboxylic acid analogues presented significant purification difficulties, as they 
were not amenable to silica gel chromatography.  
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Scheme 2.3: Synthesis of morpholino analogue.  
 
 
Scheme 2.4: Alternative synthesis of R1 substituted quinolines.  
 
 Additional efforts were made to evaluate amine-containing analogues at the C4 position 
(Scheme 2.5). An analogue (36) containing the same amide functional group as 4 was generated 
from 32 using a modified acid chloride protocol.26 A tetrazole analogue (37) was made using a 
single pot 3-step reaction protocol. Refluxing 32 in methanolic ammonia generated the 
corresponding amide, which was converted to a nitrile with neat POCl3 utilizating a modified 
protocol of Borkin et al.27 Tetrazole formation followed upon exposure of the nitrile intermediate 
to sodium azide at high temperatures in DMF, which was a modified protocol of Lassig et al.28 
and successfully generated 37 in a 13% overall yield.  
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Scheme 2.5: Synthesis of quinoline amide analogues 
 
 
2.5 Structure activity relationships 
To assess the essential pharmacophore required for activity, a cell-based SAR campaign 
was pursued. Cellular activity was measured using MTT assays in BxPC-3 and MiaPaca-2 
pancreatic cancer cell lines. BxPC-3 contains wild-type KRAS (define KRAS) whereas 
MiaPaca-2 contains mutant KRAS. A comparison between the two cell lines may indicate if the 
lead compound targets an enzyme associated with the KRAS pathway. Evaluation of toxicity in 
the "non-cancerous" HFF-1 cell line provided selectivity assessment and helped to ascertain an 
analogue's toxicity. We were aware that these compounds contained a relatively planar structure 
and possessed a high cLogP. Both of these properties may lead to non-specific molecular 
aggregation, so we sought to minimize that risk by limiting the maximum dose evaluated in cells 
to 30 µM.  
Removal of the cyclohexyl ring of 1 to give analogue 6 did not cause a significant 
reduction in potency in HCT-116 (Table 2.1). However, in MIA PaCa-2 6 did not inhibit cell 
growth within our screening limits. It is possible that despite their structural similarity, 1 and 6 
may target different enzymes. The methyl ester analogue of 6 did not have activity in any cell 
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line (5, Table 2.1). When R1 was replaced with furans (7, 8), thiophene (9), or napthylenes (10-
13) no cell growth inhibition was observed at the screening limit (30 µM). Collectively these 
trends suggest that the phenyl ring is the best tolerated at the C2 position.  
Table 2.1 Biological activity of quinoline analogues with selected aromatic R1 substituents. 
 
 
   MTT Assay 
# R1 R2 
BxPC-3  
IC50 (µM) 
MIA PaCa-2  
IC50 (µM) 
HFF-1  
IC50 (µM) 
1 
 
CO2H 13.9 ± 5.8 18.8 ± 12  >30 
5 
 
CO2Me >30 >30 >30 
6 
 
CO2H 12.1 ± 13.9 >30 >30 
7 
 
CO2Me >30 >30 >30 
8 
 
CO2H >30 >30 >30 
9 
 
CO2H >30 >30 >30 
10 
 
CO2Me >30 >30 >30 
11 
 
CO2H >30 >30 >30 
12 
 
CO2Me >30 >30 >30 
13 
 
CO2H >30 >30 >30 
O
O
S
N R1
R2
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Our focus shifted towards substituents on the phenyl ring to further probe the binding 
site. Small attachments on the phenyl ring did not induce cell growth inhibition at or below our 
defined detection limit.  Single substituents like Br (14), methoxy (19-22), isobutyl (17), and 
isopropyl (18) were not well tolerated (Table 2.2). There were no observed differences between 
meta (21, 22) or para (19, 20) methoxy substituents. Furthermore, due to our screening 
concentrations, no significant difference was observed between these ester and acid analogues. 
However, higher concentrations were not evaluated as they increase the likelihood of false 
positives from aggregation. The biological results of analogues 5-22 suggest that larger lipophilic 
groups similar to those of 1 may be required at the C2 position of the quinoline ring. The SAR 
study on the P-selectin inhibitor (3) found that large lipophilic groups are not well tolerated at 
this position.17 This differs from brequinar’s (2) SAR that favors biaryl attachments at the C2 of 
the quinoline ring.19 Thus, our efforts shifted towards incorporating large lipophilic groups 
similar to brequinar.  
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Table 2.2 Biological activity of quinoline analogues with selected R1 substituents. 
 
 
   MTT Assay 
#           R1 R2 
BxPC-3  
IC50 (µM) 
MIA PaCa-2  
IC50 (µM) 
HFF-1  
IC50 (µM) 
14 
 
CO2H >30 >30 >30 
15 
 
CO2Me >30 >30 >30 
16 
 
CO2Me >30 >30 >30 
17 
 
CO2H >30 >30 >30 
18 
 
CO2H >30 >30 >30 
19 
 
CO2Me >30 >30 >30 
20 
 
CO2H >30 >30 >30 
21 
 
CO2Me >30 >30 >30 
22 
 
CO2H >30 >30 >30 
 
 
The incorporation of select large substituents off the C2 position of the quinoline ring 
resulted in analogues more potent than lead compound 1.  In the case of 1, the methyl ester 
analogue (23) did not inhibit cell growth in any cell line (Table 2.3). This comparison suggests 
Br
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the carboxylic acid is essential for activity. Replacement of the cyclohexyl group with similar 
bioisosteres were not tolerated. Methyl ester and carboxylic acid derivatives incorporating 
piperidine (24, 25) and morphlino (26, 27) groups in place of the cyclohexyl were inactive. 
However, potency was improved by replacing the cyclohexyl with a phenyl group. Both the 
carboxylic acid (28) and methyl ester (29) biphenyl analogues were potent. In fact, 28 had a 
lower IC50 than the lead compound. The comparison between 28 and 1 suggests that a terminal 
phenyl ring may occupy the binding pocket of its enzymatic target better than the cyclohexyl 
ring. Additionally, the results from 28 and 29 suggest that the carboxylic acid may be necessary 
to maintain interactions in the binding pocket. The potency observed for 29 can be rationalized 
by assuming an esterase within the cell hydrolyzes 29 to 28. However, more studies are needed 
to support this hypothesis. While biphenyl analogue 28 appears to be more potent than 1, we 
were concerned about non-specific aggregation giving a false positive readout. A highly 
conjugated system of aromatic rings, similar to 28, may have a flat 3D structure and be more 
susceptible to forming self-association interactions in aqueous solution.29 This molecular 
aggregation may cause non-specific cell growth inhibition. To explore this possibility, we 
focused on the generation of biaryl regioisomers, which would have similar physiochemical 
properties (Table 2.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 63	
 
Table 2.3 Biological activity of quinoline analogues with cyclic R1 substituents.	
 
 
   MTT Assay 
# R1 R2 
BxPC-3 
IC50 (µM) 
MIA PaCa-2 
IC50 (µM) 
HFF-1 
IC50 (µM) 
23 
 
CO2Me >30 >30 >30 
24 
 
CO2Me >30 >30 >30 
25 
 
CO2H >30 >30 >30 
26 
 
CO2Me >30 >30 >30 
27 
 
CO2H >30 >30 >30 
28 
 
CO2H 5.4 ± 7.4 16.2 ± 14 >30 
29 
 
CO2Me 18.2 ± 3.2 27.9 ± 15 >30 
	
The potency of analogues with a biaryl substituent appears to be dependent upon the  
connectivity pattern with 1,4 being optimal. Table 2.4 highlights a biaryl isomer of 28 and 29 
with 1,3 connectivity (30, 31). The inactivity of both the biaryl ester (31) and acid (30) suggests 
that the potential enzyme interaction seen for 28 and 29 is real and not an aggregation effect. 
N
N
N
O
N
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Furthermore, these results suggest a biaryl attachment is well suited for this compound series, 
which is similar to the SAR trends observed for brequinar. Further observations from the 
brequinar SAR suggest that the C2 position occupies a very hydrophobic pocket and does not 
tolerate hydrophilic groups. Analogues 24-27 correlate well with this trend.  Additional 
analogues containing heteroatom bioisosteres were evaluated. Incorporation of a pyridine ring 
(Table 2.5) was not well tolerated (32, 34, 35). Analogue 33 did have some activity in MIA 
PaCa-2 cell lines but not  in BxPC-3 and thus may indicate a different enzyme target than for 
lead compound 1.  
 
Table 2.4: Biological activity of quinolines analogues with 1,3 biaryl regioisomers. 
 
 
   MTT Assay 
#               R1 R2 
BxPC-3  
IC50 (µM) 
MiaPaca-2  
IC50 (µM) 
HFF-1  
IC50 (µM) 
30 
 
CO2H >30 >30 >30 
31 
 
CO2Me >30 >30 >30 
 									
N R1
R2
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 Table 2.5 Biological activity of quinolines analogues with R1 phenyl bioisosteres   
 
 
   MTT Assay 
#               R1 R2 
BxPC-3  
IC50 (µM) 
MIA PaCa-2  
IC50 (µM) 
HFF-1  
IC50 (µM) 
32 
 
CO2H >30 >30 >30 
33 
 
CO2Me >30 8.10 ± 4.0 >30 
34 
 
CO2H >30 >30 >30 
35 
 
CO2Me >30 >30 >30 
 
Additionally, to assess potential similarity with the geminin-CDT inhibitor (4), we 
incorporated its amide moiety into 32. The goal was to determine if an amide containing 
compound similar to 4 would be more potent than 1. Table 2.6 shows that the amide congener of 
the geminin inhibitor (36) possessed some cytotoxicity in BxPC-3. However, the margin of error 
was significant and not consistently below our cutoff concentration. A tetrazole bioisostere 
congener of 36 did not inhibit cell growth inhibition in MIA PaCa-2 cell lines. These limited 
results highlight the necessity of the carboxylic acid substituent for activity.  
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Table 2.6: Biological activity of amide quinoline analogues with modified acid functionality	
 
 
  MTT Assay 
#           R2 
BxPC-3  
IC50 (µM) 
MIA PaCa-2  
IC50 (µM) 
HFF-1  
IC50 (µM) 
36 
 
23.0 ±13.6 >30 >30 
37 
 
- >30 - 
	
Collectively, the pharmacophore study highlighted the type of substituents necessary at 
the C2 and C4 positions of the quinoline ring. At the C2 position, large biaryl substituents with 
the 1,4 connectivity contributed most to potency. C4 carboxylic acids were the most potent but 
the amide congener of 4 was not tolerated. These SAR trends matched those observed for 
brequinar and suggested that DHODH may be a potential enzymatic target of compound 1. 
Beyond further pharmacophore studies, our efforts shifted towards evaluating compound 1 in 
additional cell lines.  
 
2.6 Expanded cell activity and DHODH overexpression 
Our attention turned to evaluating cell growth inhibition of compound 1 in additional 
cancer cell lines. Despite initial evaluation in pancreatic cancer cell lines, we were interested in 
testing our inhibitors for efficacy in additional cell lines. Gratifyingly, 1 was observed to possess 
an IC50 = 7.4 ± 1.5 µM in HCT-116 (colon cancer) which is more potent than that observed in the 
pancreatic BxPC-3 cell line (IC50 = 13.9 ± 5.8 µM) (Table 2.7). This is a similar pattern to 
brequinar, which was more potent in HCT-116 (IC50 = 0.98 ± 0.52 µM) vs MiaPaca-2 (IC50 = 7.4 
± 2.3 µM). The expression levels of DHODH in these cell lines may provide a rationale for this 
phenomenon. HCT-116 is a colon cancer cell line and data from the Oncomine database suggest 
that DHODH is significantly overexpressed in colon cancer (Figure 2.3).30 In fact, colon cancer 
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appears to have a higher expression of DHODH than pancreatic cancer. The protein expression 
of DHODH accounts for brequinar’s improved potency in HCT-116 and may explain lead 
compound 1’s potency improvement. This further links lead compound 1 with DHODH 
inhibition. Thus, we postulated that if 1 inhibits DHODH, it should be susceptible to the same 
resistance mechanisms as brequinar.  
 
Table 2.7: Expanded cell activity of lead compound 1, green = > 50% inhibition, red = <50% inhibition	
Compound 1 BxPC-3 MIAPaCa-2 OVCAR8 NCI/ADR-Res HCT-116  
p53 +/+ 
HCT-116  
p53 -/- 
NU04 U87Mg HT29 
 
30	μM	 	 	 	 	 	 	 	 	 	
10	μM	 	 	 	 	 	 	 	 	 		
 
 
Figure 2.3: Overexpression (red) and underexpression (blue) comparison between normal and cancerous cell 
lines. Data generated from the Oncomine platform using all databases.30  
 
2.7 Uridine rescue 
Supplementation of cells with uridine overcomes growth inhibition induced by DHODH 
inhibitors.31-33 Brequinar depletes intracellular pyrimidine-based nucleotide concentrations by 
halting flux through de novo pyrimidine biosynthesis. Cellular salvage pathways utilize 
extracellular sources of uridine to restore nucleotide concentrations. If compound 1 is an 
inhibitor of DHODH, uridine should rescue cells from its induced cell growth inhibition.   
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Figure 2.4: Uridine supplementation rescues cells from lead compound 1. HCT-116 cells, 3,000 c/w, 72 hours 
MTT assay. 10 µM of compounds used for dosing.  
Uridine rescues HCT-116 cells from growth inhibition by brequinar and compound 1 
(Figure 2.4). In HCT-116, both compound 1 and brequinar induced a greater than 50% cell 
growth inhibition at 10 µM. However, this response was not observed for cells supplemented 
with uridine. In fact, neither 1 nor brequinar was able to generate >50% cell growth inhibition in 
the presence of uridine. These results were consistent with previous uridine rescue experiments 
performed on brequinar.33, 34 Furthermore, these results implicate that lead compound 1 may 
target an enzyme within the de novo pyrimidine pathway as its ability to induce cell growth 
inhibition is sensitive to uridine supplementation. Considering the structural similarity of 1 to 
brequinar, it is likely that lead compound 1 is an inhibitor of DHODH. To augment this 
argument, we evaluated our most potent compounds in a known DHODH absorbance based 
assay.35 
 
2.8 DHODH Activity 
To determine if lead compound 1 directly inhibits DHODH, an absorbance-based 
DHODH assay was utilized. DHODH catalyzes the oxidation of dihydroorotate to orotate, which 
is coupled to the reduction/oxidation of flavin mononucleotide and ubiquinone.36, 37 During 
1 Brequinar 
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DHODH catalysis, the flavin mononucleotide cofactor is reduced by dihydroorotate. This co-
factor is re-oxidized by ubiquinone, and the oxidation state of ubiquinone can be monitored 
using the 2,6-dichlorophenolindophenol (DCIP) redox dye.36 Using this assay, the IC50 values of 
both compounds 1 and 28 were determined to be below 1 µM for DHODH (Table 2.8). In fact, 
both compounds 1 (IC50 = 0.35 ± 0.07 µM) and 28 (IC50 = 0.16 ± 0.09 µM) are quite potent for 
inhibition of DHODH. These results strengthen our claim of DHODH inhibition as a primary 
mechanism of action.  
 
Table 2.8: Biological data for active compounds in comparison to brequinar. 
Compound DHODH IC50 (µM) HCT-116 IC50 (µM) MiaPaca-2 (µM) 
1 0.35 ± 0.07 7.4 ± 1.50 18.8 ± 12 
28 0.16 ± 0.09 1.10 ± 1.0 16.2 ± 14 
Brequinar 0.02 ± 0.02 0.98 ± 0.52 7.4 ± 2.3 
 
2.9 Conclusion 
Collectively, the data suggests that compound 1 is a potent DHODH inhibitor. 
Pharmacophore studies on 1 showed SAR trends similar to brequinar’s. Furthermore, compounds 
1 and 28 are most potent in cell lines overexpressing DHODH and uridine supplementation was 
able to rescue cells from 1 and brequinar’s cytotoxicity. Finally, compound 1 was discovered to 
be a potent inhibitor of DHODH (IC50 = 0.35 ± 0.07 M). These results will significantly 
expedite lead optimization studies with future studies will focused on developing a more potent 
DHODH inhibitor.  
 
2.10 Experimental 
 
General methods. Reactions were performed in oven dried glassware under an inert atmosphere, 
under nitrogen or argon. Reagents and solvents were purchased from commercial sources and 
used without further purification. Reaction progress was monitored using analytical thin-layer 
chromatography (TLC) on aluminum-backed pre-coated silica plates (Silicycle, SiliaPlate 200 
µM thickness, F254) and visualized by UV absorbance. Silica chromatography purifications were 
performed using Siliaflash® P60 (40 – 63 µM, 230 – 400 mesh). 1H NMR spectra were obtained 
using a Bruker (300 or 400 MHz) or a Varian (400 or 500 MHz).  Chemicals shifts are reported 
in ppm and calibrated based on known solvent peaks (1H using CDCl3 = 7.26 ppm, MeOD = 
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3.31 ppm, DMSO, 2.50 ppm; 13C using CDCl3 = 77.16 ppm, MeOD = 49.00 ppm, DMSO, 39.52 
ppm).38 Spectral data was reported using the following abbreviations: (s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet, dd = doublet of doublets), coupling constants are reported in 
Hz, followed by integration. 13C NMR spectra were obtained at 126 MHz on a Varian 500 MHz 
instrument with a proton decoupled probe. Data from MS spectrometry and HPLC traces were 
obtained using a Shimadzu LCMS 20-20 system, which was equipped with a photo diode UV 
detector and a Kinetex® 2.6 µm, XB-C18 100 Å, 75 x 4.6 mm column. HPLC traces were 
obtained at room temperature using a gradient method from 1% to 90% MeCN in H2O with 
0.01% formic acid over 20 minutes. The flow rate was 0.50 mL/min.39 Reverse phase 
preparatory chromatography was performed on a Shimdazu HPLC LC-20 system. The Shimdazu 
HPLC utilized a PDA detector and was equipped with a Kinetex® 5 µm XB-C18 100 Å, 150 x 
21.2 mm column. The gradient method utilized was 10% to 90% MeCN with 0.05% 
trifluoroacetic acid over a 25 minute time period.  
 
Synthesis. 
Methyl 2-hydroxyquinoline-4-carboxylate (39): 2-Hydroxyquinoline-4-
carboxylic acid (1.0 g, 5.3 mmol) was dissolved in 18 mL of anhydrous MeOH. A catalytic 
amount of H2SO4 (≈16 drops) was added to the solution and the mixture was heated at reflux for 
18 hours. Upon completion, the mixture was cooled to room temperature for 20 minutes, filtered 
over a fritted funnel, and triturated with deionized H2O and cold MeOH. The precipitant was 
dried overnight in a vacuum oven to yield methyl 2-hydroxyquinoline-4-carboxylate (955 mg, 
4.7 mmol, 88% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.11 – 8.00 (m, 1H), 7.64 – 7.53 (m, 
1H), 7.38 (d, J = 8.2 Hz, 1H), 7.32 – 7.18 (m, 1H), 6.91 (s, 1H), 3.93 (s, 3H). MS (ESI) 204..0 
[M+H]+.  
 
Methyl 2-chloroquinoline-4-carboxylate (40): Dimethylformamide (1.67 mL, 
21.35 mmol) was added to a round bottom flask containing 8 mL of 1,2 dichloroethane at 0 °C. 
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POCl3 (2 mL, 21.35 mmol) was added dropwise to the chilled solution and the mixture was 
stirred at 0 °C for 15 minutes before warming to room temperature. After 15 minutes at room 
temperature, methyl 2-hydroxyquinoline-4-carboxylate (955 mg, 4.70 mmol) was added and the 
mixture was heated to reflux for 2 hours, until starting material was no longer observed. Upon 
completion, the solution was cooled to room temperature, poured into a solution of DCM, and 
washed 6x with brine. The organic layer was dried with MgSO4, concentrated, and purified using 
silica chromatography (Hex/EtOAc gradient towards 1:1) to yield methyl 2-chloroquinoline-4-
carboxylate (951 mg, 4.30 mmol, 91% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.75 (dd, J 
= 8.6, 1.3 Hz, 1H), 8.10 (dd, J = 8.5, 1.3 Hz, 1H), 7.93 (s, 1H), 7.81 (t, J = 7.7 Hz, 1H), 7.74 – 
7.63 (m, 1H), 4.07 (d, J = 0.7 Hz, 3H). MS (ESI) 222.0 [M+H]+.  
 
Methyl 2-bromoquinoline-4-carboxylate (41): Dimethylformamide (0.5 mL, 
5.91 mmol) was added to a round bottom flask containing 4 mL of 1,2 dichloroethane at 0 °C. 
POBr3 (1.33 g, 4.92 mmol) was added slowly to the chilled solution and the mixture was stirred 
at 0 °C for 15 minutes before warming to room temperature. After 15 minutes at room 
temperature, methyl 2-hydroxyquinoline-4-carboxylate (400 mg, 1.97 mmol) was added and the 
mixture was heated to reflux for 2 hours, until starting material was no longer observed. Upon 
completion, the solution was cooled to room temperature, poured into a solution of DCM, and 
washed 6x with brine. The organic layer was dried, concentrated, and purified using silica 
chromatography (Hex/EtOAc gradient towards 1:1) to yield methyl 2-bromoquinoline-4-
carboxylate (417 mg, 1.57 mmol, 80% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.73 – 8.65 
(m, 1H), 8.07 – 7.96 (m, 1H), 7.86 (s, 1H), 7.80 – 7.71 (m, 1H), 7.67 – 7.56 (m, 1H), 4.02 (s, 
3H). MS (ESI) 265.7 [M+H]+.  
 
General Procedure for Suzuki couplings: A round bottom flask containing halogenated 
starting material (1 eq) and boronic acid (1.6 eq) was dissolved in a 2:1:1 degassed solution of 
toluene:EtOH:H2O (≈0.1 M of halogenated starting material). K2CO3 (5 eq) and Pd(PPh3)4 (5% 
mol) were added to the solution and the mixture was heated to reflux overnight. Upon 
completion, the mixture was cooled to room temperature, added to a solution of ethyl acetate, 
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and washed with H2O (1x) and brine (2x). The organic layer was dried with MgSO4, filtered, and 
purified via silica chromatography using a variety of gradients of Hex/EtOAc. 
 
Methyl 2-phenylquinoline-4-carboxylate (5): Methyl 2-chloroquinoline-4-
carboxylate (50 mg, 0.23 mmol), phenyl-boronic acid (33 mg, 0.27 mmol), Pd(PPh3)4 (10 mg), 
and K2CO3 (163 mg, 1.18 mmol) were combined in a round bottom flask and subjected to the 
conditions described in the general Suzuki coupling protocol. Methyl 2-phenylquinoline-4-
carboxylate (56 mg, 0.21 mmol, 91% yield) was recovered following purification from silica 
chromatography (Hex/EtOAc 2:1 gradient).1H NMR (300 MHz, Chloroform-d) δ 8.82 – 8.74 
(m, 1H), 8.43 (s, 1H), 8.29 – 8.19 (m, 3H), 7.84 – 7.74 (m, 1H), 7.69 – 7.62 (m, 1H), 7.61 – 7.47 
(m, 3H), 4.10 (s, 3H); LCMS (ESI) 264.8 [M+H]+; HPLC Purity at 254 nm, 98.4% 
 
Methyl 2-(furan-2-yl)quinoline-4-carboxylate (7): Methyl 2-
chloroquinoline-4-carboxylate (95 mg, 0.43 mmol), furan-2-ylboronic acid (58 mg, 0.52 mmol), 
Pd(PPh3)4 (34 mg), and K2CO3 (297 mg, 2.15 mmol) were combined in a round bottom flask and 
subjected to the conditions described in the general Suzuki coupling protocol. Methyl 2-(furan-2-
yl)quinoline-4-carboxylate (27 mg, 0.11 mmol, 26% yield) was recovered following purification 
from silica chromatography (Hex/EtOAc 9:1 gradient).1H NMR (300 MHz, Chloroform-d) δ 
8.75 – 8.69 (m, 1H), 8.34 (s, 1H), 8.22 – 8.15 (m, 1H), 7.76 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.68 
– 7.57 (m, 3H), 6.62 (dd, J = 3.5, 1.8 Hz, 1H), 4.08 (s, 3H); LCMS [ESI] 254.0 [M+H]+; HPLC 
Purity at 254 nm, 99.1% 
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Methyl 2-(naphthalen-2-yl)quinoline-4-carboxylate (10): Methyl 2-
chloroquinoline-4-carboxylate (95 mg, 0.43 mmol), naphthalen-2-ylboronic acid (118 mg, 0.69 
mmol), Pd(PPh3)4 (15 mg), and K2CO3 (297 mg, 2.15 mmol) were combined in a round bottom 
flask and subjected to the conditions described in the general Suzuki coupling protocol. Methyl 
2-(naphthalen-2-yl)quinoline-4-carboxylate (91 mg, 0.29 mmol, 67% yield) was recovered 
following purification from silica chromatography (Hex/EtOAc 9:1 gradient).1H NMR (300 
MHz, Chloroform-d) δ 8.79 (d, J = 8.6 Hz, 1H), 8.69 (s, 1H), 8.60 (s, 1H), 8.47 – 8.40 (m, 1H), 
8.31 (d, J = 8.5 Hz, 1H), 8.08 – 8.01 (m, 2H), 7.95 – 7.89 (m, 1H), 7.83 (t, J = 7.7 Hz, 1H), 7.67 
(t, J = 7.7 Hz, 1H), 7.61 – 7.53 (m, 2H), 4.14 (s, 3H); LCMS (ESI) 314.1 [M+H]+; HPLC Purity 
at 254 nm, 95.0% 
 
Methyl 2-(naphthalen-1-yl)quinoline-4-carboxylate (12): Methyl 2-
chloroquinoline-4-carboxylate (95 mg, 0.43 mmol), naphthalen-1-ylboronic acid (118 mg, 0.69 
mmol), Pd(PPh3)4 (15 mg), and K2CO3 (297 mg, 2.15 mmol) were combined in a round bottom 
flask and subjected to the conditions described in the general Suzuki coupling protocol. Methyl 
2-(naphthalen-1-yl)quinoline-4-carboxylate (81 mg, 0.26 mmol, 60% yield) was recovered 
following purification from silica chromatography (Hex/EtOAc 9:1 gradient).1H NMR (300 
MHz, Chloroform-d) δ 8.91 – 8.84 (m, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.27 (s, 1H), 8.18 – 8.10 
(m, 1H), 8.04 – 7.95 (m, 2H), 7.89 – 7.82 (m, 1H), 7.80 – 7.71 (m, 2H), 7.68 – 7.60 (m, 1H), 
7.61 – 7.49 (m, 2H), 4.07 (s, 3H); LCMS (ESI) 314.1 [M+H]+;HPLC Purity at 254 nm, 97.8% 
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 Methyl 2-(4-(2-acetamidoethyl)phenyl)quinoline-4-
carboxylate (15): Methyl 2-chloroquinoline-4-carboxylate (44 mg, 0.20 mmol), (4-(2-
acetamidoethyl)phenyl)boronic acid (50 mg, 0.24 mmol), Pd(PPh3)4 (10 mg), and K2CO3 (163 
mg, 1.18 mmol) were combined in a round bottom flask and subjected to the conditions 
described in the general Suzuki coupling protocol. Methyl 2-(4-(2-
acetamidoethyl)phenyl)quinoline-4-carboxylate (49 mg, 0.14 mmol, 70% yield) was recovered 
following purification from silica chromatography (Hex/EtOAc 9:1 gradient).1H NMR (300 
MHz, Chloroform-d) δ 8.77 (d, J = 8.5 Hz, 1H), 8.41 (s, 1H), 8.26 (d, J = 8.5 Hz, 1H), 8.17 (d, J 
= 8.0 Hz, 2H), 7.81 (t, J = 7.6 Hz, 1H), 7.72 – 7.62 (m, 1H), 7.40 (d, J = 7.9 Hz, 2H), 4.11 (s, 
3H), 3.66 – 3.54 (m, 2H), 2.94 (t, J = 6.8 Hz, 2H), 1.99 (s, 3H); LCMS (ESI) 349.2 [M+H]+; 
HPLC Purity at 254 nm, 96.9%. 
 
Methyl 2-(4-(2-morpholinoethoxy)phenyl)quinoline-4-
carboxylate (16): Methyl 2-chloroquinoline-4-carboxylate (52 mg, 0.24 mmol), (4-(2-
morpholinoethoxy)phenyl)boronic acid (75 mg, 0.26 mmol), Pd(PPh3)4 (10 mg), and K2CO3 (164 
mg, 1.19 mmol) were combined in a round bottom flask and subjected to the conditions 
described in the general Suzuki coupling protocol. Methyl 2-(4-(2-
morpholinoethoxy)phenyl)quinoline-4-carboxylate (74 mg, 0.18 mmol, 75% yield) was 
recovered following purification from silica chromatography (Hex/EtOAc 9:1 gradient). 1H 
NMR (300 MHz, Chloroform-d) δ 8.78 – 8.70 (m, 1H), 8.36 (s, 1H), 8.26 (d, J = 8.4 Hz, 1H), 
8.18 (d, J = 8.6 Hz, 2H), 7.86 – 7.77 (m, 1H), 7.70 – 7.60 (m, 1H), 7.05 (d, J = 8.6 Hz, 2H), 4.54 
– 4.47 (m, 2H), 4.10 (s, 3H), 4.03 (t, J = 4.8 Hz, 4H), 3.78 – 3.60 (m, 2H), 3.59 – 3.52 (m, 2H), 
3.19 – 3.01 (m, 2H); LCMS (ESI) 393.2 [M+H]+; HPLC Purity at 254 nm, 98.8%.  
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Methyl 2-(4-methoxyphenyl)quinoline-4-carboxylate (19): Methyl 2-
(3-methoxyphenyl)quinoline-4-carboxylate (32 mg, 0.15 mmol), (4-methoxyphenyl)boronic acid 
(26 mg, 0.17 mmol), Pd(PPh3)4 (9 mg), and K2CO3 (100 mg, 0.73 mmol) were combined in a 
round bottom flask and subjected to the conditions described in the general Suzuki coupling 
protocol. Methyl 2-(4-methoxyphenyl)quinoline-4-carboxylate (10 mg, 0.03 mmol, 23% yield) 
was recovered following purification from silica chromatography (Hex/EtOAc 9:1 gradient). 1H 
NMR (300 MHz, Chloroform-d) δ 8.73 (d, J = 8.5 Hz, 1H), 8.37 (s, 1H), 8.25 – 8.14 (m, 3H), 
7.84 – 7.73 (m, 1H), 7.65 – 7.55 (m, 1H), 7.12 – 7.02 (m, 2H), 4.08 (s, 3H), 3.90 (s, 3H); LCMS 
(ESI) 294.0 [M+H]+; HPLC Purity at 254 nm, 99.2%.  
Methyl 2-(3-methoxyphenyl)quinoline-4-carboxylate (21): Methyl 2-
chloroquinoline-4-carboxylate (67 mg, 0.30 mmol), (3-methoxyphenyl)boronic acid (50 mg, 0.33 
mmol), Pd(PPh3)4 (15 mg), and K2CO3 (207 mg, 1.5 mmol) were combined in a round bottom 
flask and subjected to the conditions described in the general Suzuki coupling protocol. Methyl 
2-(3-methoxyphenyl)quinoline-4-carboxylate (23 mg, 0.08 mmol, 27% yield) was recovered 
following purification from silica chromatography (Hex/EtOAc 9:1 gradient).1H NMR (300 
MHz, Chloroform-d) δ 8.81 – 8.73 (m, 1H), 8.40 (s, 1H), 8.30 – 8.21 (m, 1H), 7.86 – 7.74 (m, 
3H), 7.68 – 7.60 (m, 1H), 7.46 (t, J = 7.9 Hz, 1H), 7.09 – 7.01 (m, 1H), 4.08 (s, 3H), 3.95 (s, 
3H); LCMS (ESI) 294.2 [M+H]+; HPLC Purity at 254 nm, 98.4%  
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Methyl 2-(4-cyclohexylphenyl)quinoline-4-carboxylate (23): 
Methyl 2-chloroquinoline-4-carboxylate (62 mg, 0.28 mmol), (3-cyclohexylphenyl)boronic acid 
(62 mg, 0.31 mmol), Pd(PPh3)4 (12 mg), and K2CO3 (193 mg, 1.4 mmol) were combined in a 
round bottom flask and subjected to the conditions described in the general Suzuki coupling 
protocol. Methyl 2-(4-cyclohexylphenyl)quinoline-4-carboxylate (27 mg, 0.08 mmol, 29% yield) 
was recovered following purification from silica chromatography (Hex/EtOAc 9:1 gradient). 1H 
NMR (300 MHz, Chloroform-d) δ 8.76 (d, J = 8.5 Hz, 1H), 8.41 (s, 1H), 8.24 (d, J = 8.4 Hz, 
1H), 8.15 (d, J = 8.0 Hz, 2H), 7.86 – 7.71 (m, 1H), 7.69 – 7.59 (m, 1H), 7.41 (d, J = 8.0 Hz, 2H), 
4.09 (s, 3H), 2.70 – 2.57 (m, 1H), 2.03 – 1.85 (m, 4H), 1.84 – 1.67 (m, 1H), 1.61 – 1.21 (m, 5H); 
LCMS (ESI) 346.2 [M+H]+; HPLC Purity at 254 nm, 98.7% 
Methyl 2-(4-(piperidin-1-yl)phenyl)quinoline-4-carboxylate (24): 
2-(4-(Piperidin-1-yl)phenyl)quinoline-4-carboxylic acid (30 mg, 0.09 mmol) was dissolved in 2 
mL MeOH and a catalytic amount of H2SO4 (4 drops). The mixture was heated to reflux 
overnight, concentrated, and dried with MgSO4. Upon filtration, the organic layer was 
concentrated and product was purified using silica chromatography (DCM/MeOH 9:1 gradient) 
to yield methyl 2-(4-(piperidin-1-yl)phenyl)quinoline-4-carboxylate as a dark red solid (29 mg, 
0.08 mmol, 88%). 1H NMR (400 MHz, Chloroform-d) δ 8.71 (dd, J = 8.5, 1.4 Hz, 1H), 8.38 (s, 
1H), 8.21 – 8.12 (m, 3H), 7.80 – 7.70 (m, 1H), 7.63 – 7.53 (m, 1H), 7.13 – 7.00 (m, 2H), 4.08 (d, 
J = 1.0 Hz, 3H), 3.39 – 3.28 (m, 4H), 1.80 – 1.71 (m, 4H), 1.70 – 1.60 (m, 2H); LCMS (ESI) 
347.2 [M+H]+; HPLC Purity at 254 nm, 97.3% 
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Methyl 2-(4-morpholinophenyl)quinoline-4-carboxylate (26): 
Methyl 2-(4-bromophenyl)quinoline-4-carboxylate (80 mg, 0.23 mmol), morpholine (0.23 mL, 
0.28 mmol), Pd2dba3 (11 mg), BINAP (21 mg, 0.04 mmol), and KOtBu (37 mg, 0.33 mmol) 
were combined in a degased solution of 2.5 mL toluene. The mixture was heated to reflux 
overnight, before addition of water, and extraction with dichloromethane. The organic layer was 
dried with MgSO4, filtered, concentrated and purified via silica chromatography (DCM/MeOH 
9:1 gradient). Methyl 2-(4-morpholinophenyl)quinoline-4-carboxylate was collected as a thick 
yellow oil (11 mg, 0.03 mmol, 13%).  
Alternate route using esterification: 2-(4-morpholinophenyl)quinoline-4-carboxylic acid (31 mg, 
0.09 mmol) was dissolved in 2 mL MeOH with catalytic H2SO4 (16 drops) and the mixture was 
refluxed overnight. The mixture was concentrated and partitioned between 1M KOH and EtOAc. 
The organic layer was dried with MgSO4, filtered, concentrated, and purified via silica 
chromatography. Methyl 2-(4-morpholinophenyl)quinoline-4-carboxylate was recovered as a red 
solid (28 mg, 0.08 mmol, 88%). 1H NMR (300 MHz, Chloroform-d) δ 8.80 – 8.66 (m, 2H), 8.43 
(s, 1H), 8.18 (d, J = 8.5 Hz, 2H), 8.01 (t, J = 7.9 Hz, 1H), 7.81 (t, J = 7.8 Hz, 1H), 7.03 (d, J = 
8.4 Hz, 2H), 4.17 (s, 3H), 3.90 (t, J = 4.9 Hz, 4H), 3.45 (t, J = 5.0 Hz, 4H); LCMS (ESI) 349.2 
[M+H]+; HPLC Purity at 254 nm, 98.0% 
Methyl 2-([1,1'-biphenyl]-4-yl)quinoline-4-carboxylate (29): 
Methyl 2-chloroquinoline-4-carboxylate (95 mg, 0.43 mmol), [1,1'-biphenyl]-4-ylboronic acid 
(136 mg, 0.69 mmol), Pd(PPh3)4 (15 mg), and K2CO3 (297 mg, 2.15 mmol) were combined in a 
round bottom flask and subjected to the conditions described in the general Suzuki coupling 
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protocol. Methyl 2-([1,1'-biphenyl]-4-yl)quinoline-4-carboxylate (91 mg, 0.27 mmol, 63%) was 
recovered following purification from silica chromatography (Hex/EtOAc 9:1 gradient).1H 
NMR (300 MHz, Chloroform-d) δ 8.76 (dd, J = 8.6, 1.3 Hz, 1H), 8.46 (s, 1H), 8.35 – 8.20 (m, 
3H), 7.85 – 7.73 (m, 3H), 7.74 – 7.58 (m, 3H), 7.49 (t, J = 7.4 Hz, 2H), 4.09 (s, 3H); LCMS 
(ESI) 340.10 [M+H]+; HPLC Purity at 254 nm, 99.5%. 
 
 Methyl 2-([1,1'-biphenyl]-3-yl)quinoline-4-carboxylate (31): Methyl 2-
chloroquinoline-4-carboxylate (95 mg, 0.43 mmol), [1,1'-biphenyl]-3-ylboronic acid (137 mg, 
0.69 mmol), Pd(PPh3)4 (22 mg), and K2CO3 (297 mg, 2.15 mmol) were combined in a round 
bottom flask and subjected to the conditions described in the general Suzuki coupling protocol. 
Methyl 2-([1,1'-biphenyl]-3-yl)quinoline-4-carboxylate (83 mg, 0.24 mmol, 56% yield) was 
recovered following purification from silica chromatography (Hex/EtOAc 9:1 gradient).1H 
NMR (400 MHz, Chloroform-d) δ 8.80 (m, 1H), 8.49 (s, 1H), 8.46 (m, 1H), 8.29 (m, 1H), 8.21 
(m, 1H), 7.82 (m 1H), 7.75 (m, 3H), 7.71 – 7.60 (m, 2H), 7.58 – 7.50 (m, 2H), 7.47 – 7.40 (m, 
1H), 4.11 (s, 3H); LCMS (ESI) 340.1 [M+H]+; HPLC purity at 254 nm, 96.2% 
 
Methyl 2-(4-(pyridin-3-yl)phenyl)quinoline-4-carboxylate (33): 
Methyl 2-(4-bromophenyl)quinoline-4-carboxylate (60 mg, 0.18 mmol), pyridin-3-ylboronic acid 
(23 mg, 0.19 mmol), Pd(PPh3)4 (10 mg), and K2CO3 (72 mg, 0.53 mmol) were combined in a 
round bottom flask and subjected the conditions described in the general Suzuki coupling 
protocol. Methyl 2-(4-(pyridin-3-yl)phenyl)quinoline-4-carboxylate (20 mg, 0.06 mmol, 33%) 
was recovered following purification from silica chromatography (Hex/EtOAc 9:1 gradient). 1H 
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NMR (300 MHz, Chloroform-d) δ 8.92 (s, 1H), 8.74 (d, J = 8.5 Hz, 1H), 8.62 (d, J = 4.8 Hz, 
1H), 8.40 (s, 1H), 8.29 (d, J = 8.2 Hz, 2H), 8.21 (d, J = 8.4 Hz, 1H), 7.91 (dd, J = 8.0, 2.0 Hz, 
1H), 7.82 – 7.68 (m, 3H), 7.66 – 7.57 (m, 1H), 7.37 (dd, J = 7.9, 4.8 Hz, 1H), 4.23 – 3.94 (m, 
3H); LCMS (ESI) 341.10 [M+H]+; HPLC Chromatogram purity at 254 nm, 99.6%.  
 
 Methyl 2-(4-(pyridin-4-yl)phenyl)quinoline-4-carboxylate (35): 
Methyl 2-(4-bromophenyl)quinoline-4-carboxylate (60 mg, 0.18 mmol), pyridin-4-ylboronic acid 
(23 mg, 0.19 mmol), Pd(PPh3)4 (20 mg), and K2CO3 (72 mg, 0.53 mmol) were combined in a 
round bottom flask and subjected the conditions described in the general Suzuki coupling 
protocol. Methyl 2-(4-(pyridin-4-yl)phenyl)quinoline-4-carboxylate (7 mg, 0.02 mmol, 11%) 
was recovered following purification from silica chromatography (Hex/EtOAc 9:1 gradient), 
recrystallization using 2-propanol and diethyl ether. 1H NMR (300 MHz, Chloroform-d) δ 8.80 – 
8.67 (m, 3H), 8.44 (s, 1H), 8.39 – 8.30 (m, 2H), 8.28 – 8.20 (m, 1H), 7.79 (dd, J = 8.8, 6.7 Hz, 
3H), 7.70 – 7.55 (m, 3H), 4.09 (s, 3H); LCMS (ESI) 341.1 [M+H]+; HPLC Purity at 254 nm, 
99.6% 
 
Methyl 2-(thiophen-2-yl)quinoline-4-carboxylate (42): Methyl 2-
chloroquinoline-4-carboxylate (100 mg, 0.45 mmol), thiophen-2-ylboronic acid (81 mg, 0.63 
mmol), Pd(PPh3)4 (78 mg), and K2CO3 (310 mg, 2.25 mmol) were combined in a round bottom 
flask and subjected to the conditions described in the general Suzuki coupling protocol. Methyl 
2-(thiophen-2-yl)quinoline-4-carboxylate (70 mg, 0.26 mmol, 58% yield) was recovered 
following purification from silica chromatography (Hex/EtOAc 9:1 gradient). 1H NMR (300 
MHz, Chloroform-d) δ 8.74 – 8.66 (m, 1H), 8.31 (s, 1H), 8.20 – 8.09 (m, 1H), 7.84 – 7.70 (m, 
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2H), 7.64 – 7.56 (m, 1H), 7.51 (dd, J = 5.0, 1.1 Hz, 1H), 7.22 – 7.13 (m, 1H), 4.08 (s, 3H); MS 
(ESI) 270.0 [M+H]+. 
 
 Methyl 2-(4-bromophenyl)quinoline-4-carboxylate (43): Methyl 2-
bromoquinoline-4-carboxylate (358 mg, 1.35 mmol), (4-bromophenyl)boronic acid (298 mg, 
1.48 mmol), Pd(dppf)Cl2:CH2Cl2 (65 mg), and K2CO3 (650 mg, 4.71 mmol) were combined in a 
round bottom flask at 0 °C. The mixture was slowly warmed to room temperature over 1 hour, 
heated to 50 °C for 30 minutes, then followed the general Suzuki coupling workup conditions.  
Methyl 2-(4-bromophenyl)quinoline-4-carboxylate (417 mg, 1.22 mmol, 91% yield) was 
recovered following purification from silica chromatography (Hex/EtOAc 9:1 gradient). 1H 
NMR (300 MHz, Chloroform-d) δ 8.79 – 8.71 (m, 1H), 8.36 (s, 1H), 8.25 – 8.17 (m, 1H), 8.14 – 
8.06 (m, 2H), 7.83 – 7.74 (m, 1H), 7.71 – 7.61 (m, 3H), 4.09 (s, 3H); MS (ESI) 342.0 [M+H]+.  
 
General conditions for ester hydrolysis: A round bottom flask containing the ester starting 
material (1 eq) and a large excess of NaOH (5-10 eq) was dissolved in a 1:1 mixture of THF:H2O 
(≈0.1 - 0.5 M of ester). The solution was heated to 40 °C until starting material was no longer 
detectable by TLC. Upon completion, the mixture was cooled to room temperature, concentrated 
under reduced pressure, redissolved in 1 M KOH, and washed with EtOAc (3x). The basic 
aqueous layer was acidified with HCl until a pH ≈ 2-3 was obtained; formed precipitant was 
filtered over a fritted funnel, washed with cold deionized H2O, and dried overnight in a vacuum 
oven.  
2-(4-Cyclohexylphenyl)quinoline-4-carboxylic acid (1): Methyl 2-
(4-cyclohexylphenyl)quinoline-4-carboxylate (15 mg, 0.04 mmol) and NaOH (40 mg, 1.05 
mmol) was dissolved in a 1:1 mixture of THF/H2O and followed the general ester hydrolysis 
N
CO2Me
Br
N
CO2H
	 81	
conditions.  A white solid was collected from the vacuum oven to yield 2-(4-
cyclohexylphenyl)quinoline-4-carboxylic acid (7 mg, 0.02 mmol, 50%).1H NMR (500 MHz, 
DMSO-d6) δ 8.64 (d, J = 8.6 Hz, 1H), 8.41 (d, J = 1.8 Hz, 1H), 8.21 – 8.15 (m, 2H), 8.14 – 8.08 
(m, 1H), 7.85 – 7.79 (m, 1H), 7.71 – 7.61 (m, 1H), 7.40 – 7.34 (m, 2H), 2.59 – 2.50 (m, 1H), 
1.83 – 1.73 (m, 4H), 1.72 – 1.65 (m, 1H), 1.49 – 1.27 (m, 4H), 1.27 – 1.10 (m, 1H). 13C NMR 
(126 MHz, DMSO-d6)) δ 168.09, 156.23, 150.06, 148.86, 138.00, 136.02, 130.55, 130.14, 
127.97, 127.72 (2H), 127.64 (2H), 125.85, 123.81, 119.42, 44.03, 34.22 (2H), 26.73 (2H), 26.00; 
LCMS (ESI) 332.20 [M+H]+ 330.20 [M-H]-; HPLC Purity at 254 nm, 98.6% 
 
2-Phenylquinoline-4-carboxylic acid (6): Methyl 2-phenylquinoline-4-
carboxylate (25 mg, 0.10 mmol) was dissolved in a 1:1 mixture of THF/H2O and followed the 
general ester hydrolysis conditions.  A yellow solid was collected from the vacuum oven to yield 
2-phenylquinoline-4-carboxylic acid (9 mg, 0.04 mmol, 40%).1H NMR (300 MHz, DMSO-d6) δ 
8.72 – 8.62 (m, 1H), 8.47 (s, 1H), 8.35 – 8.27 (m, 2H), 8.23 – 8.13 (m, 1H), 7.91 – 7.79 (m, 1H), 
7.76 – 7.66 (m, 1H), 7.63 – 7.49 (m, 3H); LCMS (ESI) 250.1 [M+H]+; HPLC Purity at 254 nm, 
96.4% 
 
2-(Furan-2-yl)quinoline-4-carboxylic acid (8): Methyl 2-(furan-2-
yl)quinoline-4-carboxylate (15 mg, 0.06 mmol) and NaOH (59 mg, 1.48 mmol) was dissolved in 
a 1:1 mixture of THF/H2O and followed the general ester hydrolysis conditions.  A brown/tan 
solid was collected from the vacuum oven to yield 2-(furan-2-yl)quinoline-4-carboxylic acid (8 
mg, 0.03 mmol, 50%).1H NMR (300 MHz, DMSO-d6) δ 8.68 – 8.61 (m, 1H), 8.30 (s, 1H), 8.08 
(d, J = 8.4 Hz, 1H), 8.01 – 7.96 (m, 1H), 7.86 – 7.78 (m, 1H), 7.72 – 7.62 (m, 1H), 7.46 (d, J = 
3.5 Hz, 1H), 6.78 – 6.72 (m, 1H); LCMS (ESI) 240.2 [M+H]+; , HPLC Purity at 254 nm, 97.1% 
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2-(Thiophen-2-yl)quinoline-4-carboxylic acid (9): Methyl 2-(thiophen-2-
yl)quinoline-4-carboxylate (20 mg, 0.07 mmol) and NaOH (46 mg, 1.15 mmol) was dissolved in 
a 1:1 mixture of THF/H2O and followed the general ester hydrolysis conditions.  A yellow solid 
was collected from the vacuum oven to yield methyl 2-(thiophen-2-yl)quinoline-4-carboxylate (3 
mg, 0.004 mmol, 6%). 1H NMR (300 MHz, DMSO-d6) δ 8.63 – 8.54 (m, 1H), 8.43 (s, 1H), 8.13 
– 8.02 (m, 2H), 7.87 – 7.74 (m, 2H), 7.70 – 7.59 (m, 1H), 7.29 – 7.20 (m, 1H); LCMS (ESI) 
256.0 [M+H]+; HPLC Purity at 254 nm, 96.8%  
 
2-(Naphthalen-2-yl)quinoline-4-carboxylic acid (11): Methyl 2-
(naphthalen-2-yl)quinoline-4-carboxylate (40 mg, 0.13 mmol) was dissolved in a 1:1 mixture of 
THF/H2O and followed the general ester hydrolysis protocol.  A yellow solid was collected from 
the vacuum oven to yield 2-(naphthalen-2-yl)quinoline-4-carboxylic acid (17 mg, 0.06 mmol, 
46%). 1H NMR (300 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.73 (d, J = 8.4 Hz, 1H), 8.48 (d, J = 8.6 
Hz, 1H), 8.24 (s, 1H), 8.18 – 8.10 (m, 1H), 8.07 (t, J = 7.5 Hz, 2H), 7.99 (m, 1H), 7.70 (t, J = 7.5 
Hz, 1H), 7.58 (m, 2H), 7.51 (t, J = 7.7 Hz, 1H); LCMS (ESI) 300.1 [M+H]+; HPLC purity at 
254 nm, 98.8% 
 
2-(Naphthalen-1-yl)quinoline-4-carboxylic acid (13): Methyl 2-
(naphthalen-1-yl)quinoline-4-carboxylate (22 mg, 0.07 mmol) and LiOH (71 mg, 3.08 mmol) 
were dissolved in a 1:1 THF/H2O solution and followed the general ester hydrolysis protocol. A 
white solid was collected from the vacuum oven to yield 2-(naphthalen-1-yl)quinoline-4-
carboxylic acid (13 mg, 0.04 mmol, 57%). 1H NMR (300 MHz, DMSO-d6) δ 8.75 (d, J = 8.4 
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Hz, 1H), 8.12 (d, J = 8.2 Hz, 1H), 8.09 – 8.01 (m, 3H), 7.84 – 7.48 (m, 7H); LCMS (ESI) 300.1 
[M+H]+; HPLC purity at 254 nm, 96.2% 
 
2-(4-Bromophenyl)quinoline-4-carboxylic acid (14): Methyl 2-(4-
bromophenyl)quinoline-4-carboxylate (25 mg, 0.07 mmol) and NaOH (42 mg, 1.05 mmol) was 
dissolved in a 1:1 mixture of THF/H2O and followed the general ester hydrolysis protocol.  A 
off-white solid was collected from the vacuum oven to yield 2-(4-bromophenyl)quinoline-4-
carboxylic acid (17 mg, 0.05 mmol, 71%). 1H NMR (300 MHz, DMSO-d6) δ 8.68 (d, J = 8.3 
Hz, 1H), 8.20 (d, J = 8.5 Hz, 2H), 8.08 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.72 (dd, J = 12.5, 8.1 
Hz, 3H), 7.53 (t, J = 7.6 Hz, 1H); LCMS (ESI) 328.0 [M+H]+; HPLC Purity at 254 nm, 98.2% 
 
 2-(4-Methoxyphenyl)quinoline-4-carboxylic acid (20): Methyl 2-(4-
methoxyphenyl)quinoline-4-carboxylate (3 mg, 0.01 mmol) and NaOH (42 mg, 1.05 mmol) were 
dissolved in a 1:1 mixture of THF/H2O and followed the general ester hydrolysis conditions.  A 
cakey brown solid was collected from the vacuum oven to yield 2-(4-methoxyphenyl)quinoline-
4-carboxylic acid (1 mg, 0.004 mmol, 40%).1H NMR (300 MHz, DMSO-d6) δ 8.64 (d, J = 8.5 
Hz, 1H), 8.42 (s, 1H), 8.26 (d, J = 8.4 Hz, 2H), 8.12 (d, J = 8.4 Hz, 1H), 7.81 (t, J = 7.7 Hz, 1H), 
7.66 (t, J = 7.7 Hz, 1H), 7.10 (d, J = 8.4 Hz, 2H), 3.84 (s, 3H); LCMS (ESI) 280.1 [M+H]+; 
HPLC Purity at 254 nm, 99.9% 
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2-(3-Methoxyphenyl)quinoline-4-carboxylic acid (22): Methyl 2-(3-
methoxyphenyl)quinoline-4-carboxylate (20 mg, 0.07 mmol) and NaOH (73 mg, 1.83 mmol) 
was dissolved in a 1:1 mixture of THF/H2O and followed the general ester hydrolysis conditions.  
A tan solid was collected from the vacuum oven to yield 2-(3-methoxyphenyl)quinoline-4-
carboxylic acid (12 mg, 0.04 mmol, 57%). 1H NMR (300 MHz, DMSO-d6) δ 8.64 (d, J = 8.4 Hz, 
1H), 8.46 (s, 1H), 8.20 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 8.3 Hz, 3H), 7.72 (t, J = 7.7 Hz, 1H), 
7.50 (t, J = 7.9 Hz, 1H), 7.12 (dd, J = 8.3, 2.4 Hz, 1H), 3.89 (s, 3H); LCMS (ESI) 280.0 [M+H]+, 
278.1 [M-H]-; HPLC Purity at 254 nm, 99.9% 
 
2-([1,1'-Biphenyl]-4-yl)quinoline-4-carboxylic acid (28): Methyl 2-
([1,1'-biphenyl]-4-yl)quinoline-4-carboxylate (50 mg, 0.15 mmol) and NaOH (29 mg, 0.74 
mmol) was dissolved in a 1:1 mixture of THF/H2O and followed the general ester hydrolysis 
conditions.  A white solid was collected from the vacuum oven to yield 2-([1,1'-biphenyl]-4-
yl)quinoline-4-carboxylic acid (36 mg, 0.11 mmol, 78%).1H NMR (300 MHz, Methanol-d4) δ 
8.46 – 8.36 (m, 1H), 8.19 (d, J = 8.4 Hz, 2H), 8.14 – 8.02 (m, 2H), 7.83 – 7.63 (m, 5H), 7.56 
(ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 7.44 (t, J = 7.4 Hz, 2H), 7.40 – 7.28 (m, 1H); LCMS (ESI) 
326.15 [M+H]+, 324.10 [M-H]-;  HPLC Purity at 254 nm, 98.9%. 
 
N
CO2H
OMe
N
CO2H
	 85	
2-([1,1'-Biphenyl]-3-yl)quinoline-4-carboxylic acid (30): Methyl 2-([1,1'-
biphenyl]-3-yl)quinoline-4-carboxylate (31 mg, 0.09 mmol) and NaOH (153 mg, 3.83 mmol) 
was dissolved in a 1:1 mixture of THF/H2O and followed the general ester hydrolysis conditions.  
A white solid was collected from the vacuum oven to yield 2-([1,1'-biphenyl]-3-yl)quinoline-4-
carboxylic acid (21 mg, 0.06 mmol, 67%).1H NMR (300 MHz, DMSO-d6) δ 8.68 (d, J = 8.5 Hz, 
1H), 8.46 (s, 1H), 8.22 (d, J = 7.7 Hz, 1H), 8.15 (s, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 7.7 
Hz, 3H), 7.74 – 7.61 (m, 2H), 7.53 (t, J = 7.4 Hz, 3H), 7.42 (t, J = 7.6 Hz, 1H); LCMS (ESI) 
326.1 [M+H]+; HPLC Purity at 254 nm, 99.9% 
 
2-(4-(Pyridin-3-yl)phenyl)quinoline-4-carboxylic acid (32): 
Methyl 2-(4-(pyridin-3-yl)phenyl)quinoline-4-carboxylate (8 mg, 0.02 mmol) and NaOH (45 mg, 
1.13 mmol) was dissolved in a 1:1 mixture of THF/H2O and followed the general ester 
hydrolysis conditions.  A white solid was collected from the vacuum oven to yield 2-(4-(pyridin-
3-yl)phenyl)quinoline-4-carboxylic acid (2 mg, 0.006 mmol, 30%).1H NMR (400 MHz, DMSO-
d6) δ 9.24 – 9.20 (m, 1H), 8.82 – 8.78 (m, 1H), 8.67 (d, J = 8.5, 1.5, 0.6 Hz, 1H), 8.64 – 8.61 (m, 
1H), 8.56 (s, 1H), 8.50 (d, J = 8.5 Hz, 2H), 8.21 (d, 1H), 8.05 (d, J = 8.5 Hz, 2H), 7.93 – 7.85 (m, 
2H), 7.78 – 7.71 (m, 1H); LCMS (ESI) 326.90 [M+H]+, 324.85 [M-H]-; HPLC Purity at 254 
nm, 95.2%.   
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2-(4-(Pyridin-4-yl)phenyl)quinoline-4-carboxylic acid (34): 
Methyl 2-(4-(pyridin-4-yl)phenyl)quinoline-4-carboxylate (14 mg, 0.04 mmol) and NaOH (62 
mg, 1.59 mmol) was dissolved in a 1:1 mixture of THF/H2O and followed the general ester 
hydrolysis protocol.  A white solid was collected from the vacuum oven to yield 2-(4-(Pyridin-4-
yl)phenyl)quinoline-4-carboxylic acid (2 mg, 0.006 mmol, 15%). 1H NMR (400 MHz, DMSO-
d6) δ 8.72 – 8.66 (m, 3H), 8.39 (d, J = 8.3 Hz, 2H), 8.08 (s, 1H), 8.04 – 7.99 (m, 3H), 7.85 – 7.80 
(m, 2H), 7.73 – 7.66 (m, 1H), 7.53 – 7.47 (m, 1H); LCMS (ESI) 326.85 [M+H]+ 324.80 [M-H]-; 
HPLC Chromatogram purity at 254 nm, 95.1% 
 
General conditions for Pfitizinger reaction: A round bottom flask containing isatin (1 eq), the 
corresponding acetophenone (1 eq), and KOH (3-6 eq) were dissolved in mixture of EtOH and 
H2O. The mixture was heated to reflux overnight and EtOH was removed under reduced pressure 
upon completion. The residue was re-dissolved in 1 M KOH and washed with EtOAc (3x). The 
aqueous layer was acidified using HCl to pH 2-3, the solution was chilled overnight at 2-8 °C, 
and precipitant was collected upon filtration. Precipitant was washed with de-ionized water and 
used without further purification unless otherwise noted.  
 
2-(4-Isobutylphenyl)quinoline-4-carboxylic acid (17): Isatin (500 
mg, 3.40 mmol), 1-(4-isobutylphenyl)ethan-1-one (0.57 mL, 3.08 mmol), and KOH (1.14 g, 20.4 
mmol). were dissolved in 12 mL EtOH + 2 mL H2O. Following the general Pfitizinger 
purification protocol, 2-(4-isobutylphenyl)quinoline-4-carboxylic acid was recovered as a pink 
solid after recrystallization from EtOH (101 mg, 0.33 mmol, 10% yield). 1H NMR (300 MHz, 
DMSO-d6)  8.68 (d, J = 8.4 Hz, 1H), 8.14 (d, J = 7.9 Hz, 2H), 8.03 – 7.94 (m, 2H), 7.66 (t, J = 
N
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7.6 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.33 (d, J = 7.9 Hz, 2H), 2.59 – 2.52 (m, 2H), 2.00 – 1.85 
(m, 1H), 0.91 (d, J = 6.6 Hz, 6H); LCMS (ESI) 306.10 [M+H]+., 304.20 [M-H]-; HPLC Purity 
at 254 nm, 99.9%.   
 
2-(4-Isopropylphenyl)quinoline-4-carboxylic acid (18): Isatin (264 
mg, 1.8 mmol), 1-(4-isopropylphenyl)ethan-1-one (0.27 mL,  1.6 mmol), and KOH (275 mg, 
4.92 mmol) were dissolved in 7 mL EtOH. Following the general Pfitizinger protocol, 2-(4-
isopropylphenyl)quinoline-4-carboxylic acid was recovered as a tan solid (130 mg, 0.44 mmol, 
28%) after recrystallization from diethyl ether and EtOH. 1H NMR (400 MHz, DMSO-d6) δ 8.65 
(d, J = 8.5, 1.3 Hz, 1H), 8.44 (s, 1H), 8.23 (d, J = 8.3 Hz, 2H), 8.16 (d, J = 8.5, 1.2 Hz, 1H), 7.89 
– 7.81 (m, 1H), 7.75 – 7.67 (m, 1H), 7.46 (d, J = 8.3 Hz, 2H), 3.09 – 2.94 (m, 1H), 1.28 (d, J = 
6.9 Hz, 6H); LCMS (ESI) 292.20 [M+H]+, 290.15 [M-H]-; HPLC Chromatogram purity: 95.8% 
 
2-(4-(Piperidin-1-yl)phenyl)quinoline-4-carboxylic acid (25): 
Isatin (247 mg, 1.7 mmol), 1-(4-(piperidin-1-yl)phenyl)ethan-1-one (200 mg, 1.0 mmol), and 
KOH (336 mg, 6.0 mmol) were dissolved in 7 mL EtOH and 1 mL H2O.  Following the general 
Pfitizinger protocol, 2-(4-(piperidin-1-yl)phenyl)quinoline-4-carboxylic acid was recovered as a 
red solid (88 mg, 0.27 mmol, 27%).1H NMR (400 MHz, DMSO-d6) δ 8.59 (d, J = 8.4 Hz, 1H), 
8.37 (s, 1H), 8.18 (d, J = 8.6 Hz, 2H), 8.09 (d, J = 8.4 Hz, 1H), 7.85 – 7.76 (m, 1H), 7.68 – 7.58 
(m, 1H), 7.16 – 7.04 (m, 2H), 3.34 – 3.27 (m, 4H), 1.71 – 1.54 (m, 6H). LCMS (ESI) 333.25 
[M+H]+, 331.15 [M-H]-; HPLC Chromatogram purity: 99.7% 
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2-(4-Morpholinophenyl)quinoline-4-carboxylic acid (27): Isatin 
(247 mg,  1.7 mmol), 1-(4-morpholinophenyl)ethan-1-one (200 mg,  1.0 mmol), and KOH (336 
mg, 6.0 mmol) were dissolved in 7 mL EtOH and 1 mL H2O. Following the general Pfitizinger 
protocol, 2-(4-morpholinophenyl)quinoline-4-carboxylic acid as a bright red solid after 
recrystallization from EtOH (132 mg, 0.39 mmol, 39%).1H NMR (400 MHz, DMSO-d6) δ 8.60 
(d, J = 8.5 Hz, 1H), 8.39 (s, 1H), 8.21 (d, J = 8.7 Hz, 2H), 8.10 (d, J = 8.4 Hz, 1H), 7.85 – 7.76 
(m, 1H), 7.68 – 7.59 (m, 1H), 7.11 (d, J = 8.7 Hz, 2H), 3.77 (t, J = 4.8 Hz, 4H), 3.26 (t, J = 4.9 
Hz, 4H); LCMS (ESI) 335.90 [M+H]+, 333.15 [M-H]-; HPLC Chromatogram purity: 98.8% 
 
N-(pyridin-2-ylmethyl)-2-(4-(pyridin-3-yl)phenyl)quinoline-4-
carboxamide (36): 2-(4-(Pyridin-3-yl)phenyl)quinoline-4-carboxylic acid (50 mg, 0.15 mmol) 
was dissolved in 2 mL 1,2 dichloroethane and 2 drops of anhydrous DMF. SOCl2 (0.06 mL, 0.83 
mmol) was added slowly and the mixture was heated to 60 °C for 2 hours. Acid chloride 
formation was monitored by esterifying reaction aliquots with MeOH and TEA for TLC. After 2 
hours, the mixture was concentrated under reduced pressure, dissolved in 1,2 dichloroethane, and 
re-concentrated (3x). The mixture was redissolved again in 2 mL 1,2 dichloroethane and added 
dropwise to a 0 °C stirring solution of 3-picolylamine (0.03 mL, 0.33 mmol) and triethylamine 
(0.17 mL, 1.22 mmol) in 1,2 dichloroethane. The mixture was stirred overnight and allowed to 
warm to room temperature. Upon completion, the solution was concentrated, redissolved in 
EtOAc and washed with brine (3x). The product was then extracted from the EtOAc through 
subsequent washing with 6 M HCl (3x). The acidified layer was neutralized with NaHCO3, and 
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product was extracted using EtOAc (3x). The organic layer was dried with MgSO4, filtered, 
concentrated, and recrystallized in 2-propanol to yield N-(pyridin-2-ylmethyl)-2-(4-(pyridin-3-
yl)phenyl)quinoline-4-carboxamide as a beige solid (23 mg, 0.06 mmol, 39%).1H NMR (400 
MHz, Chloroform-d) δ 8.98 – 8.92 (m, 1H), 8.67 – 8.63 (m, 1H), 8.59 – 8.55 (m, 1H), 8.36 – 
8.30 (m, 3H), 8.28 – 8.21 (m, 1H), 8.11 (s, 1H), 8.02 – 7.95 (m, 1H), 7.84 – 7.70 (m, 4H), 7.64 – 
7.58 (m, 1H), 7.47 – 7.37 (m, 2H), 7.28 – 7.26 (m, 0H), 4.94 (d, J = 4.8 Hz, 2H); LCMS (ESI) 
417.2 [M+H]+; HPLC Purity at 254 nm, 98.7% 
 
2-(4-(Pyridin-3-yl)phenyl)-4-(1H-tetrazol-5-yl)quinoline (37): 2-
(4-(Pyridin-3-yl)phenyl)quinoline-4-carboxylic acid (25 mg, 0.08 mmol) was dissolved in 2 mL 
of 7 N NH3 in MeOH. The mixture was refluxed for 36 hours. Upon completion, the mixture was 
concentrated and product was used without further purification. Following a modification 
protocol from Borkin et al.27, the residue was re-dissolved in 3 mL of POCl3 and heated to 100 
°C for 24 hours. The mixture was concentrated and used without further purification. A modified 
protocol of Lassig’s et al.28 was followed for the next step and the residue was re-dissolved in 
anhydrous DMF with NaN3 (3 mg, 0.05 mmol) and NH4Cl (3 mg, 0.05 mmol) and heated to 120 
°C for 24 hours. Upon completion, the mixture was concentrated and product was purified by 
reverse phase preparatory chromatography. 2-(4-(Pyridin-3-yl)phenyl)-4-(1H-tetrazol-5-
yl)quinoline was recovered as an amorphous solid (3 mg, 0.01 mmol, 13% yield over 3 steps). 
1H NMR (300 MHz, Methanol-d4) δ 9.01 – 8.95 (m, 1H), 8.84 (d, J = 8.7 Hz, 1H), 8.60 (s, 1H), 
8.55 (s, 1H), 8.43 (d, J = 8.3 Hz, 2H), 8.31 – 8.21 (m, 2H), 7.94 (d, J = 8.4 Hz, 2H), 7.92 – 7.84 
(m, 1H), 7.74 – 7.59 (m, 2H); LCMS (ESI) 351.2 [M+H]+, 349.2 [M-H]-; HPLC Purity at 254 
nm, 96.2%.   
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hDHODH expression and purification. DHODH expression and purification followed the 
protocol published by Madak et al.39 The hDHODH construct was provided by the De Brabander 
lab at UT Southwestern.37 hDHODH was expressed in E. coli Rosetta 2 (DE3) in LB medium 
with ampicillin (100 µg/mL) and 0.1 mM FMN. Cells were grown at 37 °C to OD600 = 0.6, then 
induced with 1 mM IPTG for 3 hours. Cells were harvested by centrifugation at 4,000 x g for 15 
min at 4 °C. The pellet was re-suspended in lysis buffer (50 mM Tris-HCl, pH 8.5, 300 mM 
NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 10 mM imidazole, 2% Triton X-100, 0.5 mM 
FMN, 200 µM PMSF, 1 mg/mL lysozyme). The cell suspension was incubated on ice for 2 
hours, followed by sonication. The lysate was clarified by centrifugation at 35,000 x g for 20 min 
at 4 °C. After the supernatant was incubated with Ni-NTA resin for 1 h at 4 °C, the resin was 
loaded onto a column. The column was washed with wash buffer (50 mM Tris-HCl, pH 8.5, 300 
mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 25 mM imidazole, 0.1 mM FMN) and 
hDHODH was eluted with elution buffer (wash buffer containing 300 mM imidazole). Buffer 
exchange was carried out using an Amicon concentrator into storage buffer (100 mM HEPES, 
pH 8.0, 150 mM NaCl, 10% glycerol) and hDHODH was stored at -80 °C. 
DHODH activity assay. DHODH activity was monitored using the same protocol published by 
Madak et al.39 DHODH activity was monitored as previously described with modifications.35 
First, 1 µL of test compound (50x) or DMSO, 60 nM DHODH, 100 µM DCIP, and 20 µM 
CoQ10 (final concentrations for 50 µL) in the assay buffer (100 mM HEPES pH 8.0, 150 mM 
NaCl, 10% glycerol, 0.1% Triton X-100) in a total of 40 µL were incubated together for 30 min. 
The assay began with the addition of 10 µL of dihydroorotate to a final concentration of 200 µM. 
The reduction of DCIP was measured by monitoring the absorbance at 600 nm over 1 hr at room 
temperature using a microplate reader (BMG Labtech). Data were exported to Microsoft Excel 
for analysis and IC50 values were determined using Prism 6 software. 
Cell culture. Cells were cultured following the protocol described by Madak et al.39 HCT116 
P53 +/+ and MiaPaca-2 cells were maintained in RPMI-1640 (Gibco) supplemented with 10% 
heat-inactivated FBS (Gibco). Cells were grown at 37 °C in a humidified atmosphere of 5% CO2. 
For subculture and counting, cells were washed with DPBS (Gibco) without calcium or 
magnesium, incubated with 0.25% trypsin-EDTA solution (Gibco) for 5 min, neutralized with 
full medium, centrifuged, re-suspended with culture medium and counted by Countess II FL. All 
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experiments were performed using cells in exponential growth. Cells were checked for 
Mycoplasma contamination. 
Growth inhibition assay. Growth inhibition assay followed the same protocol published by 
Madak et al.39 HCT116 p53+/+ cells or MiaPaCa-2 cells were seeded 2500-3000 cells per well 
in 96-well microtiter plates, and allowed to attach overnight before the addition of the serial 
dilution of compounds (10X). After 72h, cells were incubated with 0.3 mg/mL 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (VWR) for an additional 3h at 37 °C. 
After removal of the supernatant, DMSO was added to the wells, and the absorbance was read at 
570 nm. All assays were performed in triplicate. Percentage of cell growth inhibition was 
expressed as (1 − A/C) × 100% (A and C were the absorbance values from experimental and 
control cells, respectively). IC50 values were determined for each drug from nonlinear regression 
analysis of log (drug concentration) vs. percentage of cell growth inhibition using Prism 7.0. SD 
or SEM was calculated based on the IC50 values obtained from at least three independent 
experiment. 
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Chapter 3 
Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors 
of Dihydroorotate Dehydrogenasec 
 
3.1 Introduction  
 Dihydroorotate dehydrogenase (DHODH) catalyzes the oxidation of dihydroorotate to 
orotate, which represents a committed step in the de novo pyrimidine biosynthesis pathway.1, 2 
Inhibitors of DHODH induce pyrimidine depletion and halt cell cycle progression at S-phase, 
where a sufficient concentration of nucleotides is required for continued growth.3 Beyond 
directly halting cell growth, DHODH inhibitors sensitize cells to doxorubicin4, fludarabine,5, 6 
and TRAIL therapy.7 Additionally, PTEN-deficient cancer cells are significantly sensitive to 
DHODH inhibition.8 DHODH inhibitors have also been shown to induce differentiation and to 
thwart self-renewal capacity of different cell types.9,10 Collectively, these studies bolster interest 
for DHODH as an anticancer target. 
 Previous DHODH inhibitors have failed in clinical trials as single agents and in selected 
drug combinations for the treatment of various cancers. This includes the well-known DHODH 
inhibitors, brequinar (2) and leflunomide (45, Figure 3.1), which have not demonstrated 
widespread success in anticancer clinical trials. Despite promising preclinical data, brequinar 
failed to generate an objective response in multiple phase II clinical trials for breast,11 colon,12 
head and neck, 13gastrointestinal,14 lung,15 and skin16 cancers. Brequinar sodium has poor water 
solubility (< 0.10 mg/mL in room temperature water at pH 7.4) and molecular aggregation 
occurs at high concentrations.17 In addition, common serum electrolytes, such as sodium chloride 
have been demonstrated to reduce aqueous solubility by over 200-fold.17  As such, a previous 
attempt to utilize brequinar in combination with cyclosporine A changed brequinar’s 
pharmacokinetic profile in which its terminal half-life was extended and oral clearance rate was 
lowered.18 Altered pharmacokinetic properties such as this present a significant liability for safe 																																																								c	Author contributions: Joseph Madak designed, synthesized, and characterized all compounds. Christine Cuthbertson and Yoshinari Miyata 
evaluated compounds in biochemical and cellular assays. Elyse Petrunak and Dr. Jeanne Stuckey generated and solved co-crystal structures. Dr. 
Duxin Sun, Yanyan Han, and Miao He evaluated the compounds pharmacokinetic properties. Dr. Hollis Showalter and Dr. Nouri Neamati are 
corresponding authors.	
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dosing, thus limiting the selection of potential patient populations for combination therapy. 
Leflunomide, an FDA approved drug for rheumatoid and psoriatic arthritis,19 is currently being 
evaluated as a single agent in clinical trials for multiple myeloma (ClinicalTrials.gov, 
NCT02509052)20 but is no longer being evaluated in combination with vemurafenib for 
melanoma (ClinicalTrials.gov, NCT01611675).21 Leflunomide is a reported agonist for the aryl-
hydrocarbon receptor, which controls expression of drug metabolizing enzymes.22, 23 Despite the 
disappointing results of both these agents in clinical trials, we feel that DHODH remains a 
promising anticancer target awaiting the discovery of a small molecule inhibitors with better 
drug-like properties. Additionally, we believe that DHODH presents a vital anticancer target for 
combination therapy. In this chapter, we report the design and synthesis of novel class of 
brequinar-like inhibitors toward the discovery of agents with improved physicochemical 
properties, principally better aqueous solubility that we hypothesized would translate into 
improved enzyme and cellular potency.  
 
Figure 3.1. Selected DHODH inhibitors  
 
3.2 Analogue Design 
Our project was guided by the basic pharmacophore interactions between brequinar and 
DHODH. Initially, we began with an unbiased cell-based screening approach to identify new 
small molecule hits possessing antiproliferative properties. This led to lead compound (1) that 
showed potent DHODH activity (IC50 = 0.347 ± 0.072 µM) (Figure 3.1). We postulated that 1 
occupies a similar binding site as brequinar based on its structural similarity. The brequinar 
binding pocket of DHODH is primarily filled with nonpolar residues, therefore requiring 
lipophilic moieties. A high-resolution co-crystal structure of DHODH with a brequinar analogue 
(PDB: 1D3G) provided insight into the essential pharmacophore.24 The carboxylate of brequinar 
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forms a salt bridge with R136 and a potential hydrogen bond interaction with Q47, exemplifying 
the importance of the carboxylic acid.24, 25 The remaining interactions between brequinar and 
DHODH occur in a hydrophobic channel with the biphenyl group or the quinoline core.26 To 
develop a DHODH inhibitor with a lower cLogP, we identified sites where ring heteroatom 
replacements could be tolerated toward enhancing binding without disrupting the essential 
pharmacophore.  
Two potential regions were identified for the formation of new electrostatic interactions. 
The first region, located within a hydrophobic channel has two hydroxyls, one on Y38 and 
another on T63. Each region is in close proximity to form an interaction with the meta position 
of the distal phenyl of a brequinar analogue (Figure 3.2).24 The distance is suitable for an H-
bonding interaction and, if achieved, may provide an inhibitor with improved enthalpy-driven 
potency and a lower cLogP.27 Additionally, the hydroxyl of Y356 is nearly 2.5 Å away from C7 
on the quinoline ring (Figure 3.2) and presents another opportunity to form an electrostatic 
interaction. With these residues in mind, we postulated that strategically positioned H-bond 
acceptors on the brequinar pharmacophore would improve potency while lowering the cLogP. 
The overall decrease in cLogP should significantly improve the aqueous solubility leading to 
inhibitors with better drug-like properties.  
 
 
Figure 3.2. Co-crystal structure of a brequinar analogue in DHODH with new proposed 
interactions. Proposed interactions are depicted. Y356 is 2.5 Å from C7 of the quinoline ring; 
Y38 and T63 are 3.7 Å, 3.9 Å respectively from the meta position of the second phenyl ring. 
Y356	
Y38	
T63	
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Measurements were calculated from the hydrogen of side chain hydroxyl groups. Figure 
generated using PDB file 1D3G, resolution 1.6 Å.  
 
To optimize our screening lead, designed analogues were evaluated in the DHODH enzyme 
assay and MTT assay. We sought to develop analogues with a lower cLogP that may interact 
with T63 and Y356. Obviously, reducing the cLogP with analogues containing an ionizable acid 
could significantly reduce cellular permeability. However, we rationalized that, if necessary, an 
improved DHODH inhibitor could utilize a pro-drug strategy to address this issue.29 Therefore, 
our optimization process was primarily informed by a DHODH enzyme assay. Cellular activity 
was evaluated in HCT-116, a colon cancer cell line, and MIA PaCa-2, a pancreatic cancer cell 
line. Colon cancer has a high expression of DHODH and HCT-116 is sensitive to DHODH 
inhibition (Figure 2.4). DHODH is not overexpressed in pancreatic cancer and should be less 
sensitive to DHODH inhibitors. Collectively, these two cell lines may help distinguish between 
DHODH induced growth inhibition and potential off-target effects. Additionally, cLogP and 
LipE calculators were utilized to approximate aqueous solubility.28  
  
3.3 Synthesis 
The synthesis of analogues containing the quinoline core utilized the classic Pfitzinger 
condensation.30 2,4-Substituted quinoline analogues were generated using synthetic routes A-C 
(Scheme 3.1). Route A generates analogues in one step. However, this approach was limited 
primarily to commercially available 4’-substituted acetophenones.  To expand our SAR beyond 
these limitations, we developed routes B and C, which introduce diversity through carbon-carbon 
bond coupling via the Suzuki reaction on suitable precursors. These routes differ principally 
when such couplings take place with a phenyl-R1 moiety generated at a late and early stage, 
respectively. The advantage of Route B (Scheme 3.1) is that R1 moieties sensitive to the harsh 
Pfitizinger reaction conditions can be successfully installed, whereas Route C (Scheme 3.1) is 
less tolerant to such moieties. 
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Scheme 3.1. Synthesis of quinoline analogues without a C3 methyl group. 
 
 Analogues containing a C3 methyl were incorporated through the Pfitzinger reaction with 
the appropriate 4'-bromopropiophenone (84-87, Scheme 3.2). Surprisingly, Fischer-Speier 
esterification conditions were low-yielding on carboxylic acid analogues containing the C3 
methyl. Alternatively, methyl ester analogues (89-92) were obtained through generation of the 
cesium salt of the carboxylic acid followed by exposure to iodomethane. Subsequent Suzuki 
coupling was used for installation of the terminal R1 substituent (109-120). However, the C3 
methyl thwarted mild ester hydrolysis, therefore harsher conditions with strong base (> 60 °C 
with NaOH) were required for the reaction to occur. Unfortunately, this favored side product 
formation with little to no generation of acid, thus alternative deprotection methods were 
evaluated. Gratifyingly, the carboxylic acid could be unveiled upon exposure to BBr3 in 
dichloromethane at room temperature with minimal side product formation (64-74, Scheme 3.2).  
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Scheme 3.2. Synthesis of quinoline analogues with a C3 methyl substituent. 
 
Additional analogues were generated to evaluate a scaffold hop from the quinoline series to 
the synthetically challenging naphthyridines. As previously noted, we postulated that Y356 is 
close enough to potentially form an H-bond interaction with the 7’-nitrogen of a 1,7-
naphthyridine (Figure 3.2, Scheme 3.3). Initial attempts to generate the naphthyridine core 
focused on oxidation of aza-indoles to yield the corresponding aza-isatin for subsequent 
Pfitzinger condensation. However, reactions involving PCC oxidation31 or a reusable poly-
aniline catalyst32 on 1,6-aza-indoles did not provide the desired 1,6-aza-isatin. Inspired by the 
work of Stockmann et al.33 and Zong et al.,34 we sought to generate our naphthyridine series by 
installing an α-keto ester on an aminopyridine amide precursor,34 which would provide an 
intermediate for a subsequent Pfitzinger condensation. Drawing on the work of Turner et al.,35 
Meanwell et al.,36 and Zong et al.,34 we generated our desired intermediate through directed 
metalation to control regioselectivity as shown in Scheme 3.3. A pivaloyl amide (122-125) was 
utilized to direct ortho-lithiation. Exposure of the intermediate to n-BuLi/TMEDA complex 
under strict temperature control provided the anion, which was then quenched with diethyl 
oxalate to give the key α-keto-ester (127-130). This intermediate was then used to generate the 
naphthyridine (75-80) through base-catalyzed cyclization under Pfitzinger-type reaction 
conditions.  
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Scheme 3.3. Synthesis of naphtyridine core analogues.  
 
 The synthesis of C6 substituted 1,7-naphthyridines presented an obstacle for SAR 
evaluation. Attempts to generate the C6-fluoro substituted 1,7-naphthyridine were foiled by the 
harsh reaction conditions necessary for the Pfitzinger cyclization (Scheme 3.3, Box i). The high 
temperatures and basic conditions favor fluorine displacement through an SNAr mechanism, 
which would likely proceed at a faster rate than the cyclization reaction. LCMS studies indicated 
that when the reaction temperature was above 50 °C, the fluorine was displaced under basic 
conditions within a few hours. Attempts to generate the C6 substituted methyl analogue were 
foiled during the ortho-lithiation protocol, as the excess of n-BuLi favored kinetic deprotonation 
of the methyl group and led to a variety of unwanted side products (Scheme 3.3, Box ii). To 
overcome this difficulty, we focused on generation of the C6 trifluoromethyl analogue and were 
gratified to generate the product through ortho-lithiation (Scheme 3.3), despite low yields.  
The overall low yield of our synthetic route to 1,7-naphthyridines presented an obstacle to 
expanding the SAR around this core. Efforts to improve the ortho-lithiation/acylation step 
initially focused on improving the electrophile’s reactivity. The diethyl oxalate electrophile was 
replaced with asymmetric electrophiles such as ethyl chlorooxoacetate or ethyl 2-
(methoxy(methyl)amino)-2-oxoacetate (Weinreb amide derivative), but without any yield 
enhancement. We then shifted our efforts to improving the Pfitzinger cyclization reactions 
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(Scheme 3.3, (c)). LCMS traces indicated that ester hydrolysis was followed by decarboxylation, 
which occurred at a faster rate than hydrolysis of the pivaloyl amide, resulting in low yields of 
cyclization product. To avoid the unwanted decarboxylation, we decided to swap the ortho-
lithiating pivaloyl amide group with a Boc carbamate. Formation of the oxalate ester followed by 
mild Boc acid hydrolysis could then unmask the amine needed for intramolecular cyclization 
onto an α-keto acid. The reduction of this to practice is shown in Scheme 3.4. With the α-keto 
ester intermediate 131 in hand, acid hydrolysis unveiled the amine, followed by condensation 
with the 4’-bromopropionone and cyclization to provide the key 1,7-naphthyridine intermediate. 
Methyl esterification via a cesium salt/methyl iodide failed, but was successful using TMS-
diazomethane to give 132. Suzuki coupling resulting in installation of the terminal 2-
fluorophenyl substituent was followed by methyl ester hydrolysis to yield the final product 
(Scheme 3.4, 82). Alternatively, initial ester hydrolysis followed by Suzuki coupling on the 
resultant carboxylic acid successfully yielded final product 81 (Scheme 3.4). With the improved 
reaction conditions, we were able to incorporate the C6 CF3 substituent into the 1,7 
naphthyridine scaffold. This methodology should be readily amenable to the synthesis of 
additional naphthyridine analogues.  
 
Scheme 3.4. Synthesis of naphthyridine core analogues with terminal diversity. 
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3.4 Structure activity relationships 
 Our initial goal was to validate that our synthesized analogues followed the same SAR 
trends (Table 3.1) as observed previously for the brequinar series.25 With screen lead 1 and 
subsequent analogues, we noted an immediate decrease in potency for analogues containing a 
methyl ester substituent (e.g., compare 1 to 23, Table 3.1). Attempts to lower cLogP by 
incorporating piperidine (25) or morpholine (27) moieties were not well tolerated and resulted in 
a marked potency decrease in comparison to 1. Replacement of the cyclohexyl group with 
branched aliphatic groups (17, 18) maintained modest potency in the DHODH assay, but were 
far less potent than 3. As expected, replacement of the cyclohexyl ring with a phenyl ring 
resulted in potency enhancement (28). This analogue has a lower cLogP than 1 but substitution 
of the conformationally flexible cyclohexyl with the planar phenyl allows for formation of 
stacking interactions at high concentrations in aqueous solutions. In cells, there is a strong 
correlation with DHODH inhibition and HCT-116 growth inhibition. Inhibitors with a lower 
DHODH IC50 were generally more potent in HCT-116 cells than MIA PaCa-2 cells (e.g. 1, 28). 
Overall, these SAR trends are consistent with those observed for established DHODH inhibitors 
and suggest that our inhibitors bind in a similar pocket as brequinar.25 To further confirm that 
DHODH is the primary target for cell growth inhibition, we evaluated screen lead 1 in the 
presence of excess uridine, a nucleoside capable of entering the pyrimidine salvage pathway 
which overcomes DHODH inhibition.37, 38 In the absence of uridine, cells are susceptible to 
growth inhibition by 1 and brequinar (Chapter 2, Figure 2.5). However, uridine supplementation 
(5 µM) significantly decreased cell growth inhibition (below 50%), suggesting 1 inhibits an 
enzyme upstream of uridine nucleotide production. This data strengthened our initial postulation 
that 1 has a similar mechanism of action as brequinar, which shifted our attention towards 
incorporation of H-bond acceptors into our next set of analogues. 
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Table 3.1. Biological activity of quinolines with selected R1 substituents.a  
 
   DHODH  
Assay 
  MTT Assay 
      HCT-116 MIA PaCa-2 
# R1 R2 IC50 (µM) cLogP LipE IC50 (µM) IC50 (µM) 
2 (Breq)   0.020 ± 0.02 5.94  0.98 ± 0.52 7.4 ± 2.3 
1 
 
CO2H 0.347 ± 0.072 6.49 0.03 7.40 ± 1.50 18.8 ± 12 
23 
 
CO2Me > 200 6.72 NA > 100 > 100 
25 
 
CO2H 10.2 ± 1.6 4.71 0.28 24.3 ± 14 57.0 ± 13 
24 
 
CO2Me > 200 4.93 NA 54.5 ± 24 55.7 ± 26 
27 
 
CO2H 130 ± 52 3.23 0.66 > 100 > 100 
18 
 
CO2H 3.70 ± 0.40 5.30 0.13 52.2 ± 23 > 100 
17 
 
CO2H 1.60 ± 1.00 5.83 0.03 16.9 ± 6.3 > 100 
6 
 CO2H 124 ± 48 3.87 0.04 > 100 > 100 
28 
 
CO2H 0.0721 ± 0.046 5.76 1.38 1.10 ± 1.0 16.2 ± 14 
29 
 
CO2Me > 200 5.98 NA 13.1 ± 5.3 27.9 ± 15 
a Data for cLogP values was predicted using ChemBioDraw Professional 16, Lipophilic ligand 
efficiency (LipE) calculated LipE = pIC50 (M) – cLogP.28 
 
Pyridine rings were incorporated at the R1 to probe for potential interactions with Y38 and 
T63. Our first goal was to evaluate positional pyridine isomers (Table 3.2). In the DHODH 
assay, the pyridine analogue 32 is 10- and 6-fold more potent than pyridine analogues 46 and 34, 
respectively. This potency difference between 32, 34, and 46 suggests a potential interaction 
N
R2
R1
2
3
4
6
N
N
N
O
H
	 105	
between the pyridine nitrogen of 32 and DHODH.  In cells, 32 has a modest effect on cell growth 
in the HCT-116 line. In contrast, the methyl ester analogue 33 is inactive in the DHODH assay 
but possesses improved cytotoxicity in cells, which may be a result of improved permeability 
followed by intracellular hydrolysis to generate 32. However, this has not been confirmed 
experimentally. The methoxy electron-donating substituent was added at the 2’ position of the 
pyridine ring to increase the electron density onto the pyridine nitrogen to give 47, which 
improves potency in both the DHODH assay and cell-based viability assays. However, this 
enhancement is greater for phenyl analogue 48, suggesting that improvements from 32 to 47 are 
not due to electronic effects alone. In HCT-116 cells, 48 is more potent than 47, which may be a 
result of decreased permeability considering the relative cLogP values and modest DHODH 
potency differences.  
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Table 3.2. Biological activity of quinolines with R1 pyridine and pyrimidine moieties.a 
 
   DHODH  
Assay 
  MTT Assay 
      HCT-116 MIA PaCa-2 
# R1 R2 IC50 (µM) cLogP LipE IC50 (µM) IC50 (µM) 
46 
 
CO2H 13.9 ± 4.8 4.47 0.39 > 50 > 50 
32 
 
CO2H 0.844 ± 0.12 4.26 1.8 29.4 ± 11 58.6 ± 2.9 
33 
 
CO2Me > 200 4.49 NA 7.20 ± 2.80 8.10 ± 4.0 
34 
 
CO2H 9.10 ± 2.00 4.26 0.75 > 50 > 50 
47 
 
CO2H 0.284 ± 0.17 4.02 2.53 11.1 ± 2.30 23.4 ± 2.90 
48 
 
CO2H 0.179 ± 0.04 5.12 1.63 6.60 ± 2.50 12.8 ± 2.2 
49 
 
CO2H 44.0 ± 13.0 2.76 1.60 > 50 > 50 
50 
 
CO2H 34.0 ± 39.0 3.24 1.23 > 50 > 50 
51 
 
CO2H > 200 2.97 NA > 50 > 50 
a cLogP values were calculated using ChemBioDraw Professional 16, Calculated lipophilic 
ligand efficiency (LipE) = pIC50 (M) – cLogP.28 
 
Replacement of the pyridine ring with pyrimidine 49 resulted in a marked decrease in 
potency. Incorporation of the additional nitrogen increases tPSA, which may result in a repulsive 
interaction in a lipophilic pocket as this potency decrease is also observed with pyridazine 50 and 
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reverse pyrimidine 51. The electron withdrawing CF3 substituent was incorporated at the 2’ (52) 
and 4’ (53) positions using the pyridine ring numbering (Table 3.3). Analogue 52 is more potent 
than 53 in the DHODH assay but shows no significant difference in cells. The same is observed 
for methyl substituents (55, 56) installed at various positions. Installation of a strongly electron-
withdrawing fluoro substituent at the 2’ (58) and 6’ (57) positions of the pyridine ring resulted in 
a marked loss of potency. In fact, compound 58 is 47-fold less potent than 56 and 9-fold less 
potent than 52 suggesting that steric effects also play an important role. Based on this hypothesis, 
we incorporated a chlorine to provide 59. Chlorine has a similar van der Waals radius as a 
methyl group but different inductive effects. Compound 59 is amongst the most potent analogues 
synthesized with predicted metabolic stability better than 56. In cells, compound 59 is more 
potent in HCT-116 and MIA PaCa-2 than 56. Further installation of a methyl group at the 6’ 
position (60) of the pyridine ring was undertaken to increase binding in a lipophilic pocket. 
However, this does not improve potency. Neither does replacement of the pyridine with an 
imidazole (61).  
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Table 3.3. Biological activity of quinolines with R1 substituted pyridines.a
 
   DHODH 
Assay 
  MTT Assay 
      HCT-116 MIA PaCa-2 
# R1 R2 IC50 (µM) cLogP LipE IC50 (µM) IC50 (µM) 
52 
 
CO2H 0.229 ± 0.03 5.14 1.50 9.30 ± 1.70 18.0 ± 2.6 
53 
 
CO2H 2.30 ± 1.70 5.14 0.50 7.90 ± 1.60 19.2 ± 1.9 
54 
 
CO2Me > 200 5.37 NA > 100 > 100 
55 
 
CO2H 0.612 ± 0.46 4.46 1.75 22.9 ± 7.0 33.8 ± 6.7 
56 
 
CO2H 0.0435 ± 0.031 4.46 2.90 14.7 ± 3.9 24.6 ± 6.3 
57 
 
CO2H 17.4 ± 1.9 4.40 0.36 71.0 ± 14.0 >100 
58 
 
CO2H 2.01 ± 0.84 4.40 1.30 52.2  ± 4.3 >100 
59 
 
CO2H 0.0455 ± 0.025 4.72 2.62 7.3 ± 2.1 11.4 ± 0.44 
60 
 
CO2H 0.274 ± 0.025 5.22 1.30 24.0 ± 8.0 39.7 ± 11 
61 
 
CO2H 18.1 ± 6.3 3.52 1.22 > 100 > 100 
a cLogP values were calculated using ChemBioDraw Professional 16, Calculated lipophilic 
ligand efficiency (LipE) = pIC50 (M) – cLogP.28 
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Altogether, 2’-substutited pyridine analogues (e.g., 56, 59) are amongst the most potent of 
the core quinoline series. Potency differences between 2’ position substituents may be a 
reflection of lipophilicity, inductive, or entropic effects that lower the total number of 
conformations the pyridine ring can adopt. A comparison between 47 and 52 suggests that 
inductive effects may not have a significant effect on potency. However, a comparison of 
analogues 47, 52, 56, 58, and 59 suggests that substituent size may be a contributing factor. The 
size of the substituent may factor into undesirable clashes or limit the degrees of conformational 
freedom. Nonetheless, since analogues 56 and 59 were the most potent analogues synthesized at 
this stage of the project, the SAR was extended around 59. 
On the basis of SAR developed around the pendant R1 position (Tables 3.1-3.3), we focused 
on further incorporating a C3 methyl substituent as is found in brequinar (Figure 3.1). We 
postulated that this added substituent would further limit conformational freedom around the C2 
biaryl bond and hence minimize entropic penalties required for interaction with the nitrogen on 
the pendant pyridine ring for analogues shown in Tables 3.2 and 3.3. Additionally, the C3 methyl 
substituent should minimize potential stacking interactions between molecules in solution 
leading to better aqueous solubility. Synthesized analogues with the C3 methyl were generally 
more potent than the corresponding C3 desmethyl congeners in the DHODH assay with the 
notable exceptions of 62 and 65 (Table 3.4). Analogue 62 is less potent than 28 in the DHODH 
and cell based assays whereas 65 is moderately less potent than 59 in both assays.   
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Table 3.4. Biological activity of C3 methyl-substituted quinolines.a 
 
  DHODH 
Assay 
  MTT Assay 
     HCT-116 MIA PaCa-2 
# R1 IC50 (µM) cLogP LipE IC50 (µM) IC50 (µM) 
62 
 
0.131 ± 0.027 5.66 1.23 12.8 ± 2.4 10.9 ± 1.4 
63 
 
0.850 ± 0.47 4.30 0.61 71.0 ± 20.0 >100 
64 
 
3.93 ± 1.6 4.80 0.61 >100 >100 
65 
 
0.0772 ± 0.055 4.62 2.49 23.0 ± 10.0 28.7 ± 16 
66 
 
0.274 ± 0.025 5.12 1.44 30.0 ± 6.3 15.7 ± 4.5 
a cLogP values were calculated using ChemBioDraw Professional 16, Calculated lipophilic 
ligand efficiency (LipE) = pIC50 (M) – cLogP.28 
 
 The next iteration of our optimization campaign was to evaluate core modifications of the 
C6 position of the quinoline ring. In general, the crystal structure (PDB: 1D3G) depicts a small 
pocket that could be occupied by a suitable C6 substituent (Figure 3.3). Additionally, 
SMARTCyp, a software for predicting cytochrome P450-mediated metabolism, identified the C6 
position of a non-substituted analogue as a site of metabolic liability.39 Thus, incorporation of a 
C6 substituent may improve potency and decrease metabolic liabilities. The SAR around this 
position was limited to substituents that could be easily incorporated by our synthetic 
methodology. The data in Table 3.5 show that C6 –F analogues are more potent than 
corresponding C6 -Cl or CH3 congeners. This may be attributed to the size of the substituent, 
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suggesting that smaller lipophilic functional groups are better tolerated. For analogues with the 
C6 substituents, 71 (IC50 = 0.0106 ± 0.0011 µM) possesses an IC50 on par with brequinar (IC50 = 
0.020 ± 0.02 µM) but with a lower cLogP (4.76 vs 5.94). The lowered cLogP may explain the 
potency differences in the HCT-116 cell line. Despite similar potency in the DHODH assay, 71 
is less potent than brequinar in HCT-116 (IC50 = 7.30 ± 2.0 µM vs. IC50 = 0.98 ± 0.52 µM, 
respectively). This may be due to analogue 71 being less cell permeable than brequinar. 
Nonetheless, compound 71 is our most potent analogue in the DHODH assay within the 
quinoline series.  
 
Figure 3.3. Depicted binding cavity of a brequinar analogue. The pocket for a C6 substituent is 
depicted from PDB file 1D3G.  
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Table 3.5. Biological activity of C6 / R1 substituted quinolines.a 
 
   DHODH  
Assay 
  MTT Assay 
      HCT-116 MIA PaCa-2 
# R1 R2 IC50 (µM) cLogP LipE IC50 (µM) IC50 (µM) 
67 
 
F 0.173 ± 0.2 4.45 2.31 15.0 ± 5.0 53.1 ± 44 
68 
 
Cl 0.246 ± 0.03 5.02 1.60 25.0 ± 19.0 26.0 ± 13 
69 
 
Me 0.0593 ± 0.020 5.12 2.11 24.0 ± 3.2 >100 
70 
 
F 5.67 ± 0.63 4.95 0.30 >100 >100 
71 
 
F 0.0106 ± 0.0011 4.76 3.21 7.30 ± 2.0 23.3 ± 22 
72 
 
Cl 0.0437 ± 0.0086 5.34 2.02 9.40 ± 1.6 >100 
73 
 
F 0.0329 ± 0.046 5.27 2.21 6.10 ± 0.70 13.0 ± 0.71 
74 
 
Cl 0.107 ± 0.02 5.84 1.13 9.47 ± 4.2 31.4 ± 25 
a cLogP values were calculated using ChemBioDraw Professional 16, Calculated lipophilic 
ligand efficiency (LipE) = pIC50 (M) – cLogP.28 
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To form potential interactions with Y356, a scaffold hop was made from the quinoline to 
naphthyridine core (Table 3.6). The SAR highlights that 1,7-naphthyridines are the most potent 
within the broad series synthesized and support our hypothesis of the importance of H-bonding 
interactions with Y356. Both the 1,6- and 1,8- naphthyridines (77 and 75) are less potent than the 
quinoline (62) and suggest that these nitrogen placements generate unfavorable interactions. In 
contrast, the 1,7-naphthyridine (76) displays greater potency than the quinoline congener (IC50 = 
0.0539 ± 0.017 µM vs. IC50 = 0.131 ± 0.027 µM, respectively).  
 
Table 3.6. Biological activity of naphthyridines.a 
 
   DHODH Assay   MTT Assay 
      HCT-116 MIA PaCa-2 
# R1 R2 IC50 (µM) cLogP LipE IC50 (µM) IC50 (µM) 
62 
 
Me 0.131 ± 0.027 5.66  12.8 ± 2.4 10.9 ± 1.4 
75 
 
Me 4.18 ± 0.61 4.16 1.22 > 100 > 100 
76 
 
Me 0.0539 ± 0.017 4.16 3.11 24.0 ± 8.0 41.8 ± 36 
77 
 
Me 3.75 ± 2.70 4.16 1.27 >100 >100 
78 
 
Me 0.0257 ± 0.0062 5.04 2.56 3.21 ± 2.6 17.7 ± 14 
a cLogP values were calculated using ChemBioDraw Professional 16, Calculated lipophilic 
ligand efficiency (LipE) = pIC50 (M) – cLogP.28 
 
Our focus then shifted to C6 substituted 1,7-naphthyridines. For the quinoline series, 
analogues possessing a C6 substitution are far more potent than their non-substituted analogues 
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(65 vs 71, 66 vs 73). We postulated that a C6 substituted 1,7-naphthyridine would be more 
potent than the corresponding C6 substituted quinolines and possess a lower cLogP. The data 
(Table 3.6) suggest that C6 substituents on the 1,7-naphthyridine result in a more potent series as 
78 is 2-fold more potent than 76. Based on this observation, we sought to incorporate the 
terminal 2-chloro-3-pyridine moiety onto the core 1,7-naphthyridine scaffold. 
Unfortunately, 1,7-naphthyridines analogues with a pyridine terminal attachment (79-81) 
(Table 3.7) are not as potent as the naphthyridines with a terminal phenyl group (76, 78) or 
corresponding analogues within the quinoline series (71, 73). This may be due to an induced fit 
binding. If the naphthyridine forces an induced fit to interact with Y356, then the distance 
between the pyridine nitrogen and Y38 and T63 may be too large to form an interaction and 
result in an unfavorable clashing with hydrophobic residues. Furthermore, while these analogues 
possess modest activity in the DHODH assay, they are not active in HCT-116 cells. In fact, 
analogues with a cLogP lower than 4 (79, 80) do not adversely affect cell growth below 100 µM. 
In contrast, analogue 82, containing the terminal fluorophenyl like brequinar, is potent in both 
the DHODH and MTT assays. Collectively, the potency of the 1,7-naphthyridines in the 
DHODH assay suggests potential interactions are being formed with DHODH, possibly via 
Y356.  
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Table 3.7. Biological activity of R2 pyridine-substituted naphthyridines.a 
 
   DHODH  
Assay 
  MTT Assay 
      HCT-116 MIA PaCa-
2 
# R1 R2 IC50 (µM) cLogP LipE IC50 (µM) IC50 (µM) 
79 
 
 
0.353 ± 0.05 3.13 3.32 >100 >100 
80 
 
 
10.2 ± 3.6 3.63 1.36 >100 >100 
81 
  
0.226 ± 0.110 4.01 2.64 54.5 ± 17 >100 
82 
  
0.0125 ± 
0.0011 5.19 2.71 
1.01 ± 
0.27 38.0 ± 41.0 
a cLogP values were calculated using ChemBioDraw Professional 16, Calculated lipophilic 
ligand efficiency (LipE) = pIC50 (M) – cLogP.28 
 
3.5 Crystallography  
The structures of DHODH co-crystallized with 73 and 76 were solved to 1.46 Å and 2.70 Å 
resolution, respectively. DHODH:73 was solved with two molecules in the asymmetric unit, 
while DHODH:76 contained only one. Their overall structures are similar in that the single chain 
of DHODH:76 aligns with RMSD values of 0.734 Å and 0.732 Å to the A and B chains of 
DHODH:73, respectively. The structures also adopt the same fold as other brequinar analogues 
bound to DHODH reported in the literature.24, 40, 41  
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Figure 3.4. Interactions between DHODH and analogues 76 and 73. Noncovalent interactions 
of DHODH with 76 (cyan) and 73 (yellow). (A) and (B) outline hydrophobic interactions and 
(C) and (D) demonstrate hydrogen-bonding (dashed lines). 73 shown modeled in predominant 
conformation.  Nitrogen is shown in blue, oxygen (red), sulfur (yellow), chlorine (green), and 
fluorine (light blue), hydrogens (white). 
 
Consistent with previous structures of DHODH bound to brequinar analogs,24, 40, 41 inhibitors 
73 and 76 occupy the proposed ubiquinone binding site, a hydrophobic channel formed by α1 
and α2 helices directed toward the proximal redox site with the 4-carboxylic acid quinoline ring 
system oriented toward the active site.  Both compounds are stabilized by a substantial number 
of hydrophobic interactions with the side chains of DHODH residues lining the pocket (L42, 
M43, L46, P52, A55, A59, F62, and T63) (Figure 3.4, A and B).  The more deeply buried 
quinoline ring of 73 and naphthyridine ring of 76 form van der Waals contacts with a series of 
hydrophobic residues near the redox site including F96, V134, V143, T360, Y356, L359, and 
P364 (Figure 3.4, A and B).  The C7-fluorine substituent of 73 is directed toward the FMN 
cofactor as in previous structures with other brequinar analogs,24, 41 and the C4 carboxylate of 
both inhibitors form salt bridges with R136 and participate in H-bonding with Q47 and T360 
through a water molecule (Figure 3.4, C and D). 
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 In contrast to previous structures, the additional nitrogen incorporated into the 1,7-
naphthyridine ring of 76 is within 2.9 Å of the Y356 hydroxyl group, allowing this inhibitor to 
participate in an additional H-bonding interaction within the binding site (Figure 3.4C). 
 In place of the unsubstituted phenyl ring of 76 and the 2-fluorophenyl ring of brequinar, 
73 features a 2-chloro-6-methyl pyridine ring that can adopt two different orientations.  Based on 
the ligand omit map density, the chlorine substituent can be directed toward the α1 helix, but this 
orientation has low occupancy, likely in part due to steric clashes with the hydrophobic residues 
lining the binding pocket.  The higher occupancy orientation of the pyridine ring directs the 
chlorine toward F98.  In this orientation, the pyridine nitrogen is directed toward space usually 
occupied by the disordered 68-72 loop.  In one molecule of the asymmetric unit, density 
corresponding to a water lies within 3.2 Å of the pyridine nitrogen and mediates a H-bond with 
the side chain of T63 (Figure 3.4D).  The 6-methyl substituent is also directed toward space 
usually occupied by the loop connecting the two domains; steric clashes with this highly flexible 
loop might contribute to the intrinsic disorder of this loop and explain why density corresponding 
to residues 68-70 is absent in the structure with 73 in contrast to the DHODH:76, in which these 
residues were able to be modeled. 
There is additional density near the solvent-exposed entrance to the channel occupied by the 
inhibitor.  The extra electron density in this site has been reported in previous structures of 
DHODH with brequinar analogs.24, 41 Liu and colleagues modeled a detergent, DDAO, in this 
site.24  In our structures of DHODH:73 and DHODH:76, we modeled the aliphatic chain in 
common to the two detergents, Anzergent 3-10 and HEGA-8, used for crystallization. The 
aliphatic chain forms van der Waals interactions with the side chains of F62 and P69 as well as 
the backbone of residues 67-69. Additionally, the detergent makes contact with the phenyl group 
of 76. In the DHODH:73 structure, the aliphatic chain does not interact with the loop, but forms 
van der Waals interactions with the side chains of F62, L46, L42 and F37 along with the terminal 
substituted pyridine of 73.  Although the detergent is not physiologically relevant, it is likely that 
this face of the protein and the bound inhibitor make contacts with aliphatic chains of 
phospholipids comprising the membrane.24 
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3.6 Pharmacokinetic evaluation and thermodynamic solubility  
We deemed compound 71 to possess an overall profile that merited pharmacokinetic 
evaluation in mice (Table 3.8). When 71 was administered either orally or intravenously, a 
similar elimination half-life of 2.73-2.78 hours was observed. Oral bioavailability for 71 is 56%, 
which is suitable for DHODH inhibition considering its potency. For PO dosing, the Cmax was 
5313 ng/mL and was reached in 0.25 h. The low Cmax of 71 may be an indication of poor 
intestinal membrane permeability. This may be improved through development of formulations 
or pro-drug approaches. However, the clearance rate and volume of distribution are favorable for 
continuous inhibition, suggesting that 71 is well suited for further investigation.  
Analogue 76 is more soluble in aqueous solutions than compounds of the quinoline series. In 
comparison to brequinar, compound 76 is 2.5 – 3x more soluble in PBS at pH 7.4 (Table 3.9). 
The nitrogen of the naphthyridine core significantly increases the aqueous solubility in 
comparison to the quinoline core. However, a comparison between 71 and brequinar highlights 
that despite a lower cLogP, 71’s aqueous solubility is not significantly different from that of 
brequinar. The large chlorine group may limit the total solvent exposure of 71’s pyridine moiety, 
which minimizes its effect on aqueous solubility. Nonetheless, compound 76 is endowed with 
better drug-like properties compared to brequinar, with potent DHODH inhibition and improved 
aqueous solubility.  
Table 3.8. Pharmacokinetic parameters of analogue 71.a 
Route Dose C0/Cmax Tmax AUC 
(0-
TLDC) 
AUD 
(0-
INF) 
t1/2 CL CL-F Vss Vz_F %F 
 mg/kg ng/mL h h*ng/mL h mL/h/kg mL/kg % 
IV 10 45381 NA 32261 32306 2.73 309 N/A 496 NA N/A 
PO 20 5313 0.25 35896 36035 2.78 N/A 555 NA 2226 56% 
aPK parameters were estimated using non-compartmental analysis with Phoenix/WINONLIN. C0 
= initial concentration, Cmax = Maximum observed concentration, Tmax = Time to reach Cmax, 
AUC(0-TLDC) = Area under the concentration-time curve from time zero to time of last 
detectable concentration, AUC(0-inf) = Area under the concentration-time curve from time zero 
to infinite, CL = Systemic clearance, CL_F = Apparent clearance, Vss = Volume of distribution 
at steady state, Vz_F = Volume of distribution associated with the terminal elimination phrase, 
Terminal elimination half-life (t½) was calculated based on data points (≥3) in the terminal phase 
with correlation of coefficient > 0.90, %F = bioavailability. 
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Table 3.9. Thermodynamic solubility of selected analogues.a 
   Initial dose 
concentration 
pH after assay 
# µM µg/mL mg/mL  
2 (brequinar) 1085.2 407.4 6.2 7.4 
 1048.6 393.6 6.4 7.4 
1 43.9 14.5 2.9 7.4 
 48.0 15.9 4.9 7.4 
71 1000.1 392.8 5.8 7.4 
 982.1 385.8 4.9 7.4 
76 2628.4 894.6 6.7 7.4 
 3096.3 1053.6 8.7 7.4 
aAssay performed using CLND in phosphate buffer saline, pH 7.4. Analyte concentrations were 
determined via a standard calibration curve.  
 
3.7 Conclusions 
This study reports our efforts towards the development of a novel DHODH inhibitor with 
improved potency and aqueous solubility. Our efforts toward designing molecular interactions 
with T63 led to the potent inhibitors 71 (DHODH IC50 = 0.0106 ± 0.0011 µM) and 73 (DHODH 
IC50 = 0.0329 ± 0.046 µM) both possessing a lower cLogP than brequinar (4.76, 5.27 vs. 5.94 
respectively). A co-crystal structure of 73 and DHODH depicts a water-mediated H-bonding 
interaction with the terminal pyridine and T63 (Figure 3.4D). Efforts to form an interaction with 
Y365 led to the 1,7-naphthyridine inhibitors; 76 (DHODH IC50 = 0.0539 ± 0.017 µM), 78 
(DHODH IC50 = 0.0257 ± 0.0062 µM), and 82 (DHODH IC50 = 0.0125 ± 0.0011 µM). In a co-
crystal structure with DHODH, the 7’ nitrogen of 76’s core forms a H-bond with the hydroxyl of 
Y356 (Figure 3.4C). Furthermore, analogue 76 is significantly more soluble in aqueous solution 
than brequinar. Pharmacokinetic evaluation of 71 highlights suitable oral bioavailability (%F = 
56%) and half-life (t1/2 = 2.78 h), suitable for further investigation. Collectively, these inhibitors 
depict the potential to enhance binding with DHODH through novel H-bonding interactions. The 
results of this study delineate the possibility to simultaneously improve potency while lowering 
the cLogP for inhibitors that occupy a lipophilic binding pocket. The inhibitors disclosed in this 
study present suitable leads for further inhibitor design and early stage development. Future 
studies will seek to improve cell permeability by optimizing pro-drug design. Additionally, the 
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ability of these inhibitors to induce differentiation in acute myeloid leukemia will be evaluated 
along with in vivo efficacy studies.  
 
3.8 Experimental 
 
General methods. Reagents and anhydrous solvents were used without further purification and 
purchased from commercial sources. Cinchophen and brequinar were purchased from 
commercial sources and utilized without further purification. A Biotage® Initiator+ was used to 
perform microwave catalyzed reactions in sealed vials. Reaction progress was monitored by UV 
absorbance using thin-layer chromatography (TLC) on aluminum-backed precoated silica plates 
from Silicycle (SiliaPlate™, 200 µm thickness, F254). Purifications using flash chromatography 
were performed using Silicycle silica gel (SiliaFlash® F60, 40-63 µm, 230-400 mesh, PN: 
R10030B) and a small percentage of compounds were purified using a Biotage® Isolera 
Chromatography system equipped with 10 g and 25 g Ultra-SNAP Cartridge columns (25 µM 
spherical silica). Glassware for reactions were oven dried in preparation and reactions were 
performed using nitrogen or argon atmosphere using standard inert conditions. 1H NMR spectra 
were obtained using a Bruker (300 or 400 MHz) or a Varian (400 or 500 MHz) instrument.  
Spectral data are reported using the following abbreviations: (s = singlet, d = doublet, t = triplet, 
q = quartet, m = multiplet, dd = doublet of doublets), coupling constants are reported in Hz, 
followed by integration. 13C NMR spectra were obtained at 126 MHz on a Varian 500 MHz 
instrument with a proton decoupled probe. A Shimdazu LCMS 20-20 system was utilized for 
generating HPLC traces and obtaining mass spectrometry data. The system is equipped with a 
PDA UV detector and Kinetex® 2.6 µm, XB-C18 100 Å, 75 x 4.6 mm column, which was used 
at room temperature. HPLC gradient method utilized a 1% to 90% MeCN in H2O with 0.01% 
formic acid over 20 minutes with a 0.50 mL/min flow rate. Reverse-phase preparatory 
purifications were performed on a Shimdazu LC-20 modular HPLC system. This system utilized 
a PDA detector and a Kinetex® 5 µm XB-C18 100 Å, 150 x 21.2 mm column. Purification 
methods used a 27-minute gradient from 10% to 90% MeCN in H2O with 0.02% trifluoroacetic 
acid. The chemicals n-BuLi and TMS-diazomethane present hazards. The chemical n-BuLi is 
pyrophoric and must be utilized under an inert atmosphere. The chemical TMS-diazomethane is 
toxic and potentially explosive. Caution should be utilized when working with these chemicals.  
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General protocol A, Pfitzinger synthesis: Isatin (1.0 -1.2 eq) was added to a room temperature 
solution of KOH (4.0 eq) in an EtOH/H2O solution and mixed with various para-substituted 
derivatives of acetophenone (1.0 eq). The solution was heated to reflux for 24-48 hours, 
concentrated in vacuo, and re-dissolved in 1 M NaOH/EtOAc. The aqueous layer was washed 
with EtOAc (3x) and acidified using HCl or glacial acetic acid until precipitant was observed 
(pH 2-3). The precipitant was filtered over a fritted funnel, washed with 1 M HCl, and washed 
again with 2-propanol, diethyl ether, or ethanol to yield final compounds (2-81%).  
 
 2-(4-Cyclohexylphenyl)quinoline-4-carboxylic acid (1): Isatin (987 
mg, 6.71 mmol), 1-(4-cyclohexylphenyl)ethan-1-one (1.00 g,  4.95 mmol), and KOH (1.55 g, 
27.6 mmol) were dissolved in 30 mL EtOH and 10 mL H2O. Following general protocol A, 2-(4-
cyclohexylphenyl)quinoline-4-carboxylic acid was recovered as a white powder (374 mg, 1.13 
mmol, 23%). 1H NMR (500 MHz, DMSO-d6) δ 8.64 (d, J = 8.6 Hz, 1H), 8.41 (d, J = 1.8 Hz, 
1H), 8.21 – 8.15 (m, 2H), 8.14 – 8.08 (m, 1H), 7.85 – 7.79 (m, 1H), 7.71 – 7.61 (m, 1H), 7.40 – 
7.34 (m, 2H), 2.59 – 2.50 (m, 1H), 1.83 – 1.73 (m, 4H), 1.72 – 1.65 (m, 1H), 1.49 – 1.27 (m, 
4H), 1.27 – 1.10 (m, 1H); 13C NMR (126 MHz, DMSO-d6)) δ 168.09, 156.23, 150.06, 148.86, 
138.00, 136.02, 130.55, 130.14, 127.97, 127.72 (2H), 127.64 (2H), 125.85, 123.81, 119.42, 
44.03, 34.22 (2H), 26.73 (2H), 26.00; LCMS (ESI) 332.2 [M+H]+, 330.2 [M-H]-; HPLC Purity 
at 254 nm, 98.6%.   
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 2-(4-(Piperidin-1-yl)phenyl)quinoline-4-carboxylic acid (25): 
Isatin (247 mg, 1.68 mmol), 1-(4-(piperidin-1-yl)phenyl)ethan-1-one (200 mg, 0.99 mmol), and 
KOH (336 mg, 6.00 mmol) were dissolved in 7 mL EtOH and 2 mL H2O. Following general 
protocol A, 2-(4-(piperidin-1-yl)phenyl)quinoline-4-carboxylic acid was recovered as a red solid 
(88 mg, 0.27 mmol, 27%). 1H NMR (400 MHz, DMSO-d6) δ 8.59 (d, J = 8.4 Hz, 1H), 8.37 (s, 
1H), 8.18 (d, J = 8.6 Hz, 2H), 8.09 (d, J = 8.4 Hz, 1H), 7.80 (t, J = 8.4, 6.9 Hz, 1H), 7.68 – 7.58 
(m, 1H), 7.16 – 7.04 (m, 2H), 3.34 – 3.27 (m, 4H), 1.71 – 1.54 (m, 6H); LCMS (ESI) 333.3 
[M+H]+ , 331.2 [M-H]-; HPLC Purity at 254 nm, 99.7%. 
 
 2-(4-Morpholinophenyl)quinoline-4-carboxylic acid (27): Isatin 
(247 mg,  1.68 mmol), 1-(4-morpholinophenyl)ethan-1-one (200 mg,  0.98 mmol), and KOH 
(336 mg, 6.00 mmol) were dissolved in 7 mL EtOH and 1 mL H2O. Following general protocol 
A, 2-(4-morpholinophenyl)quinoline-4-carboxylic acid was recovered as a red solid (132 mg, 
0.40 mmol, 41%).1H NMR (400 MHz, DMSO-d6) δ 8.60 (d, J = 8.5 Hz, 1H), 8.39 (s, 1H), 8.21 
(d, J = 8.7 Hz, 2H), 8.10 (d, J = 8.4 Hz, 1H), 7.85 – 7.76 (m, 1H), 7.68 – 7.59 (m, 1H), 7.11 (d, J 
= 8.7 Hz, 2H), 3.77 (t, J = 4.8 Hz, 4H), 3.26 (t, J = 4.9 Hz, 4H); LCMS (ESI) 335.9 [M+H]+ , 
333.2 [M-H]-; HPLC Purity at 254 nm, 98.8%. 
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 2-(4-Isopropylphenyl)quinoline-4-carboxylic acid  (18): Isatin (264 
mg, 1.79 mmol), 1-(4-isopropylphenyl)ethan-1-one (0.27 mL, 1.62 mmol), and KOH (275 mg, 
4.91 mmol) were dissolved in 7 mL EtOH and 1 mL H2O. Following general protocol A, 2-(4-
isopropylphenyl)quinoline-4-carboxylic acid was recovered as a yellow solid (130 mg, 0.45 
mmol, 28%). 1H NMR (400 MHz, DMSO-d6) δ 8.65 (d, J = 8.3 Hz, 1H), 8.44 (s, 1H), 8.23 (d, J 
= 8.3 Hz, 2H), 8.16 (d, J = 8.5 Hz, 1H), 7.89 – 7.81 (m, 1H), 7.75 – 7.67 (m, 1H), 7.46 (d, J = 
8.3 Hz, 2H), 3.09 – 2.94 (m, 1H), 1.28 (d, J = 6.9 Hz, 6H); LCMS (ESI) 292.2 [M+H]+ , 290.2 
[M-H]-; HPLC Purity at 254 nm, 95.8%. 
 
 2-(4-Isobutylphenyl)quinoline-4-carboxylic acid (17): Isatin (500 
mg, 3.40 mmol), 1-(4-isobutylphenyl)ethan-1-one (0.57 mL, 3.08 mmol), and KOH (1.14 g, 20.4 
mmol) were dissolved in 12 mL EtOH + 2 mL H2O. Following general protocol A, 2-(4-
isobutylphenyl)quinoline-4-carboxylic acid was recovered as a pink solid (101 mg, 0.33 mmol, 
10% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.68 (d, J = 8.4 Hz, 1H), 8.14 (d, J = 7.9 Hz, 2H), 
8.03 – 7.94 (m, 2H), 7.66 (t, J = 7.6 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.33 (d, J = 7.9 Hz, 2H), 
2.59 – 2.52 (m, 2H), 2.00 – 1.85 (m, 1H), 0.91 (d, J = 6.6 Hz, 6H); LCMS (ESI) 306.1 [M+H]+, 
304.2 [M-H]-; HPLC Purity at 254 nm, 99.9%.   
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 2-([1,1'-Biphenyl]-4-yl)quinoline-4-carboxylic acid (28): Isatin 
(168 mg, 1.14 mmol), 1-([1,1'-biphenyl]-4-yl)ethan-1-one (200 mg, 1.02 mmol), KOH (230 mg, 
4.11 mmol)  were dissolved in 3 mL EtOH with 1 mL H2O. Following general protocol A, 2-
([1,1'-biphenyl]-4-yl)quinoline-4-carboxylic acid was recovered as a beige solid (74 mg, 0.23 
mmol, 20% yield) after recrystallization from ethanol. 1H NMR (300 MHz, CD3OD-d4) δ 8.46 – 
8.36 (m, 1H), 8.19 (d, J = 8.4 Hz, 2H), 8.14 – 8.02 (m, 2H), 7.83 – 7.63 (m, 5H), 7.56 (ddd, J = 
8.2, 6.8, 1.2 Hz, 1H), 7.44 (t, J = 7.4 Hz, 2H), 7.40 – 7.28 (m, 1H); LCMS (ESI) 326.2 [M+H]+, 
324.1 [M-H]-; HPLC Purity at 254 nm, 98.9%.  
 
 2-(4-(Pyridin-2-yl)phenyl)quinoline-4-carboxylic acid (46): Isatin 
(82 mg, 0.56 mmol), intermediate 93 (100 mg,  0.51 mmol), and KOH (112 mg, 2.00 mmol) 
were dissolved 4 mL in EtOH with 1 mL H2O. Following general protocol A, 2-(4-(pyridin-2-
yl)phenyl)quinoline-4-carboxylic acid was recovered as a tan solid (62 mg, 0.19 mmol, 37%). 1H 
NMR (300 MHz, CD3OD-d4) δ 8.71 – 8.64 (m, 1H), 8.46 (d, J = 8.4 Hz, 1H), 8.31 (d, J = 8.1 
Hz, 2H), 8.22 – 8.10 (m, 4H), 8.04 – 7.94 (m, 2H), 7.78 (t, J = 7.7 Hz, 1H), 7.61 (t, J = 7.7 Hz, 
1H), 7.42 (t, J = 6.0 Hz, 1H); LCMS (ESI) 326.9 [M+H]+, 324.9 [M-H]-; HPLC Purity at 254 
nm, 99.4%.   
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 2-(4-(Pyrimidin-5-yl)phenyl)quinoline-4-carboxylic acid (49): 
Isatin (56 mg, 0.38 mmol), intermediate 94 (75 mg, 0.38 mmol), and KOH (64 mg, 1.14 mmol) 
were dissolved in 3 mL EtOH and 1 mL H2O. Following general protocol A, 2-(4-(pyrimidin-5-
yl)phenyl)quinoline-4-carboxylic acid was recovered as a yellow solid (24 mg, 0.07 mmol, 18% 
yield). 1H NMR (300 MHz, DMSO-d6) δ 9.31 – 9.21 (m, 3H), 8.66 (d, J = 8.5 Hz, 1H), 8.56 (s, 
1H), 8.48 (d, J = 8.3 Hz, 2H), 8.21 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 8.4 Hz, 2H), 7.94 – 7.85 (m, 
1H), 7.79 – 7.68 (m, 1H); LCMS (ESI) 328.2 [M+H]+, 326.9 [M-H]-; HPLC Purity at 254 nm, 
99.5%.   
 
 2-(4-(Pyridazin-3-yl)phenyl)quinoline-4-carboxylic acid (50): 
(Isatin (203 mg, 1.38 mmol), intermediate 95 (273 mg, 1.38 mmol), and KOH (309 mg, 5.52 
mmol) were dissolved in 10 mL EtOH. Following general protocol A, 2-(4-(pyridazin-3-
yl)phenyl)quinoline-4-carboxylic acid was recovered as a tan solid (160 mg, 0.49 mmol, 36%). 
1H NMR (400 MHz, DMSO-d6) δ 9.25 (dd, J = 4.8, 1.5 Hz, 1H), 8.66 (d, J = 8.5 Hz, 1H), 8.56 
(s, 1H), 8.50 (d, J = 8.3 Hz, 2H), 8.42 – 8.29 (m, 3H), 8.20 (d, J = 8.4 Hz, 1H), 7.91 – 7.79 (m, 
2H), 7.74-7.70 (m, 1H); LCMS (ESI) 327.9 [M+H]+, 325.9 [M-H]-; HPLC Purity at 254 nm, 
96.7%.   
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 2-(4-(Pyrimidin-2-yl)phenyl)quinoline-4-carboxylic acid (51): 
Isatin (67 mg, 0.46 mmol), intermediate 96 (109 mg, 0.55 mmol), KOH (103 mg, 1.84 mmol) 
were dissolved in 3 mL EtOH and 1 mL H2O. Following general protocol A, 2-(4-(pyrimidin-2-
yl)phenyl)quinoline-4-carboxylic acid was recovered as a tan solid (80 mg, 0.24 mmol, 52%). 1H 
NMR (400 MHz, DMSO-d6) δ 8.96 (d, J = 4.8 Hz, 2H), 8.67 (d, J = 8.2 Hz, 1H), 8.61 – 8.54 
(m, 3H), 8.50 – 8.46 (m, 2H), 8.20 (d, J = 8.4 Hz, 1H), 7.90 – 7.84 (m, 1H), 7.75 – 7.69 (m, 1H), 
7.50 (t, J = 4.8 Hz, 1H); LCMS 328.1 [M+H]+, 326.1 [M-H]-; HPLC Purity at 254 nm, 96.8% 
 
 2-(4-(2-(trifluoromethyl)pyridin-3-yl)phenyl)quinoline-4-
carboxylic acid (52): (2-(Trifluoromethyl)pyridin-3-yl)boronic acid (190 mg, 1.12 mmol), 1-(4-
bromophenyl)ethan-1-one (200 mg, 1.02 mmol), K2CO3 (563 mg, 4.08 mmol), and Pd(PPh3)4 
(118 mg, 10% mol) were dissolved in dioxane (10 mL) and heated to reflux overnight. The 
solvent was concentrated and the residue was partitioned between EtOAc and H2O. Product was 
extracted with EtOAc (3x), poured over a silica pad, and eluted with additional EtOAc. The 
elution was concentrated for use in next step. 1-(4-(2-(Trifluoromethyl)pyridin-3-
yl)phenyl)ethan-1-one, isatin (160 mg, 1.02 mmol) and KOH (227 mg, 4.06 mmol) were 
dissolved in 5 mL EtOH and 1 mL H2O. The mixture was stirred under refluxing conditions for 
24 hours and then concentrated. Residue was re-dissolved in 1 M KOH and washed with EtOAc 
(3x). The aqueous layer was acidified with AcOH until precipitant formation was observed, pH 
3-4. The solid was collected and washed with Et2O and 2-propanol to yield 2-(4-(2-
(trifluoromethyl)pyridin-3-yl)phenyl)quinoline-4-carboxylic acid as a tan solid (39 mg, 0.10 
mmol, 10% yield over two steps). 1H NMR (400 MHz, DMSO-d6) δ 8.83 (dd, J = 4.7, 1.5 Hz, 
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1H), 8.71 – 8.66 (m, 1H), 8.55 (s, 1H), 8.43 (d, J = 8.4 Hz, 2H), 8.21 (d, J = 8.4 Hz, 1H), 8.05 – 
8.02 (m, 1H), 7.92 – 7.82 (m, 2H), 7.77 – 7.71 (m, 1H), 7.59 (d, J = 8.1 Hz, 2H); LCMS (ESI) 
395.1 [M+H]+, 393.1 [M-H]-; HPLC Purity at 254 nm, 99.8%. 
 
 2-(4-(4-(Trifluoromethyl)pyridin-3-yl)phenyl)quinoline-4-
carboxylic acid (53): Isatin (220 mg, 1.50 mmol), intermediate 97 (235 mg, 0.89 mmol), and 
KOH (300 mg, 5.36 mmol) were dissolved 10 mL absolute EtOH. Following general protocol A, 
2-(4-(4-(trifluoromethyl)pyridin-3-yl)phenyl)quinoline-4-carboxylic acid was recovered as a tan 
solid (88 mg, 0.22 mmol, 25%). 1H NMR (400 MHz, DMSO-d6) δ 8.97 – 8.90 (m, 1H), 8.80 (s, 
1H), 8.69 (d, J = 8.5 Hz, 1H), 8.58 – 8.53 (m, 1H), 8.47 – 8.40 (m, 2H), 8.21 (d, J = 8.4 Hz, 1H), 
7.95 – 7.85 (m, 2H), 7.74 (t, 1H), 7.62 (d, J = 8.0 Hz, 2H); LCMS (ESI) 394.9 [M+H]+, 392.9 
[M-H]-; HPLC Purity at 254 nm, 97.1%.  
 
 2-(4-(4-Methylpyridin-3-yl)phenyl)quinoline-4-carboxylic acid 
(55): Isatin (140 mg, 0.95 mmol), intermediate 98 (200 mg, 0.95 mmol), and KOH (320 mg, 5.71 
mmol) were dissolved in 4 mL EtOH and 2 mL H2O. Following general protocol A, 2-(4-(4-
Methylpyridin-3-yl)phenyl)quinoline-4-carboxylic acid was recovered as a beige solid (85 mg, 
0.25 mmol, 26% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.85 – 8.74 (m, 2H), 8.68 (d, J = 8.5 
Hz, 1H), 8.56 (s, 1H), 8.48 (d, J = 8.1 Hz, 2H), 8.20 (d, J = 8.4 Hz, 1H), 7.95 – 7.84 (m, 2H), 
7.78 – 7.68 (m, 3H), 2.53 (s, 4H); LCMS (ESI) 341.2 [M+H]+, 339.2 [M-H]-; HPLC Purity at 
254 nm, 99.8%.   
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 2-(4-(2-Methylpyridin-3-yl)phenyl)quinoline-4-carboxylic acid 
(56): Isatin (173 mg, 1.18 mmol), intermediate 99 (249 mg, 1.18 mmol) and KOH (394 mg, 7.04 
mmol) were dissolved in 4 mL EtOH and 2 mL H2O. Following general protocol A, 2-(4-(2-
methylpyridin-3-yl)phenyl)quinoline-4-carboxylic acid recovered as a tan solid, (228 mg, 0.67 
mmol, 57% yield). 1H NMR (400 MHz, DMSO-d6) δ 8.75 – 8.68 (m, 1H), 8.50 (dd, J = 4.9, 1.7 
Hz, 1H), 8.38 – 8.32 (m, 2H), 8.19 (s, 1H), 8.09 – 8.02 (m, 1H), 7.77 – 7.68 (m, 2H), 7.62 – 7.51 
(m, 3H), 7.35 (dd, J = 7.7, 4.8 Hz, 1H), 2.51 (s, 8H); LCMS (ESI) 341.2 [M+H]+, 339.1 [M-H]-; 
HPLC Purity at 254 nm, 99.6 %.   
 
 2-(4-(1H-Imidazol-1-yl)phenyl)quinoline-4-carboxylic acid (61): 
Isatin (265 mg, 1.80 mmol), 1-(4-(1H-imidazol-1-yl)phenyl)ethan-1-one  (200 mg, 1.08 mmol), 
and KOH (242 mg, 4.32 mmol) were dissolved in 7 mL EtOH and 1 mL H2O. Following general 
protocol A, 2-(4-(1H-imidazol-1-yl)phenyl)quinoline-4-carboxylic acid was recovered as a tan 
solid (116 mg, 0.36 mmol, 33%). 1H NMR (400 MHz, DMSO-d6) δ 8.64 (dd, J = 8.5, 1.4 Hz, 
1H), 8.50 (s, 1H), 8.49 – 8.40 (m, 3H), 8.22 – 8.14 (m, 1H), 7.92 – 7.82 (m, 4H), 7.75 – 7.66 (m, 
1H), 7.18 (s, 1H); LCMS (ESI) 315.9 [M+H]+, 313.9 [M-H]-; HPLC Purity at 254 nm, 95.4%.   
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 2-([1,1'-Biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid (62): 
Isatin (200 mg, 1.36 mmol), 1-([1,1'-biphenyl]-4-yl)propan-1-one (237 mg, 1.13 mmol), and 
KOH (266 mg, 4.75 mmol) were dissolved in 5 mL EtOH and 2 mL H2O. Following general 
protocol A, 2-([1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid was recovered as a tan 
solid (8 mg, 0.02 mmol, 2%) after trituration with diethyl ether and 2-propanol and then 
recrystallization from EtOH. 1H NMR (300 MHz, DMSO-d6) δ 8.08 (d, J = 8.2 Hz, 1H), 7.87 – 
7.66 (m, 9H), 7.52 (t, J = 7.5 Hz, 2H), 7.42 (t, J = 7.3 Hz, 1H), 2.46 (s, 3H); LCMS (ESI) 340.2 
[M+H]+, 338.1 [M-H]-; HPLC Purity at 254 nm, 97.5%.  
 
 2-(4-Bromophenyl)quinoline-4-carboxylic acid (83): Isatin (5.00 g, 
34.0 mmol), 1-(4-bromophenyl)ethan-1-one (6.70 g, 34.0 mmol), KOH (11.4 g, 204 mmol) were 
dissolved in 55 mL EtOH and 24 mL H2O. Following general protocol A, 2-(4-
bromophenyl)quinoline-4-carboxylic acid was recovered as a yellow solid (9.02 g, 27.7 mmol, 
81%). 1H NMR (300 MHz, DMSO-d6) δ 8.68 (d, J = 8.3 Hz, 1H), 8.20 (d, J = 8.5 Hz, 2H), 8.08 
(s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.72 (dd, J = 12.5, 8.1 Hz, 3H), 7.53 (t, J = 7.6 Hz, 1H); MS 
(ESI) 328.0 [M+H]+.  
 
 2-(4-Bromophenyl)-3-methylquinoline-4-carboxylic acid (84): Isatin 
(5.00 g, 34.0 mmol), 1-(4-bromophenyl)propan-1-one (7.41 g, 34.7 mmol), and KOH (11.4 g, 
204 mmol) were dissolved in 55 mL EtOH and 24 mL H2O. Following general protocol A, 2-(4-
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bromophenyl)-3-methylquinoline-4-carboxylic acid was recovered as a white solid (8.73 g, 25.6 
mmol, 75%) upon recrystallization in EtOH. 1H NMR (300 MHz, DMSO-d6) δ 8.03 (d, J = 8.5 
Hz, 1H), 7.81 – 7.56 (m, 7H), 2.36 (s, 3H); MS (ESI) 342.0, 343.9 [M+H]+, 342.0, 340.0 [M-H]-.  
 
 2-(4-Bromophenyl)-6-fluoro-3-methylquinoline-4-carboxylic acid 
(85): 5-Fluoroisatin (1.00 g, 6.06 mmol), 1-(4-bromophenyl)propan-1-one (1.29 g, 6.06 mmol), 
and KOH (1.02 g, 18.2 mmol) were dissolved in 10 mL EtOH and 3 mL H2O. Following general 
protocol A, 2-(4-bromophenyl)-6-fluoro-3-methylquinoline-4-carboxylic acid was recovered as a 
beige solid (853 mg, 2.38 mmol, 39%) 1H NMR (500 MHz, DMSO-d6) δ = 8.14 – 8.10 (m, 1H), 
7.73 – 7.67 (m, 3H), 7.57 (d, J = 8.1 Hz, 2H), 7.51 – 7.47 (m, 1H), 2.39 (s, 3H); MS (ESI+) 
360.0, 361.9 [M+H]+ 358.1, 360.2 [M-H]-. 
 
 2-(4-Bromophenyl)-6-chloro-3-methylquinoline-4-carboxylic 
acid (86): 5-Chloroisatin (1.00 g, 5.49 mmol), 1-(4-bromophenyl)propan-1-one (1.20 g, 5.63 
mmol), and KOH (1.23 g, 22.0 mmol) were dissolved in 20 mL EtOH and 10 mL H2O. 
Following general protocol A, 2-(4-bromophenyl)-6-chloro-3-methylquinoline-4-carboxylic acid 
was recovered as a tan solid (1.57 g, 4.18 mmol, 76%). 1H NMR (400 MHz, DMSO-d6) δ 8.13 
(d, J = 8.8 Hz, 1H), 7.88 – 7.81 (m, 2H), 7.79 – 7.75 (m, 2H), 7.68 – 7.62 (m, 2H), 2.47 (s, 3H); 
MS (ESI) 376.0, 377.9 [M+H]+.  
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 2-(4-Bromophenyl)-3,6-dimethylquinoline-4-carboxylic acid (87): 
5-Methylisatin (1.00 g, 6.21 mmol), 1-(4-bromophenyl)propan-1-one (1.32 g, 6.20 mmol), and 
KOH (1.39 g, 24.8 mmol) were dissolved in 10 mL EtOH and 3 mL H2O. Following general 
protocol A, 2-(4-bromophenyl)-3,6-dimethylquinoline-4-carboxylic acid was recovered as a tan 
solid (1.14 g, 3.20 mmol, 52%). 1H NMR (400 MHz, DMSO-d6) δ 8.07 (d, J = 8.6 Hz, 1H), 7.79 
– 7.70 (m, 3H), 7.66 – 7.60 (m, 3H), 2.56 (s, 3H), 2.38 (s, 3H); MS (ESI) 356.0 [M+H]+.  
 
General protocol B, acid catalyzed esterification: The corresponding carboxylic acid (1.0 eq) 
was dissolved in solution containing anhydrous MeOH and a catalytic amount of H2SO4. The 
reaction mixture was refluxed overnight before concentrating MeOH. Residue was re-dissolved 
in H2O and neutralized before extracting product with EtOAc (3x). The organic layer was dried 
with MgSO4, filtered, concentrated, and purified via flash chromatography using a gradient 
method from 5 to 60% EtOAc in hexane (63-88%).  
  
 Methyl 2-(4-cyclohexylphenyl)quinoline-4-carboxylate (23): 
Compound 1 (25 mg, 0.08 mmol) was dissolved in 2 mL MeOH. H2SO4 (16 drops, catalyst) was 
added to the reaction mixture and the mixture was heated to reflux overnight. Following general 
protocol B, methyl 2-(4-cyclohexylphenyl)quinoline-4-carboxylate was recovered as an off-
white solid (25 mg, 0.07 mmol, 88%) 1H NMR (300 MHz, CDCl3-d) δ 8.76 (d, J = 8.5 Hz, 1H), 
8.41 (s, 1H), 8.24 (d, J = 8.4 Hz, 1H), 8.15 (d, J = 8.0 Hz, 2H), 7.86 – 7.71 (m, 1H), 7.69 – 7.59 
(m, 1H), 7.41 (d, J = 8.0 Hz, 2H), 4.09 (s, 3H), 2.70 – 2.57 (m, 1H), 2.03 – 1.85 (m, 4H), 1.84 – 
1.67 (m, 1H), 1.61 – 1.21 (m, 5H); LCMS (ESI) 346.2 [M+H]+; HPLC Purity at 254 nm, 98.7%. 
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 Methyl 2-(4-(piperidin-1-yl)phenyl)quinoline-4-carboxylate (24): 
Compound 25 (30 mg, 0.09 mmol) was dissolved in 2 mL MeOH. H2SO4 (16 drops, catalyst) 
was added to the reaction mixture and the mixture was heated to reflux for 12 hours. Following 
general protocol B, methyl 2-(4-(piperidin-1-yl)phenyl)quinoline-4-carboxylate was recovered as 
a yellow solid (29 mg, 0.08 mmol, 88%). 1H NMR (400 MHz, CDCl3-d) δ 8.71 (dd, J = 8.5, 1.4 
Hz, 1H), 8.38 (s, 1H), 8.21 – 8.12 (m, 3H), 7.80 – 7.70 (m, 1H), 7.63 – 7.53 (m, 1H), 7.13 – 7.00 
(m, 2H), 4.08 (d, J = 1.0 Hz, 3H), 3.39 – 3.28 (m, 4H), 1.80 – 1.71 (m, 4H), 1.70 – 1.60 (m, 2H); 
LCMS (ESI) 347.2 [M+H]+; HPLC Purity at 254 nm, 97.3%. 
 
 Methyl 2-(4-(4-(trifluoromethyl)pyridin-3-yl)phenyl)quinoline-4-
carboxylate (54): Compound 53 (30 mg, 0.08 mmol) was dissolved in anhydrous MeOH with a 
catalytic amount of H2SO4 (30 drops). Following general protocol B, methyl 2-(4-(4-
(trifluoromethyl)pyridin-3-yl)phenyl)quinoline-4-carboxylate was recovered as a white solid (19 
mg, 0.05 mmol, 63%). 1H NMR (400 MHz, CDCl3-d) δ 8.90 – 8.73 (m, 3H), 8.50 (s, 1H), 8.34 
(d, J = 8.2 Hz, 2H), 8.31 – 8.25 (m, 1H), 7.82 (ddd, J = 8.5, 6.8, 1.5 Hz, 1H), 7.71 – 7.65 (m, 
2H), 7.56 (d, J = 8.0 Hz, 2H), 4.12 (s, 3H); LCMS (ESI) 409.1 [M+H]+; HPLC Purity at 254 
nm, 99.9%. 
 
General protocol C, base catalyzed esterification: The corresponding carboxylic acid (1.0 eq), 
Cs2CO3 (1.2 eq), and MeI (2.0 eq) were dissolved in anhydrous DMF. The mixture was stirred at 
room temperature overnight. Upon completion, the mixture was diluted EtOAc and washed with 
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brine (8x). The organic layer was dried with MgSO4, filtered, concentrated, and purified via flash 
chromatography using a gradient method from 5 to 60% EtOAc in hexane (43-93%).  
 
 Methyl 2-(4-bromophenyl)quinoline-4-carboxylate (88): Intermediate 
83 (9.00 g, 27.4 mmol), Cs2CO3 (10.8 g, 33.3 mmol) and MeI (3.48 mL, 55.4 mmol) were stirred 
at room temperature in 139 mL DMF overnight. Following general protocol C, methyl 2-(4-
bromophenyl)quinoline-4-carboxylate (4.07 g, 11.9 mmol, 43%) was recovered as a white solid. 
1H NMR (300 MHz, CDCl3-d) δ 8.79 – 8.71 (m, 1H), 8.36 (s, 1H), 8.25 – 8.17 (m, 1H), 8.14 – 
8.06 (m, 2H), 7.83 – 7.74 (m, 1H), 7.71 – 7.61 (m, 3H), 4.09 (s, 3H); MS (ESI) 342.0 [M+H]+.  
 
 Methyl 2-(4-bromophenyl)-3-methylquinoline-4-carboxylate (89): 
Intermediate 84 (8.73 g, 25.6 mmol), Cs2CO3 (9.98 g, 30.7 mmol) and MeI (3.22 mL, 51.2 
mmol) were stirred at room temperature in 140 mL DMF overnight. Following general protocol 
C, methyl 2-(4-bromophenyl)-3-methylquinoline-4-carboxylate (7.55 g, 21.2 mmol, 83%) was 
recovered as a white cake-like powder. 1H NMR (300 MHz, CDCl3-d) δ 8.15 (d, J = 8.6 Hz, 
1H), 7.78 – 7.69 (m, 2H), 7.70 – 7.57 (m, 3H), 7.47 (d, J = 7.5 Hz, 2H), 4.12 (s, 3H), 2.41 (s, 
3H); MS (ESI) 356.0, 357.9 [M+H]+.  
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 Methyl 2-(4-bromophenyl)-6-fluoro-3-methylquinoline-4-
carboxylate (90): Intermediate 85 (853 mg, 2.38 mmol), Cs2CO3 (928 mg, 2.86 mmol), and MeI 
(0.3 mL, 4.76 mmol) were stirred at room temperature in 12 mL DMF overnight. Following 
general protocol C, methyl 2-(4-bromophenyl)-6-fluoro-3-methylquinoline-4-carboxylate 
recovered (636 mg, 1.71 mmol, 71%) as a solid. 1H NMR (300 MHz, CDCl3-d) δ 8.13 (dd, J = 
9.2, 5.4 Hz, 1H), 7.70 – 7.63 (m, 2H), 7.54 – 7.43 (m, 3H), 7.42 – 7.35 (m, 1H), 4.11 (s, 3H), 
2.42 (s, 3H); MS (ESI) 374.0, 376.0 [M+H]+. 
 
 Methyl 2-(4-bromophenyl)-6-chloro-3-methylquinoline-4-
carboxylate (91): Intermediate 86 (1.57 g, 4.18 mmol), Cs2CO3 (1.63 g, 5.02 mmol) and MeI 
(0.53 mL, 8.36 mmol) were stirred at room temperature in 40 mL DMF overnight. Following 
general protocol C, methyl 2-(4-bromophenyl)-6-chloro-3-methylquinoline-4-carboxylate (1.21 
g, 3.13 mmol, 75%) was recovered as an orange solid. 1H NMR (300 MHz, CDCl3-d) δ 8.07 (d, 
J = 9.0 Hz, 1H), 7.75 – 7.71 (m, 1H), 7.66 (d, J = 8.1 Hz, 3H), 7.49 – 7.42 (m, 2H), 4.13 (s, 2H), 
2.42 (s, 3H); MS (ESI) 389.9, 392.0 [M+H]+. 
 
 Methyl 2-(4-bromophenyl)-3,6-dimethylquinoline-4-carboxylate 
(92): Intermediate 87 (1.14 g, 3.08 mmol), Cs2CO3 (1.20 g, 3.69 mmol) and MeI (0.38 mL, 6.16 
mmol) were stirred at room temperature in 40 mL DMF overnight. Following general protocol C, 
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methyl 2-(4-bromophenyl)-3,6-dimethylquinoline-4-carboxylate (1.06 g, 2.87 mmol, 93%) was 
recovered as an orange solid. 1H NMR (300 MHz, CDCl3-d) δ 8.03 (d, J = 8.6 Hz, 1H), 7.68 – 
7.60 (m, 2H), 7.59 – 7.53 (m, 1H), 7.50 – 7.42 (m, 3H), 4.12 (s, 3H), 2.57 (s, 3H), 2.39 (s, 3H); 
MS (ESI) 370.0, 371.9 [M+H]+.  
 
General procedure D, Suzuki coupling Non-microwave protocol: To a degassed round bottom 
flask containing brominated starting material (1 eq), boronic acid (1.2-1.5 eq), K2CO3 (3-4 eq), 
Pd(PPh3)4  (5-10% mol) was dissolved in dioxane or toluene. The reaction was heated at reflux 
until loss of starting material was observed via TLC (12-48 hrs). The reaction mixture was 
concentrated, partitioned between EtOAc/H2O, and washed with EtOAc (3x). The organic layer 
was dried with MgSO4 and concentrated to a residue, which was then purified by flash silica 
chromatography using a gradient of 10 to 60% EtOAc in hexane.  
 
Microwave protocol: Brominated starting material (1 eq), corresponding boronic acid (1.5 eq), 
base (Na2CO3 or K2HPO4, 3-4 eq), and Pd(PPh3)4 (≈ 5% eq) were dissolved in 2:1 dioxane/H2O 
or toluene/H2O in a microwave vial. The vial was capped, purged with argon, and used in a 
microwave synthesizer. The reaction was heated at 125-130 °C for 1.5 – 2 hrs and followed the 
same purification as the non-microwave protocol.  Yields for both protocols ranged from 7 – 
97%.  
 
 1-(4-(Pyridin-2-yl)phenyl)ethan-1-one (93): (4-Acetylphenyl)boronic acid 
(1.04 g, 6.34 mmol), 2-iodopyridine (0.52 mL, 4.85 mmol),  K2CO3 (2.68 g, 19.4 mmol), and 
Pd(PPh3)4  (280 mg) were dissolved 10 mL dioxane and 1 mL H2O. The reaction was heated to 
100 °C overnight. Following general protocol D, 1-(4-(pyridin-2-yl)phenyl)ethan-1-one was 
recovered as a white solid (185 mg, 0.93 mmol, 19%). 1H NMR (400 MHz, CDCl3-d) δ 8.78 – 
8.74 (m, 1H), 8.15 – 8.06 (m, 4H), 7.84 – 7.80 (m, 2H), 7.34 – 7.29 (m, 1H), 2.67 (s, 3H); MS 
(ESI) 198.0 [M+H]+.  
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 1-(4-(Pyrimidin-5-yl)phenyl)ethan-1-one (94): (4-Acetylphenyl)boronic 
acid (155 mg, 0.94 mmol), 5-bromopyrimidine (100 mg, 0.63 mmol),  K2HPO3 (219 g, 1.26 
mmol), and Pd(OAc)2  (2 mg) were dissolved 10 mL ethylene glycol. The reaction was heated to 
80 °C for 4 hours. Following general protocol D, 1-(4-(pyrimidin-5-yl)phenyl)ethan-1-one was 
recovered as a white solid (104 mg, 0.52 mmol, 55%).1H NMR (300 MHz, CDCl3-d) δ 9.33 (s, 
1H), 9.05 (s, 2H), 8.14 (d, J = 8.3 Hz, 2H), 7.72 (d, J = 8.3 Hz, 2H), 2.69 (s, 3H); MS (ESI) 
199.0 [M+H]+.  
 
 1-(4-(Pyridazin-3-yl)phenyl)ethan-1-one (95): (4-Acetylphenyl)boronic 
acid (670 mg, 4.08 mmol), 3-bromopyridazine (500 mg, 3.15 mmol),  K2CO3 (1.74 g, 12.6 
mmol), and Pd(PPh3)4  (182 mg) were dissolved 10 mL dioxane and 1 mL H2O. The reaction was 
heated to 100 °C overnight. Following general protocol D, 1-(4-(pyridin-2-yl)phenyl)ethan-1-one 
was recovered as a white solid (301 mg, 1.52 mmol, 48%). 1H NMR (400 MHz, CDCl3-d) δ 8.12 
– 8.05 (m, 2H), 7.97 – 7.89 (m, 1H), 7.77 – 7.70 (m, 2H), 7.00 – 6.91 (m, 1H), 2.69 (s, 3H); MS 
(ESI) 199.2 [M+H]+. 
 
 1-(4-(Pyrimidin-2-yl)phenyl)ethan-1-one (96): (4-Acetylphenyl)boronic 
acid (1.08 g, 6.60 mmol), 3-2-bromopyrimidine (700 mg, 4.40 mmol),  K2CO3 (2.43 g, 17.6 
mmol), and Pd(PPh3)4 (254 mg) were dissolved 10 mL dioxane. The reaction was heated to 100 
°C for 10 hr. Following general protocol D, 1-(4-(pyrimidin-2-yl)phenyl)ethan-1-one was 
recovered as a white solid (109 mg, 0.55 mmol, 13%). 1H NMR (400 MHz, CDCl3-d) δ 8.87 (d, 
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J = 4.8 Hz, 2H), 8.60 – 8.54 (m, 2H), 8.12 – 8.07 (m, 2H), 7.30 – 7.26 (m, 1H), 2.69 (s, 3H); MS 
(ESI) 199.1 [M+H]+.  
 
 1-(4-(4-(Trifluoromethyl)pyridin-3-yl)phenyl)ethan-1-one (97): (4-
Acetylphenyl)boronic acid (100 mg, 0.44 mmol), 3-bromo-4-(trifluoromethyl)pyridine (109 mg, 
0.66 mmol),  K2HPO4 (230 mg, 1.32 mmol), and Pd(PPh3)4 (25 mg) were dissolved 2 mL 
dioxane and 1 mL H2O. The mixture was heated to 130 °C for 1.5 hours in a microwave reactor. 
Following general protocol D, 1-(4-(4-(trifluoromethyl)pyridin-3-yl)phenyl)ethan-1-one was 
recovered as a clear oil (60 mg, 0.23 mmol, 53%).1H NMR (300 MHz, CDCl3-d) δ 8.87 – 8.81 
(m, 1H), 8.66 (s, 1H), 8.11 – 8.02 (m, 2H), 7.66 (d, J = 5.1 Hz, 1H), 7.46 (d, J = 8.1 Hz, 2H), 
2.67 (s, 3H); MS (ESI) 266.0 [M+H]+.  
 
 1-(4-(4-Methylpyridin-3-yl)phenyl)ethan-1-one (98): (4-
Acetylphenyl)boronic acid (570 mg, 3.47 mmol), 3-bromo-4-methylpyridine (0.20 mL, 1.79 
mmol),  Na2CO3 (1.47 g, 13.9 mmol), and Pd(PPh3)4 (200 mg) were dissolved 10 mL toluene and 
1 mL H2O. The reaction was heated to 120 °C for 10 hr. Following general protocol D, 1-(4-(4-
methylpyridin-3-yl)phenyl)ethan-1-one was recovered (368 mg, 1.74 mmol, 97%) as a white 
solid. 1H NMR (300 MHz, CDCl3-d) δ 8.38 – 8.27 (m, 2H), 7.93 (d, J = 8.0, 1.6 Hz, 2H), 7.31 
(d, J = 8.1, 1.6 Hz, 2H), 7.09 (d, J = 5.1 Hz, 1H), 2.52 (s, 3H), 2.17 (s, 3H); MS (ESI) 212.1 
[M+H]+.  
 
O
N
F F
F
O
N
	 138	
 1-(4-(2-Methylpyridin-3-yl)phenyl)ethan-1-one (99): (4-
Acetylphenyl)boronic acid (570 mg, 3.47 mmol), 3-bromo-2-methylpyridine (0.20 mL, 1.73 
mmol),  Na2CO3 (1.47 g, 13.88 mmol), and Pd(PPh3)4 (200 mg) were dissolved 10 mL toluene 
and 1 mL H2O. The reaction was heated to 120 °C for 10 hr. Following general protocol D, 1-(4-
(2-methylpyridin-3-yl)phenyl)ethan-1-one was recovered as an oil (249 mg, 1.18 mmol, 68%). 
1H NMR (400 MHz, CDCl3-d) δ 8.57 – 8.54 (m, 1H), 8.09 – 8.04 (m, 2H), 7.58 – 7.53 (m, 1H), 
7.47 – 7.42 (m, 2H), 7.27 – 7.22 (m, 1H), 2.68 (s, 3H), 2.54 (s, 3H); MS (ESI) 212.1 [M+H]+.  
 
 1-(4-(2-Chloropyridin-3-yl)phenyl)propan-1-one (100): 4’-
Bromopropiophenone (300 mg, 1.41 mmol), 2-chloropryidine-3-boronic acid (332 mg, 2.11 
mmol), K2HPO4 (736 mg, 4.23 mmol), and Pd(PPh3)4 (81 mg) were added to a microwave vial in 
2 mL dioxane and 1 mL H2O. The mixture was heated to 100 °C for 12 hours. Following general 
protocol D, 1-(4-(2-Chloropyridin-3-yl)phenyl)propan-1-one was recovered as a white solid (134 
mg, 0.55 mmol, 39%). 1H NMR (300 MHz, CDCl3-d) δ 8.43 (dd, J = 4.8, 1.9 Hz, 1H), 8.06 (d, 
2H), 7.71 (dd, J = 7.5, 1.9 Hz, 1H), 7.56 (d, 2H), 7.41 – 7.34 (m, 1H), 3.06 (q, J = 7.2 Hz, 2H), 
1.25 (t, J = 7.2 Hz, 3H); MS (ESI) 246.0 [M+H]+.  
 
 1-(4-(2-Chloro-6-methylpyridin-3-yl)phenyl)propan-1-one (101): 4’-
Bromopropiophenone (220 mg, 1.03 mmol), (2-chloro-6-methylpyridin-3-yl)boronic acid (264 
mg, 1.54 mmol), K2HPO4 (538 mg, 3.09 mmol), and Pd(PPh3)4 (60 mg, 5% mmol) were 
dissolved in 2 mL dioxane and 1 mL H2O. The mixture was heated to 130 °C for 1.5 hours in a 
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microwave reactor. Following general protocol D, 1-(4-(2-Chloro-6-methylpyridin-3-
yl)phenyl)propan-1-one was recovered as a white solid (137 mg, 0.53 mmol, 51%). 1H NMR 
(300 MHz, CDCl3-d) δ 8.07 – 7.99 (m, 2H), 7.59 – 7.49 (m, 3H), 7.19 (d, J = 7.7 Hz, 1H), 3.04 
(q, J = 7.2 Hz, 2H), 2.58 (s, 3H), 1.24 (t, J = 7.2 Hz, 3H); MS (ESI) 260.0 [M+H]+.  
 
 Methyl 2-([1,1'-biphenyl]-4-yl)quinoline-4-carboxylate (29): 
Intermediate 88 (100 mg, 0.29 mmol), phenylboronic acid (53 mg, 0.43 mmol), K2HPO4 (151 
mg, 0.87 mmol), and Pd(PPh3)4 (17 mg, 0.01 mmol) were dissolved in 2 mL dioxane and 1 mL 
H2O. The mixture was heated to 130 °C for 1.5 hours in a microwave reactor. Following general 
protocol D, Methyl 2-([1,1'-biphenyl]-4-yl)quinoline-4-carboxylate was recovered as a white 
crystal (28 mg, 0.08 mmol, 28%). 1H NMR (300 MHz, CDCl3-d) δ 8.76 (dd, J = 8.6, 1.3 Hz, 
1H), 8.46 (s, 1H), 8.35 – 8.20 (m, 3H), 7.85 – 7.73 (m, 3H), 7.74 – 7.58 (m, 3H), 7.49 (t, J = 7.4 
Hz, 2H), 4.09 (s, 3H); LCMS (ESI) 340.1 [M+H]+; HPLC Purity at 254 nm, 99.5%.  
 
 Methyl 2-(4-(pyridin-3-yl)phenyl)quinoline-4-carboxylate (33): 
Intermediate 88 (60 mg, 0.18 mmol), pyridin-3-ylboronic acid (23 mg, 0.19 mmol), Pd(PPh3)4 
(10 mg), and K2CO3 (72 mg, 0.53 mmol) were combined in 3 mL toluene and 1 mL H2O. The 
mixture was heated at 110 °C overnight. Following general protocol D, methyl 2-(4-(pyridin-3-
yl)phenyl)quinoline-4-carboxylate was recovered as a white solid (20 mg, 0.06 mmol, 33%). 1H 
NMR (300 MHz, CDCl3-d) δ 8.92 (s, 1H), 8.74 (d, J = 8.5 Hz, 1H), 8.62 (d, J = 4.8 Hz, 1H), 
8.40 (s, 1H), 8.29 (d, J = 8.2 Hz, 2H), 8.21 (d, J = 8.4 Hz, 1H), 7.91 (dd, J = 8.0, 2.0 Hz, 1H), 
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7.82 – 7.68 (m, 3H), 7.66 – 7.57 (m, 1H), 7.37 (dd, J = 7.9, 4.8 Hz, 1H), 4.23 – 3.94 (m, 3H); 
LCMS (ESI) 341.1 [M+H]+; HPLC Purity at 254 nm, 99.6%. 
 
 Methyl 2-(4-(pyridin-4-yl)phenyl)quinoline-4-carboxylate (102): 
Intermediate 88 (100 mg, 0.29 mmol), 4-pyridineboronic acid pinacol ester (84 mg, 0.41 mmol), 
Pd(PPh3)4 (17 mg), and K2CO3 (151 mg, 0.87 mmol) were dissolved in 2 ml dioxane and 1 mL 
H2O. The mixture was heated to 130 °C for 1.5 hours in a microwave reactor. Following general 
protocol D, methyl 2-(4-(pyridin-4-yl)phenyl)quinoline-4-carboxylate was recovered as an off-
white solid (34 mg, 0.10 mmol, 34%). 1H NMR (300 MHz, CDCl3-d) δ 8.80 – 8.67 (m, 3H), 
8.44 (s, 1H), 8.39 – 8.30 (m, 2H), 8.28 – 8.20 (m, 1H), 7.79 (dd, J = 8.8, 6.7 Hz, 3H), 7.70 – 7.55 
(m, 3H), 4.09 (s, 3H); LCMS (ESI) 341.1 [M+H]+; HPLC Purity at 254 nm, 99.6%. 
 
 Methyl 2-(4-(2-methoxypyridin-3-yl)phenyl)quinoline-4-
carboxylate (103): Intermediate 88 (200 mg, 0.59 mmol), (2-methoxypyridin-3-yl)boronic acid 
(108 mg, 0.70 mmol), K2CO3 (326 mg, 2.36 mmol), and Pd(PPh3)4 (67 mg) were dissolved in 5 
mL toluene and 2 mL H2O. The mixture was heated to reflux overnight. Following general 
protocol D, methyl 2-(4-(2-methoxypyridin-3-yl)phenyl)quinoline-4-carboxylate was recovered 
as an off-white solid (15 mg, 0.04 mmol, 7%). 1H NMR (300 MHz, CDCl3-d) δ 8.78 (d, J = 8.5 
Hz, 1H), 8.48 (s, 1H), 8.34 – 8.19 (m, 4H), 7.86 – 7.61 (m, 5H), 7.08 – 7.00 (m, 1H), 4.11 (s, 
3H), 4.03 (s, 3H); MS (ESI) 371.1 [M+H]+.  
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 Methyl 2-(2'-methoxy-[1,1'-biphenyl]-4-yl)quinoline-4-
carboxylate (104): Intermediate 88 (140 mg, 0.41 mmol), (2-methoxyphenyl)boronic acid (87 
mg, 0.57 mmol), K2CO3 (250 mg, 1.81 mmol), and Pd(PPh3)4 (26 mg) were dissolved in 6 mL 
anhydrous dioxane. The mixture was heated to reflux overnight. Following general protocol D, 
methyl 2-(2'-methoxy-[1,1'-biphenyl]-4-yl)quinoline-4-carboxylate (14 mg, 0.04 mmol, 10%). 
1H NMR (300 MHz, CDCl3-d) δ 8.84 – 8.75 (m, 1H), 8.49 (s, 1H), 8.35 – 8.25 (m, 3H), 7.84 – 
7.73 (m, 3H), 7.69 – 7.62 (m, 1H), 7.46 – 7.35 (m, 2H), 7.15 – 7.01 (m, 2H), 4.11 (s, 3H), 3.87 
(s, 2H); MS (ESI) 370.1 [M+H]+. 
 
 Methyl 2-(4-(6-fluoropyridin-3-yl)phenyl)quinoline-4-
carboxylate (105): Intermediate 88 (50 mg, 0.15 mmol), (6-fluoropyridin-3-yl)boronic acid (35 
mg, 0.25 mmol), K2HPO4 (73 mg, 0.42 mmol) and Pd(PPh3)4 (8 mg, 7.0x10-3 mmol) were 
dissolved in 1 mL dioxane and 0.5 mL H2O. The mixture was heated to 130 °C for 1.5 hours in a 
microwave reactor. Following general protocol D, methyl 2-(4-(6-fluoropyridin-3-
yl)phenyl)quinoline-4-carboxylate was recovered as a beige solid (45 mg, 0.13 mmol, 93% 
yield). 1H NMR (300 MHz, CDCl3-d) δ 8.82 – 8.74 (m, 1H), 8.56 – 8.49 (m, 1H), 8.46 (s, 1H), 
8.40 – 8.31 (m, 2H), 8.26 (d, J = 8.5, 0.9 Hz, 1H), 8.10 – 8.01 (m, 1H), 7.85 – 7.77 (m, 1H), 7.76 
– 7.62 (m, 3H), 7.06 (dd, J = 8.5, 3.0 Hz, 1H); MS (ESI) 359.0 [M+H]+.  
 
N
O O
OMe
N
O O
N
F
	 142	
 Methyl 2-(4-(2-fluoropyridin-3-yl)phenyl)quinoline-4-
carboxylate (106): Intermediate 88 (50 mg, 0.15 mmol), (2-fluoropyridin-3-yl)boronic acid (34 
mg, 0.24 mmol), K2HPO4 (73 mg, 0.42 mmol) and Pd(PPh3)4 (8 mg, 7.0x10-3 mmol) were 
dissolved in 1 mL dioxane and 0.5 mL H2O. The mixture was heated to 130 °C for 1.5 hours in a 
microwave reactor. Following general protocol D, methyl 2-(4-(2-fluoropyridin-3-
yl)phenyl)quinoline-4-carboxylate was recovered as a white solid (45 mg, 0.13 mmol, 93% 
yield). 1H NMR (300 MHz, CDCl3-d) δ 8.78 (d, J = 8.6, 1.3 Hz, 1H), 8.47 (s, 1H), 8.37 – 8.31 
(m, 2H), 8.30 – 8.19 (m, 1H), 8.02 – 7.92 (m, 1H), 7.85 – 7.63 (m, 5H), 7.38 – 7.31 (m, 1H); MS 
(ESI) 359.1 [M+H]+ 
 
 Methyl 2-(4-(2-chloropyridin-3-yl)phenyl)quinoline-4-
carboxylate (107): Intermediate 88 (150 mg, 0.44 mmol), (2-chloropyridin-3-yl)boronic acid 
(110 mg, 0.71 mmol), K2CO3 (243 mg, 1.76 mmol), and Pd(PPh3)4 (25 mg) were dissolved in 5 
mL dioxane and 1 mL H2O. The mixture was heated to reflux overnight. Following general 
protocol D, methyl 2-(4-(2-chloropyridin-3-yl)phenyl)quinoline-4-carboxylate was recovered as 
an off-white solid (76 mg, 0.20 mmol, 45%). 1H NMR (300 MHz, CDCl3-d) δ 8.79 (d, J = 8.5 
Hz, 1H), 8.50 – 8.43 (m, 2H), 8.33 (d, J = 8.1 Hz, 2H), 8.27 (d, J = 8.4 Hz, 1H), 7.85 – 7.73 (m, 
2H), 7.68 (dd, J = 8.4, 6.5 Hz, 3H), 7.40 – 7.34 (m, 1H), 4.11 (s, 3H); MS (ESI) 375.0 [M+H]+.  
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 Methyl 2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)quinoline-
4-carboxylate (108): Intermediate 88 (132 mg, 0.39 mmol), (2-chloro-6-methylpyridin-3-
yl)boronic acid (100 mg, 0.58 mmol), K2HPO4 (204 mg, 1.17 mmol), and Pd(PPh3)4 (23 mg) 
were dissolved in 5 mL dioxane and 1 mL H2O. The mixture was heated to reflux overnight. 
Following general protocol D, methyl 2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)quinoline-4-
carboxylate (109 mg, 0.29 mmol, 74%). 1H NMR (300 MHz, CDCl3-d) δ 8.83 – 8.74 (m, 1H), 
8.47 (s, 1H), 8.35 – 8.22 (m, 3H), 7.86 – 7.77 (m, 1H), 7.72 – 7.61 (m, 4H), 7.21 (d, J = 7.6 Hz, 
1H), 4.10 (s, 3H), 2.63 (s, 3H); MS (ESI) 389.1 [M+H]+. 
 
 Methyl 2-(4-(2-fluoropyridin-3-yl)phenyl)-3-methylquinoline-4-
carboxylate (109): Intermediate 89 (100 mg, 0.28 mmol),  (2-fluoropyridin-3-yl)boronic acid 
(60 mg, 0.42 mmol),  K2HPO4 (146 mg, 0.84 mmol), and Pd(PPh3)4 (16 mg, 0.01 mmol) were 
dissolved 2 mL dioxane and 1 mL H2O. The mixture was heated to 130 °C for 1.5 hours in a 
microwave reactor. Following general protocol D, methyl 2-(4-(2-fluoropyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylate was recovered as a white solid (82 mg, 0.22 mmol, 79%).1H 
NMR (300 MHz, CDCl3-d) δ 8.26 – 8.22 (m, 1H), 8.20 – 8.15 (m, 1H), 7.98 – 7.90 (m, 1H), 
7.78 – 7.67 (m, 6H), 7.64 – 7.56 (m, 1H), 7.35 – 7.29 (m, 1H), 4.12 (s, 3H), 2.48 (s, 3H); MS 
(ESI) 373.1 [M+H]+.  
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 Methyl 2-(4-(2-fluoro-6-methylpyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylate (110): Intermediate 89 (50 mg, 0.13 mmol),  (2-fluoro-6-
methylpyridin-3-yl)boronic acid (31 mg, 0.20 mmol),  K2HPO4 (73 mg, 0.42 mmol), and 
Pd(PPh3)4 (7 mg, 6.0x10-3 mmol) were dissolved 1 mL dioxane and 0.5 mL H2O. The mixture 
was heated to 130 °C for 1.5 hours in a microwave reactor. Following general protocol D, methyl 
2-(4-(2-fluoro-6-methylpyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylate was recovered as 
a white solid (22 mg, 0.06 mmol, 43%). 1H NMR (300 MHz, CDCl3-d) δ 8.17 (d, J = 8.6, 1.5 
Hz, 1H), 7.89 – 7.79 (m, 1H), 7.78 – 7.66 (m, 6H), 7.60 (t, J = 7.3, 6.9, 1.3 Hz, 1H), 7.18 (d, J = 
7.6, 1.8 Hz, 1H), 4.13 (s, 3H), 2.59 (s, 3H), 2.48 (s, 3H); MS (ESI) 387.2 [M+H]+. 
 
 Methyl 2-(4-(2-chloropyridin-3-yl)phenyl)-3-methylquinoline-4-
carboxylate (111): Intermediate 89 (50 mg, 0.14 mmol), (2-chloropyridin-3-yl)boronic acid (31 
mg, 0.20 mmol), K2HPO4 (78 mg, 0.45 mmol), and Pd(PPh3)4 (8 mg) were dissolved in 2 mL 
dioxane and 1 mL H2O. The mixture was heated to 130 °C for 1.5 hours in a microwave reactor. 
Following general protocol D, methyl 2-(4-(2-chloropyridin-3-yl)phenyl)-3-methylquinoline-4-
carboxylate was recovered as a white solid (25 mg, 0.06 mmol, 43%). 1H NMR (300 MHz, 
CDCl3-d) δ 8.47 – 8.42 (m, 1H), 8.19 (d, J = 8.5 Hz, 1H), 7.80 – 7.58 (m, 8H), 7.42 – 7.33 (m, 
1H), 4.13 (s, 3H), 2.50 (s, 3H); MS (ESI) 389.1 [M+H]+.  
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 Methyl 2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylate (112): Intermediate 89 (100 mg, 0.28 mmol), (2-chloro-6-
methylpyridin-3-yl)boronic acid (72 mg, 0.42 mmol),  K2HPO4 (146  mg, 0.84 mmol), and 
Pd(PPh3)4 (16 mg, 0.01 mmol) were dissolved 2 mL dioxane and 1 mL H2O. The mixture was 
heated to 130 °C for 1.5 hours in a microwave reactor. Following general protocol D, methyl 2-
(4-(2-chloro-6-methylpyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylate was recovered as a 
white solid (43 mg, 0.10 mmol, 39%). 1H NMR (300 MHz, CDCl3-d) δ 8.21 – 8.15 (m, 1H), 
7.78 – 7.70 (m, 2H), 7.70 – 7.57 (m, 6H), 7.21 (d, J = 7.7 Hz, 1H), 4.13 (s, 3H), 2.62 (s, 3H), 
2.49 (s, 3H); MS (ESI) 403.1 [M+H]+.  
 
 Methyl 6-fluoro-2-(4-(2-fluoropyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylate (113): Intermediate 90 (50 mg, 0.13 mmol), (2-fluoropyridin-3-
yl)boronic acid (31 mg, 0.22 mmol), K2HPO4 (68 mg, 0.39 mmol) and Pd(PPh3)4 (7 mg, 6.0x10-3 
mmol) were dissolved in 1 mL dioxane and 0.5 mL H2O. The mixture was heated to 130 °C for 
1.5 hours in a microwave reactor. Following general protocol D, methyl 6-fluoro-2-(4-(2-
fluoropyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylate was recovered as a white solid (34 
mg, 0.09 mmol, 69%). 1H NMR (300 MHz, CDCl3-d) δ 8.28 – 8.24 (m, 1H), 8.17 (dd, J = 9.2, 
5.5 Hz, 1H), 8.01 – 7.91 (m, 1H), 7.78 – 7.66 (m, 4H), 7.56 – 7.46 (m, 1H), 7.44 – 7.32 (m, 2H), 
4.13 (s, 3H), 2.49 (s, 3H); MS (ESI) 291.1 [M+H]+.  
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 Methyl 6-fluoro-2-(4-(2-fluoro-6-methylpyridin-3-
yl)phenyl)-3-methylquinoline-4-carboxylate (114): Intermediate 90 (50 mg, 0.13 mmol), (2-
fluoro-6-methylpyridin-3-yl)boronic acid (30 mg, 0.20 mmol),  K2HPO4 (68 mg, 0.39 mmol), 
and Pd(PPh3)4 (7 mg, 6.0x10-3 mmol) were dissolved 1 mL dioxane and 0.5 mL H2O. The 
mixture was heated to 130 for 1.5 hours in a microwave reactor. Following general protocol D, 
methyl 6-fluoro-2-(4-(2-fluoro-6-methylpyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylate 
was recovered as a white solid. (17 mg, 0.04 mmol, 31%). 1H NMR (300 MHz, CDCl3-d) δ 8.17 
(dd, J = 9.2, 5.5 Hz, 1H), 7.88 – 7.80 (m, 1H), 7.75 – 7.64 (m, 4H), 7.55 – 7.46 (m, 1H), 7.44 – 
7.38 (m, 1H), 7.18 (d, J = 7.6, 1.8 Hz, 1H), 4.13 (s, 3H), 2.59 (s, 3H), 2.49 (s, 3H); MS (ESI) 
405.1 [M+H]+.  
 
 Methyl 2-(4-(2-chloropyridin-3-yl)phenyl)-6-fluoro-3-
methylquinoline-4-carboxylate (115): Intermediate 90 (960 mg, 2.67 mmol), (2-chloropyridin-
3-yl)boronic acid (503 mg, 3.20 mmol), K2HPO4 (1.34 g, 7.70 mmol), and Pd(PPh3)4 (80 mg) 
were dissolved in 10 mL dioxane and 4 mL H2O. The mixture was heated to reflux overnight. 
Following general protocol D, methyl 2-(4-(2-chloropyridin-3-yl)phenyl)-6-fluoro-3-
methylquinoline-4-carboxylate was recovered as a white solid (385 mg, 0.95 mmol, 36%). 1H 
NMR (300 MHz, CDCl3-d) δ 8.49 – 8.43 (m, 1H), 8.22 – 8.11 (m, 1H), 7.77 – 7.59 (m, 5H), 
7.56 – 7.48 (m, 1H), 7.45 – 7.34 (m, 2H), 4.13 (s, 3H), 2.50 (s, 3H); MS (ESI) 407.1 [M+H]+. 
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 Methyl 2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)-6-
fluoro-3-methylquinoline-4-carboxylate (116): Intermediate 90 (1.00 g, 2.68 mmol), (2-chloro-
6-methylpyridin-3-yl)boronic acid (688 mg, 4.02 mmol), K2HPO4 (1.40 g, 8.04 mmol), and 
Pd(PPh3)4 (155 mg) were dissolved in 11 mL dioxane and 3 mL H2O. The mixture was heated to 
reflux overnight. Following general protocol D, methyl 2-(4-(2-chloro-6-methylpyridin-3-
yl)phenyl)-6-fluoro-3-methylquinoline-4-carboxylate was recovered as a white solid (474 mg, 
1.13 mmol, 42%). 1H NMR (300 MHz, CDCl3-d) δ 8.20 – 8.13 (m, 1H), 7.68 – 7.57 (m, 5H), 
7.56 – 7.45 (m, 1H), 7.43 – 7.36 (m, 1H), 7.21 (d, J = 7.7 Hz, 1H), 4.12 (s, 3H), 2.61 (s, 3H), 
2.49 (s, 3H); MS (ESI) 421.1 [M+H]+. 
 
 Methyl 6-chloro-2-(4-(2-fluoropyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylate (117): Intermediate 91 (50 mg, 0.13 mmol), (2-fluoropyridin-3-
yl)boronic acid (31 mg, 0.22 mmol), K2HPO4 (68 mg, 0.39 mmol) and Pd(PPh3)4 (7 mg, 6.0x10-3 
mmol) were dissolved in 1 mL dioxane and 0.5 mL H2O. The mixture was heated to 130 °C for 
1.5 hours in a microwave reactor. Following general protocol D, methyl 6-chloro-2-(4-(2-
fluoropyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylate was recovered as a yellow solid (19 
mg, 0.05 mmol, 38%). 1H NMR (300 MHz, CDCl3-d) δ 8.33 – 8.21 (m, 1H), 8.10 (d, J = 8.9 Hz, 
1H), 7.96 (t, J = 8.2 Hz, 1H), 7.78 – 7.64 (m, 6H), 7.40 – 7.31 (m, 1H), 4.14 (s, 3H), 2.49 (s, 
3H); MS (ESI) 407.1 [M+H]+.  
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 Methyl 6-chloro-2-(4-(2-chloropyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylate (118): Intermediate 91 (50 mg, 0.13 mmol),  (2-chloropyridin-
3-yl)boronic acid (34 mg, 0.22 mmol),  K2HPO4 (68 mg, 0.39 mmol), and Pd(PPh3)4 (7 mg, 
6.0x10-3 mmol) were dissolved 1 mL dioxane and 0.5 mL H2O. The mixture was heated to 130 
°C for 1.5 hours in a microwave reactor. Following general protocol D, methyl 6-chloro-2-(4-(2-
fluoropyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylate was recovered  as a tan solid (4 mg, 
0.01 mmol, 8%). 1H NMR (400 MHz, CDCl3-d) δ 8.49 – 8.44 (m, 1H), 8.12 (d, J = 8.9, 0.5 Hz, 
1H), 7.77 – 7.73 (m, 2H), 7.72 – 7.66 (m, 3H), 7.64 – 7.60 (m, 2H), 7.42 – 7.35 (m, 1H), 4.15 (s, 
3H), 2.51 (s, 3H); MS (ESI) 423.0 [M+H]+.  
 
 Methyl 6-chloro-2-(4-(2-chloro-6-methylpyridin-3-
yl)phenyl)-3-methylquinoline-4-carboxylate (119): Intermediate 91 (50 mg, 0.13 mmol), (2-
chloro-6-methylpyridin-3-yl)boronic acid (35 mg, 0.20 mmol), K2HPO4 (68 mg, 0.39 mmol), 
and Pd(PPh3)4 (7 mg, 6.0x10-3 mmol) were dissolved 1 mL dioxane and 0.5 mL H2O. The 
mixture was heated to 130 °C for 1.5 hours in a microwave reactor. Following general protocol 
D, methyl 6-chloro-2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)-3-methylquinoline-4-
carboxylate was recovered as a solid (28 mg, 0.06 mmol, 46%). 1H NMR (300 MHz, CDCl3-d) δ 
8.11 (d, J = 8.9 Hz, 1H), 7.75 (d, J = 2.2 Hz, 1H), 7.70 – 7.58 (m, 6H), 7.22 (d, J = 7.7 Hz, 1H), 
4.14 (s, 3H), 2.63 (s, 3H), 2.49 (s, 3H); MS (ESI) 437.1, 438.9 [M+H]+.  
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 Methyl 2-(4-(2-chloropyridin-3-yl)phenyl)-3,6-
dimethylquinoline-4-carboxylate (120): Intermediate 92 (50 mg, 0.14 mmol), (2-chloropyridin-
3-yl)boronic acid (35 mg, 0.23 mmol), K2HPO4 (68 mg, 0.39 mmol), and Pd(PPh3)4 (7 mg, 
6.0x10-3 mmol) were dissolved in 1 mL dixoane and 0.5 mL H2O. The mixture was heated to 130 
°C for 1.5 hours in a microwave reactor. Following general protocol D, methyl 2-(4-(2-
chloropyridin-3-yl)phenyl)-3,6-dimethylquinoline-4-carboxylate was recovered an off-white 
solid (9 mg, 0.02 mmol, 16%) upon recrystallization in EtOH. 1H NMR (400 MHz, CDCl3-d) δ 
8.45 (dd, J = 4.8, 1.9 Hz, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.75 (dd, J = 7.5, 1.9 Hz, 1H), 7.71 – 
7.68 (m, 2H), 7.64 – 7.56 (m, 3H), 7.51 – 7.48 (m, 1H), 7.37 (dd, J = 7.6, 4.8 Hz, 1H), 4.14 (s, 
3H), 2.58 (d, J = 1.0 Hz, 3H), 2.48 (s, 3H); MS (ESI) 403.10 [M+H]+.  
 
 Methyl 2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methyl-6-
(trifluoromethyl)-1,7-naphthyridine-4-carboxylate (121): Intermediate 132 (14 mg, 0.03 
mmol), 2-fluorophenylboronic acid (7 mg, 0.05 mmol), K2HPO4 (17 mg, 0.10 mmol), and 
Pd(PPh3)4 (1 mg) were dissolved in 1 mL dioxane and 1 mL H2O. The mixture was heated to 130 
°C for 1.5 hours in a microwave reactor. Following general protocol D, methyl 2-(2'-fluoro-[1,1'-
biphenyl]-4-yl)-3-methyl-6-(trifluoromethyl)-1,7-naphthyridine-4-carboxylate was recovered (11 
mg, 0.02, 66%). 1H NMR (300 MHz, CDCl3-d) δ 9.65 (s, 1H), 8.07 (s, 1H), 7.80 – 7.68 (m, 4H), 
7.58 – 7.49 (m, 1H), 7.46 – 7.36 (m, 1H), 7.31 (s, 0H), 7.27 – 7.18 (m, 1H), 4.18 (s, 3H), 2.62 (s, 
3H); MS (ESI) 441.2 [M+H]+. 
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General procedure E, basic hydrolysis: Ester derivatives were combined with 1-2 pellets of 
NaOH (large excess), LiOH, or KOH and dissolved in a 1:1 mixture of THF/H2O or 
dioxane/H2O. The solution was heated to 40 °C until starting material was no longer observed (2-
6 hours). Upon completion, solvent was concentrated; residue was re-dissolved in 1 M KOH and 
washed with EtOAc (3x). The aqueous layer was acidified with HCl until pH 2-3 was reached, 
chilled overnight at 2-8 °C, then poured over a fritted funnel to collect precipitated product. 
Product cake was washed with chilled de-ionized H2O and product was dried under vacuum (15-
100%).  
 
 2-(4-(Pyridin-3-yl)phenyl)quinoline-4-carboxylic acid (32): 
Compound 33 (8 mg, 0.02 mmol) and NaOH (45 mg, 1.13 mmol) was dissolved in a 1 mL THF 
and 1 mL H2O. Following general protocol E, a white solid was collected from the vacuum oven 
to yield 2-(4-(pyridin-3-yl)phenyl)quinoline-4-carboxylic acid (2 mg, 6.13 x 10-3 mmol, 30%). 
1H NMR (400 MHz, DMSO-d6) δ 9.24 – 9.20 (m, 1H), 8.82 – 8.78 (m, 1H), 8.67 (d, J = 8.5, 1.5, 
0.6 Hz, 1H), 8.64 – 8.61 (m, 1H), 8.56 (s, 1H), 8.50 (d, J = 8.5 Hz, 2H), 8.21 (d, 1H), 8.05 (d, J = 
8.5 Hz, 2H), 7.93 – 7.85 (m, 2H), 7.78 – 7.71 (m, 1H); LCMS (ESI) 326.90 [M+H]+, 324.85 [M-
H]-; HPLC Purity at 254 nm, 95.2%.   
 
 2-(4-(Pyridin-4-yl)phenyl)quinoline-4-carboxylic acid (34): 
Intermediate 102 (14 mg, 0.04 mmol) and NaOH (62 mg, 1.59 mmol) was dissolved in 1 mL 
THF and 1 mL H2O. Following general protocol E, a white solid was collected from the vacuum 
oven to yield 2-(4-(pyridin-4-yl)phenyl)quinoline-4-carboxylic acid (2 mg, 6.13 x 10-3 mmol, 
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15%). 1H NMR (400 MHz, DMSO-d6) δ 8.72 – 8.66 (m, 3H), 8.39 (d, J = 8.3 Hz, 2H), 8.08 (s, 
1H), 8.04 – 7.99 (m, 3H), 7.85 – 7.80 (m, 2H), 7.73 – 7.66 (m, 1H), 7.53 – 7.47 (m, 1H); LCMS 
(ESI) 326.85 [M+H]+, 324.80 [M-H]-; HPLC Purity at 254 nm, 95.1%.  
 
 2-(4-(2-Methoxypyridin-3-yl)phenyl)quinoline-4-carboxylic acid 
(47): Intermediate 103 (15 mg, 0.04 mmol) and NaOH (63 mg, 1.62 mmol) were dissolved in  1 
mL THF and 1 mL H2O. Following general protocol E, 2-(4-(2-methoxypyridin-3-
yl)phenyl)quinoline-4-carboxylic acid was recovered as a beige solid (12 mg, 0.03 mmol, 75%). 
1H NMR (400 MHz, DMSO-d6) δ 8.65 (d, J = 8.5 Hz, 1H), 8.50 (s, 1H), 8.36 (d, J = 8.0 Hz, 
2H), 8.25 – 8.14 (m, 2H), 7.89 – 7.82 (m, 2H), 7.76 (d, J = 7.9 Hz, 2H), 7.70 (t, J = 7.7 Hz, 1H), 
7.13 (t, J = 6.2 Hz, 1H), 3.91 (s, 3H); LCMS (ESI) 357.1 [M+H]+, 355.1 [M-H]-; HPLC purity 
at 254 nm, 99.8%. 
 
 2-(2'-Methoxy-[1,1'-biphenyl]-4-yl)quinoline-4-carboxylic acid 
(48): Intermediate 104 (15 mg, 0.04 mmol) and NaOH (68 mg, 1.74 mmol) were dissolved in 1 
mL THF and 1 mL H2O. Following general protocol E, 2-(2'-methoxy-[1,1'-biphenyl]-4-
yl)quinoline-4-carboxylic acid was recovered as a beige solid (13 mg, 0.04 mmol, 100%). 1H 
NMR (400 MHz, DMSO-d6) δ 8.69 – 8.61 (m, 1H), 8.49 (s, 1H), 8.37 – 8.27 (m, 2H), 8.17 (d, J 
= 8.4 Hz, 1H), 7.89 – 7.82 (m, 1H), 7.73 – 7.65 (m, 3H), 7.41 – 7.34 (m, 2H), 7.17 – 7.12 (m, 
1H), 7.10 – 7.04 (m, 1H), 3.79 (s, 3H); LCMS (ESI) 356.2 [M+H]+, 354.1 [M-H]-; HPLC Purity 
at 254 nm, 98.6%.  
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 2-(4-(6-Fluoropyridin-3-yl)phenyl)quinoline-4-carboxylic acid 
(57): Intermediate 105 (27 mg, 0.08 mmol) and LiOH (45 mg, 1.95 mmol) were dissolved in 1 
mL dioxane and 1 mL H2O. Following general protocol E, 2-(4-(6-fluoropyridin-3-
yl)phenyl)quinoline-4-carboxylic acid was recovered as a tan solid (21 mg, 0.06 mmol, 75%). 1H 
NMR (300 MHz, CD3OD-d4) δ 8.63 – 8.56 (m, 1H), 8.46 (d, 1H), 8.38 – 8.27 (m, 3H), 8.19 – 
8.08 (m, 2H), 7.91 – 7.83 (m, 2H), 7.78 (t, J = 8.5, 6.9, 1.5 Hz, 1H), 7.61 (t, J = 8.3, 6.9, 1.3 Hz, 
1H), 7.22 (dd, J = 8.6, 2.6 Hz, 1H); LCMS (ESI) 345.2 [M+H]+, 343.1 [M-H]-; HPLC Purity at 
254nm, 95.8%. 
 
 2-(4-(2-Fluoropyridin-3-yl)phenyl)quinoline-4-carboxylic acid 
(58): Intermediate 106 (23 mg, 0.06 mmol) and LiOH (45 mg, 1.95 mmol) were dissolved in 1 
mL dioxane and 1 mL H2O. Following general protocol E, 2-(4-(2-fluoropyridin-3-
yl)phenyl)quinoline-4-carboxylic acid was recovered as a white solid (17 mg, 0.05 mmol, 72%). 
1H NMR (300 MHz, CD3OD-d4) δ 8.49 (d, J = 8.2 Hz, 1H), 8.30 (d, J = 8.4 Hz, 2H), 8.26 – 8.13 
(m, 4H), 7.86 – 7.75 (m, 3H), 7.63 (t, J = 7.6 Hz, 1H), 7.53 – 7.46 (m, 1H); LCMS (ESI) 345.10 
[M+H]+, 343.05 [M-H]-; HPLC Purity at 254 nm, 99.8%.  
 
N
O OH
N
F
N
O OH
N
F
	 153	
 2-(4-(2-Chloropyridin-3-yl)phenyl)quinoline-4-carboxylic acid 
(59): Intermediate 107 (76 mg, 0.20 mmol) and 115 mg KOH were dissolved in 2 mL THF and 2 
mL H2O. The mixture was stirred at 35 °C for 1 hour. Following general protocol E, 2-(4-(2-
chloropyridin-3-yl)phenyl)quinoline-4-carboxylic acid was recovered as a tan solid (34 mg, 0.09 
mmol, 45%). 1H NMR (400 MHz, DMSO-d6) δ 8.69 – 8.63 (m, 1H), 8.52 (s, 1H), 8.49 – 8.45 
(m, 1H), 8.41 (d, J = 8.3 Hz, 2H), 8.18 (d, J = 8.4 Hz, 1H), 7.99 – 7.95 (m, 1H), 7.90 – 7.83 (m, 
1H), 7.74 – 7.66 (m, 3H), 7.59 – 7.53 (m, 1H); LCMS (ESI) 361.05 [M+H]+ 359.05 [M-H]-; 
HPLC Purity at 254 nm, 98.6%. 
 
 2-(4-(2-Chloro-6-methylpyridin-3-yl)phenyl)quinoline-4-
carboxylic acid (60): Intermediate 108 (70 mg, 0.18 mmol) was dissolved in 3 mL dioxane and 
1 mL H2O with LiOH (86 mg, 1.87 mmol). Following general protocol E, 2-(4-(2-chloro-6-
methylpyridin-3-yl)phenyl)quinoline-4-carboxylic acid was recovered as a white solid (22 mg, 
33%). 1H NMR (300 MHz, DMSO-d6) δ 8.67 (d, J = 8.5 Hz, 1H), 8.54 (s, 1H), 8.42 (d, J = 8.1 
Hz, 2H), 8.20 (d, J = 8.4 Hz, 1H), 7.93 – 7.84 (m, 2H), 7.79 – 7.66 (m, 3H), 7.43 (d, J = 7.6 Hz, 
1H), 2.53 (s, 3H); LCMS (ESI) 375.10 [M+H]+, 373.05 [M-H]-; HPLC Purity at 254 nm, 
99.8%. 
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 2-(4-(2-Fluoropyridin-3-yl)phenyl)-3-methylquinoline-4-
carboxylic acid (63): Intermediate 109 (30 mg, 0.08 mmol) and LiOH (60 mg, 2.50 mmol) were 
dissolved in a 3 mL dioxane and 3 mL H2O. The mixture was heated to 100 °C for 1.5 hours. 
Following general protocol E, 2-(4-(2-fluoropyridin-3-yl)phenyl)-3-methylquinoline-4-
carboxylic acid was recovered following purification by preparative reverse-phase 
chromatography as a white solid (9 mg, 0.03 mmol, 38%).  1H NMR (300 MHz, DMSO-d6) δ 
8.32 – 8.20 (m, 2H), 8.11 – 8.05 (m, 1H), 7.86 – 7.77 (m, 6H), 7.74 – 7.66 (m, 1H), 7.57 – 7.51 
(m, 1H), 2.46 (s, 3H); LCMS (ESI) 359.1 [M+H]+, 357.2 [M-H]-; HPLC Purity at 254 nm, 
99.8%. 
 
 2-(2'-Fluoro-[1,1'-biphenyl]-4-yl)-3-methyl-6-
(trifluoromethyl)-1,7-naphthyridine-4-carboxylic acid (82): Intermediate 121 (8 mg, 0.02 
mmol) and KOH (61 mg, 1.08 mmol) were dissolved in 0.5 mL THF and 0.5 mL H2O. The 
mixture was heated to 50 °C for 4 hours. Following general protocol E, 2-(2'-fluoro-[1,1'-
biphenyl]-4-yl)-3-methyl-6-(trifluoromethyl)-1,7-naphthyridine-4-carboxylic acid was recovered 
following reverse-phase preparatory chromatography (5 mg, 0.01 mmol, 50%). 1H NMR (300 
MHz, CD3OD-d4) δ 9.48 (s, 1H), 8.29 (s, 1H), 7.78 (s, 4H), 7.66 – 7.57 (m, 1H), 7.44 (q, J = 6.3, 
5.8 Hz, 1H), 7.37 – 7.21 (m, 2H), 2.63 (s, 3H); LCMS (ESI) 427.1 [M+H]+, 425.2 [M-H]-; 
HPLC Purity at 254 nm, 98.4%. 
 
General procedure F, acidic hydrolysis: Ester derivatives were dissolved in anhydrous DCM 
and 1 M BBr3 in DCM was added to the solution. The solution was stirred at room temperature 
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overnight. Upon completion, the solvent was concentrated; residue was re-dissolved in 1 M 
KOH and washed with EtOAc (3x). The aqueous layer was acidified with HCl until pH 2-3 was 
reached, chilled overnight at 2-8 °C, then poured over a fritted funnel to collect precipitated 
product. Product cake was washed with chilled de-ionized H2O and product was dried under 
vacuum.  
 
 2-(4-(2-Fluoro-6-methylpyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylic acid (64): Intermediate 110 (22 mg, 0.06 mmol) was dissolved in 
1 mL DCM and 1 mL 1 M BBr3 in DCM. Following general protocol F, 2-(4-(2-fluoro-6-
methylpyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid was recovered as a white solid 
(13 mg, 0.03 mmol, 50%) following purification by preparative reverse-phase chromatography. 
1H NMR (300 MHz, CD3OD-d4) δ 8.12 – 8.06 (m, 1H), 8.06 – 8.00 (m, 2H), 7.82 – 7.68 (m, 
5H), 7.65 – 7.58 (m, 1H), 7.38 – 7.32 (m, 1H), 2.56 (s, 3H), 2.47 (s, 3H); LCMS (ESI) 373.15 
[M+H]+, 371.15 [M-H]-; HPLC Purity at 254 nm, 97.5%. 
 
 2-(4-(2-Chloropyridin-3-yl)phenyl)-3-methylquinoline-4-
carboxylic acid (65): Intermediate 111 (33 mg, 0.09 mmol) was dissolved in 1.5 mL DCM and 1 
mL 1 M BBr3 in DCM. Following general protocol F, 2-(4-(2-chloropyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylic acid was recovered as a white solid (24 mg, 0.06 mmol, 66%) 
following purification by preparative reverse-phase chromatography. 1H NMR (300 MHz, 
DMSO-d6) δ 8.48 (dd, J = 4.7, 1.9 Hz, 1H), 8.04 – 7.98 (m, 1H), 7.95 – 7.83 (m, 2H), 7.73 – 
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7.55 (m, 6H), 7.53 – 7.45 (m, 1H), 2.35 (s, 3H); LCMS (ESI) 375.10 [M+H]+, 373.10 [M-H]-; 
HPLC Purity at 254 nm, 99.9%.  
 
 2-(4-(2-Chloro-6-methylpyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylic acid (66): Intermediate 112 (10 mg, 0.02 mmol) was dissolved in 
1 mL DCM and 1 mL 1 M BBr3 in DCM. Following general protocol F, 2-(4-(2-chloro-6-
methylpyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid was recovered as a white solid 
(1 mg, 2.5x10-3 mmol, 10%) following purification via preparative reverse-phase 
chromatography. 1H NMR (400 MHz, CD3OD-d4) δ 8.16 (d, J = 8.4 Hz, 1H), 8.07 (d, J = 8.5 
Hz, 1H), 7.95 (t, J = 7.5 Hz, 1H), 7.88 – 7.77 (m, 4H), 7.76 – 7.72 (m, 2H), 7.44 – 7.40 (m, 1H), 
2.61 (s, 3H), 2.54 (s, 3H); LCMS (ESI) 389.15 [M+H]+, 387.15 [M-H]-; HPLC Purity at 254 
nm, 99.9%.  
 
 6-Fluoro-2-(4-(2-fluoropyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylic acid (67): Intermediate 113 (34 mg, 0.09 mmol) was dissolved in 
1 mL DCM and 1 mL 1 M BBr3 in DCM. Following general protocol F, 6-fluoro-2-(4-(2-
fluoropyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid was recovered as a white solid 
(15 mg, 0.04 mmol, 44%) following purification by preparative reverse-phase chromatography. 
1H NMR (400 MHz, DMSO-d6) δ 8.29 (d, J = 4.8 Hz, 1H), 8.27 – 8.19 (m, 1H), 8.06 – 8.00 (m, 
1H), 7.80 – 7.71 (m, 4H), 7.65 – 7.57 (m, 1H), 7.57 – 7.48 (m, 2H), 2.38 (s, 3H): LCMS (ESI) 
377.15 [M+H]+, 375.10 [M-H]-; HPLC Purity at 254 nm, 98.4%. 
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 6-Chloro-2-(4-(2-fluoropyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylic acid (68): Intermediate 117 (18 mg, 0.04 mmol) was dissolved in 
1 mL DCM and 1 mL 1 M BBr3 in DCM. Following general protocol F, 6-chloro-2-(4-(2-
fluoropyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid was recovered as a white solid 
(3 mg, 0.01 mmol, 25%) following purification by preparative reverse-phase chromatography. 
1H NMR (300 MHz, CD3OD-d4) δ 8.27 – 8.16 (m, 2H), 8.04 – 7.97 (m, 2H), 7.85 – 7.78 (m, 
2H), 7.75 – 7.66 (m, 3H), 7.52 – 7.45 (m, 1H), 2.48 (s, 3H); LCMS (ESI) 393.10 [M+H]+, 
391.10 [M-H]-; HPLC Purity at 254 nm, 95.5%.  
 
 2-(4-(2-Chloropyridin-3-yl)phenyl)-3,6-dimethylquinoline-4-
carboxylic acid (69): Intermediate 120 (17 mg, 0.04 mmol) was dissolved in 1 mL DCM and 1 
mL 1 M BBr3 in DCM. Following general protocol F, 2-(4-(2-Chloropyridin-3-yl)phenyl)-3,6-
dimethylquinoline-4-carboxylic acid was recovered as a white film (2 mg, 5.15x10-3 mmol, 4%) 
following purification by preparative reverse-phase chromatography. 1H NMR (300 MHz, 
CD3OD-d4) δ 8.05 (t, J = 8.6 Hz, 2H), 7.91 – 7.63 (m, 7H), 7.41 (d, J = 7.8 Hz, 1H), 2.60 (s, 3H), 
2.49 (s, 3H); LCMS (ESI) 389.1 [M+H]+, 387.2 [M-H]-; HPLC Purity at 254 nm, 98.4%. 
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 6-Fluoro-2-(4-(2-fluoro-6-methylpyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylic acid (70): Intermediate 114 (17 mg, 0.04 mmol) was dissolved in 
1 mL DCM and 1 mL 1 M BBr3 in DCM. Following general protocol F, 6-Fluoro-2-(4-(2-fluoro-
6-methylpyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid was recovered as a white 
solid (16 mg, 0.04 mmol, 99% yield) upon trituration with ethanol. 1H NMR (400 MHz, 
CD3OD-d4) δ 8.12 – 8.02 (m, 2H), 7.82 – 7.75 (m, 2H), 7.73 – 7.59 (m, 3H), 7.59 – 7.50 (m, 
1H), 7.37 – 7.31 (m, 1H), 2.56 (s, 3H), 2.47 (s, 3H); LCMS (ESI) 391.15 [M+H]+, 389.15 [M-
H]-; HPLC Purity at 254 nm, 97.8%.  
 
 2-(4-(2-Chloropyridin-3-yl)phenyl)-6-fluoro-3-methylquinoline-4-
carboxylic acid (71): Intermediate 115 (6 mg, 1.47x10-2 mmol) was dissolved in 1 mL DCM and 1 mL 1 M BBr3 in 
DCM. Following general protocol F, 2-(4-(2-chloropyridin-3-yl)phenyl)-6-fluoro-3-methylquinoline-4-carboxylic 
acid was recovered as a white film (5 mg, 1.27x10-2 mmol, 86%)  following purification by preparative reverse-
phase chromatography. 1H NMR (400 MHz, DMSO-d6) δ 8.53 – 8.45 (m, 1H), 8.18 – 8.11 (m, 1H), 8.06 – 7.96 (m, 
1H), 7.79 – 7.71 (m, 3H), 7.69 – 7.63 (m, 2H), 7.62 – 7.55 (m, 1H), 7.55 – 7.46 (m, 1H), 2.46 (s, 3H); LCMS (ESI) 
393.10 [M+H]+, 391.10 [M-H]-; HPLC Purity at 254 nm, 95.7%.  
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 6-Chloro-2-(4-(2-chloropyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylic acid (72): Intermediate 118 (21 mg, 0.05 mmol) was dissolved in 
1 mL DCM and 1 mL 1 M BBr3 in DCM. Following general protocol F, 6-chloro-2-(4-(2-
chloropyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid was recovered as a white solid 
after purification by preparative reverse-phase chromatography (1 mg, 2.44x10-3 mmol, 5%). 1H 
NMR (500 MHz, CD3OD-d4) δ 8.42 (d, J = 4.9 Hz, 1H), 8.03 (d, J = 9.0 Hz, 1H), 7.98 – 7.94 
(m, 2H), 7.76 – 7.66 (m, 5H), 7.53 (dd, J = 7.7, 4.8 Hz, 1H), 2.49 (s, 3H); LCMS (ESI) 409.05 
[M+H]+, 407.10 [M-H]-; HPLC Purity at 254 nm, 98.1%.  
 
 2-(4-(2-Chloro-6-methylpyridin-3-yl)phenyl)-6-fluoro-3-
methylquinoline-4-carboxylic acid (73): Intermediate 116 (13 mg, 0.03 mmol) was dissolved in 
1 mL DCM and 1 mL 1 M BBr3 in DCM. Following general protocol F, 2-(4-(2-chloro-6-
methylpyridin-3-yl)phenyl)-6-fluoro-3-methylquinoline-4-carboxylic acid was purified via 
reverse phase preparative chromatography (7 mg, 0.02 mmol, 66%). 1H NMR (300 MHz, 
CD3OD-d4) δ 8.09 – 8.01 (m, 1H), 7.89 – 7.81 (m, 1H), 7.72 – 7.60 (m, 5H), 7.59 – 7.50 (m, 
1H), 7.40 (d, J = 7.7 Hz, 1H), 2.60 (s, 3H), 2.48 (s, 3H); LCMS (ESI) 407.10 [M+H]+, 405.10 
[M-H]-; HPLC Purity at 254 nm, 95.1%.  
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 6-Chloro-2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)-3-
methylquinoline-4-carboxylic acid (74): Intermediate 119 (28 mg, 0.06 mmol) was dissolved in 
1 mL DCM and 1 mL 1 M BBr3 in DCM. Following general protocol F, 6-chloro-2-(4-(2-chloro-
6-methylpyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid was recovered as a white 
solid (1 mg, 2.37x10-3 mmol, 3%). 1H NMR (400 MHz, DMSO-d6) δ 8.13 – 8.10 (m, 1H), 7.90 
– 7.80 (m, 3H), 7.79 – 7.73 (m, 2H), 7.66 – 7.61 (m, 2H), 7.45 – 7.40 (m, 1H), 2.54 (s, 3H), 2.47 
(s, 3H); LCMS (ESI) 424.8 [M+H]+, 422.2 [M-H]-; HPLC Purity at 254 nm, 95.1%. 
 
General procedure G, pivaloyl protecting group: The corresponding aminopyridine (1 eq) 
was added to a round bottom flask containing anhydrous DCM and TEA/DIPEA (1.25 eq). The 
solution was stirred on an ice bath for 20 minutes before trimethylacetyl chloride (1.1 eq) was 
added drop-wise. The solution was allowed to warm to room temperature and quenched with 
H2O/NaHCO3. The product was extracted in DCM (3x), dried with MgSO4, and concentrated in 
vacuo. The solid was recrystallized in hexanes to afford pivaloyl-aminopyridines (53-98%).  
 
 N-(pyridin-2-yl)pivalamide (122): 2-Aminopyridine (1.00 g, 10.6 mmol), 
triethylamine (1.85 mL, 13.3 mmol), and pivaloyl chloride (1.44 mL, 11.7 mmol) were combined 
in 18 mL of anhydrous DCM following general protocol G. Product was recrystallized by 
addition of hexane to generate N-(pyridin-2-yl)pivalamide as white needles (1.81 g, 10.2 mmol, 
96%). 1H NMR (400 MHz, CDCl3-d) δ 8.26 – 8.18 (m, 3H), 7.66 (ddd, J = 8.6, 7.3, 1.9 Hz, 1H), 
7.03 – 6.95 (m, 1H), 1.29 (d, J = 1.9 Hz, 9H); MS (ESI) 179.1 [M+H]+.  
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 N-(pyridin-3-yl)pivalamide (123):  3-Aminopyridine (1.00 g, 10.6 mmol), 
triethylamine (1.85 mL, 13.3 mmol), and pivaloyl chloride (1.44 mL, 11.7 mmol) were combined 
in 18 mL of anhydrous DCM following general protocol G. Product was recrystallized by 
addition of hexane to generate N-(pyridin-3-yl)pivalamide as a tan solid (1.56 g, 10.6 mmol, 
83%). 1H NMR (400 MHz, CDCl3-d) δ 8.57 (d, J = 2.6 Hz, 1H), 8.38 – 8.33 (m, 1H), 8.22 – 
8.16 (m, 1H), 7.49 (s, 1H), 7.31 – 7.25 (m, 1H), 1.35 (s, 9H); MS  (ESI) 179.1 [M+H]+. 
 
 N-(pyridin-4-yl)pivalamide (124): 4-Aminopyridine (1.00 g, 10.6 mmol), 
triethylamine (1.85 mL, 13.3 mmol), and pivaloyl chloride (1.44 mL, 11.7 mmol) were combined 
in 18 mL of anhydrous DCM following general protocol G. Product was recrystallized by 
addition of hexane to generate N-(pyridin-4-yl)pivalamide as white needles (991 mg, 5.57 mmol, 
53%). 1H NMR (400 MHz, CDCl3-d) δ 8.57 (d, J = 2.6 Hz, 1H), 8.36 (dd, J = 4.7, 1.5 Hz, 1H), 
8.24 – 8.18 (m, 1H), 7.50 – 7.41 (m, 1H), 7.32 – 7.24 (m, 1H), 1.36 (d, J = 1.5 Hz, 9H); MS 
(ESI) 179.1 [M+H]+. 
 
 N-(6-(trifluoromethyl)pyridin-3-yl)pivalamide (125): 6-
(Trifluoromethyl)pyridin-3-amine (1.00 g, 6.17 mmol), diisopropylethyamine (1.35 mL, 7.71 
mmol), and pivaloyl chloride (0.83 mL, 6.78 mmol) were combined in 17 mL of anhydrous 
DCM following general protocol G. Product was recrystallized by addition of hexane to generate 
N-(6-(trifluoromethyl)pyridin-3-yl)pivalamide as a white powder (1.48 g, 6.04 mmol, 98%). 1H 
NMR (300 MHz, CDCl3-d) δ 8.64 – 8.61 (m, 1H), 8.35 (dd, J = 8.6, 2.5 Hz, 1H), 7.82 (s, 1H), 
7.60 (d, J = 8.6 Hz, 1H), 1.31 (s, 9H); MS (ESI) 245.2 [M+H]+. 
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 Tert-butyl (6-(trifluoromethyl)pyridin-3-yl)carbamate (126): This 
protocol was adapted from Hughes et al.42 6-(Trifluoromethyl)pyridin-3-amine (4.00 g, 24.7 
mmol) and di-tert-butyl-dicarbonate (6.73 g, 30.9 mmol) were refluxed in 50 mL anhydrous 
dioxane. After 24 hours, 1.00 g (4.59 mmol) of additional di-tert-butyl-dicarbonate was added 
and the mixture was stirred at reflux for another 24 hours. After 48 hours, the reaction mixture 
was quenched by the addition of cold H2O and extracted with EtOAc. The organic layer was 
dried with MgSO4, filtered, and concentrated before purifying via silica chromatography. Tert-
butyl (6-(trifluoromethyl)pyridin-3-yl)carbamate was recovered as a white powder (2.45 g, 9.35 
mmol, 38%). 1H NMR (300 MHz, CDCl3-d) δ 8.62 (d, J = 2.5 Hz, 1H), 8.35 (dd, J = 8.6, 2.5 
Hz, 1H), 7.82 (s, 1H), 7.60 (d, J = 8.6 Hz, 1H), 1.31 (s, 9H); MS (ESI) 263.2 [M+H]+.  
 
General protocol H, ortho-lithiation: This procedure was adapted from Estel et al.43 and Zong 
et al.34 The corresponding pivaloylamino pyridine (1.0 eq) was added to a vacuum purged round 
bottom flask under argon atmosphere. The solid was dissolved in Et2O and TMEDA (2.5 eq) 
then chilled to -78 °C. After 15 minutes, n-BuLi (1.6 M in hexanes, 2.5 eq) was added dropwise 
and the reaction mixture was stirred at -78 °C for 15 minutes and then stirred at -10 °C for 2.5 
hours. Afterwards, the temperature was lowered to -78 °C for the addition of diethyl oxalate (3.0 
eq) and warmed to room temperature over 1.5 hours. The reaction mixture was quenched with 
1.0 M solution of HCl in ice water and extracted with Et2O (3x). Organic layer was dried, 
concentrated, and purified via silica chromatography in a gradient from 1% to 10% MeOH in 
DCM gradient (1–51%).  
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 Ethyl 2-oxo-2-(2-pivalamidopyridin-3-yl)acetate (127):  Following general 
protocol H, intermediate 122 (816 mg, 4.58 mmol), TMEDA (1.38 mL, 9.16 mmol), 1.6 M n-
BuLi (5.73 mL, 9.16 mmol), and diethyl oxalate (1.03 mL, 9.16 mmol) were combined in 12 mL 
anhydrous diethyl ether. Ethyl 2-oxo-2-(2-pivalamidopyridin-3-yl)acetate was recovered as an 
yellow oil (136 mg, 0.48 mmol, 10%). 1H NMR (400 MHz, CDCl3-d) δ 9.86 (s, 1H), 8.59 – 8.48 
(m, 1H), 8.03 (dt, J = 7.8, 1.6 Hz, 1H), 7.13 (ddd, J = 7.9, 4.8, 1.3 Hz, 1H), 4.36 (qd, J = 7.2, 1.2 
Hz, 2H), 1.37 (td, J = 7.1, 1.2 Hz, 3H), 1.29 (s, 9H); MS (ESI) 277.3 [M-H]-. 
 
 Ethyl 2-oxo-2-(3-pivalamidopyridin-4-yl)acetate (128): Following general 
protocol H, intermediate 123 (1.00 g, 5.62 mmol), TMEDA (2.10 mL, 14.1 mmol), 1.6 M n-
BuLi (8.75 mL, 14.1 mmol), and diethyl oxalate (2.29 mL, 16.7 mmol) were combined in 17 mL 
anhydrous diethyl ether. Ethyl 2-oxo-2-(2-pivalamidopyridin-3-yl)acetate was recovered as an 
off-white solid (564 mg, 2.39 mmol, 43%). 1H NMR (400 MHz, CDCl3-d) δ 10.84 (s, 1H), 10.16 
(s, 1H), 8.52 (d, J = 5.1 Hz, 1H), 7.58 (d, J = 5.2 Hz, 1H), 4.50 (q, J = 7.1 Hz, 2H), 1.46 (t, J = 
7.2 Hz, 3H), 1.38 (s, 9H); MS (ESI) 277.2 [M-H]-. 
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 Ethyl 2-oxo-2-(4-pivalamidopyridin-3-yl)acetate (129): Following general 
protocol H, intermediate 124 (1.00 g, 5.62 mmol) and 1.6 M n-BuLi (7.4 mL, 11.8 mmol), and 
diethyl oxalate (2.29 mL, 16.8 mmol)  were combined in 16 mL anhydrous diethyl ether. 
TMEDA was not utilized. Ethyl 2-oxo-2-(4-pivalamidopyridin-3-yl)acetate was recovered as an 
off-white solid (796 mg, 2.86 mmol, 51%). 1H NMR (400 MHz, CDCl3-d) δ 9.78 (s, 1H), 8.37 
(d, J = 5.8 Hz, 1H), 8.26 (d, J = 5.8 Hz, 1H), 8.20 (s, 1H), 4.18 – 4.02 (m, 2H), 1.27 (s, 9H), 1.12 
(t, J = 7.1 Hz, 3H); MS (ESI) 277.2 [M-H]-.  
 
 Ethyl 2-oxo-2-(5-pivalamido-2-(trifluoromethyl)pyridin-4-yl)acetate 
(130): Following general protocol H, intermediate 125 (1.00 g, 4.07 mmol), TMEDA (1.53 mL, 
10.2 mmol), 1.6 M n-BuLi (6.35 mL, 10.2 mmol) and diethyl oxalate (1.66 mL, 12.2 mmol) 
were combined in 12 mL anhydrous diethyl ether. Ethyl 2-oxo-2-(5-pivalamido-2-
(trifluoromethyl)pyridin-4-yl)acetate was recovered as a yellow oil (188 mg, 0.54 mmol, 13%). 
1H NMR (300 MHz, CDCl3-d) δ 11.07 (s, 1H), 10.25 (s, 1H), 8.02 (s, 1H), 4.53 (q, J = 7.1 Hz, 
2H), 1.47 (t, J = 7.2 Hz, 3H), 1.38 (s, 9H); MS 345.1 [M-H]-. 
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 Ethyl 2-(5-((tert-butoxycarbonyl)amino)-2-(trifluoromethyl)pyridin-4-
yl)-2-oxoacetate (131): Following general protocol H, intermediate 126 (1.00 g, 3.82 mmol), 
TMEDA (1.20 mL, 8.02 mmol), 1.6 M n-BuLi (5.01 mL, 8.02 mmol), and diethyl oxalate (1.55 
mL, 11.4 mmol) were dissolved in 13 mL anhydrous diethyl ether. Ethyl 2-(5-((tert-
butoxycarbonyl)amino)-2-(trifluoromethyl)pyridin-4-yl)-2-oxoacetate was recovered as a yellow 
oil (44 mg, 0.17 mmol, 1%). 1H NMR (300 MHz, CDCl3-d) δ 8.51 – 8.47 (m, 1H), 7.65 – 7.58 
(m, 1H), 6.98 (s, 1H), 4.35 (q, J = 7.1 Hz, 2H), 1.52 (s, 9H), 1.37 (t, J = 7.1 Hz, 2H); MS (ESI) 
363.2 [M+H]+. 
 
General protocol I, generation of naphthyridine core: Corresponding ketone (1.0 eq), α-keto-
ester (1.0 eq), and base (KOH or KOtBu, 3-6 eq) were combined in anhydrous EtOH in a sealed 
vial. The mixture was heated to 100 °C overnight, concentrated to a residue, extracted with 1 M 
KOH, and washed with EtOAc. The basic layer was acidified by addition of HCl (pH 2-3) and 
the product was collected via filtration. Product was further purified by reverse-phase 
preparatory chromatography (3-21%). 
 
 2-([1,1'-Biphenyl]-4-yl)-3-methyl-1,8-naphthyridine-4-carboxylic 
acid (75): Intermediate 127 (40 mg, 0.14 mmol), 1-([1,1'-biphenyl]-4-yl)propan-1-one (25 mg, 
0.12 mmol), and KOtBu (78 mg, 0.7 mmol) were dissolved in 2 mL anhydrous EtOH. Following 
general protocol I, 2-([1,1'-biphenyl]-4-yl)-3-methyl-1,8-naphthyridine-4-carboxylic acid was 
recovered as a white solid (9 mg, 0.03 mmol, 21%). 1H NMR (400 MHz, DMSO-d6) δ 9.14 (s, 
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1H), 8.32 (dd, J = 8.4, 1.9 Hz, 1H), 7.90 – 7.84 (m, 2H), 7.82 – 7.78 (m, 4H), 7.76 – 7.70 (m, 
1H), 7.56 – 7.50 (m, 2H), 7.46 – 7.40 (m, 1H), 2.51 (s, 3H); LCMS 341.15 [M+H]+, 339.20 [M-
H]-; HPLC Purity at 254 nm, 99.3%. 
 
 2-([1,1'-Biphenyl]-4-yl)-3-methyl-1,7-naphthyridine-4-carboxylic 
acid (76): Intermediate 128 (198 mg, 0.71 mmol), 1-([1,1'-biphenyl]-4-yl)propan-1-one (119 mg, 
0.57 mmol), and KOH (112, 1.99 mmol) were dissolved in 10 mL anhydrous EtOH. Following 
general protocol I, 2-([1,1'-biphenyl]-4-yl)-3-methyl-1,7-naphthyridine-4-carboxylic acid was 
purified as a white solid (26 mg, 0.08 mmol, 11%). 1H NMR (400 MHz, DMSO-d6) δ 9.44 (s, 
1H), 8.73 – 8.61 (m, 1H), 7.88 – 7.82 (m, 2H), 7.81 – 7.77 (m, 4H), 7.74 (d, J = 5.7 Hz, 1H), 
7.56 – 7.50 (m, 2H), 7.46 – 7.41 (m, 1H), 2.51 (s, 3H); LCMS (ESI) 341.2 [M+H]+, 339.1 [M-
H]-; HPLC Purity at 254 nm, 97.1%. 
 
 2-([1,1'-Biphenyl]-4-yl)-3-methyl-1,6-naphthyridine-4-carboxylic 
acid (77): Intermediate 129 (81 mg, 0.29 mmol), 1-([1,1'-biphenyl]-4-yl)propan-1-one (62 mg, 
0.29 mmol), and KOH (49 mg, 0.87 mmol) were dissolved in 4 mL anhydrous EtOH. Following 
general protocol I, 2-([1,1'-biphenyl]-4-yl)-3-methyl-1,6-naphthyridine-4-carboxylic acid was 
recovered as an amorphous solid (6 mg, 0.02 mmol, 7%). 1H NMR (400 MHz, CD3OD-d4) δ 
9.38 (s, 1H), 8.66 (d, J = 6.0 Hz, 1H), 7.95 (d, J = 6.0 Hz, 1H), 7.88 – 7.82 (m, 2H), 7.79 – 7.68 
(m, 4H), 7.55 – 7.47 (m, 2H), 7.46 – 7.36 (m, 1H), 2.53 (s, 3H); LCMS (ESI) 341.1 [M+H]+, 
339.2 [M-H]-; HPLC purity at 254 nm, 96.5%. 
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 2-([1,1'-Biphenyl]-4-yl)-3-methyl-6-(trifluoromethyl)-1,7-
naphthyridine-4-carboxylic acid (78): Intermediate 130 (118 mg, 0.34 mmol), 1-([1,1'-
biphenyl]-4-yl)propan-1-one (71 mg, 0.34 mmol), and KOH (76 mg, 1.36 mmol) were dissolved 
in 5 mL anhydrous EtOH. Following general protocol I, 2-([1,1'-biphenyl]-4-yl)-3-methyl-6-
(trifluoromethyl)-1,7-naphthyridine-4-carboxylic acid (4 mg, 0.01 mmol, 3%) was recovered as a 
clear oil. 1H NMR (300 MHz, CD3OD-d4) δ 9.42 (s, 1H), 8.29 (s, 1H), 7.84 (d, J = 8.3 Hz, 2H), 
7.77 – 7.70 (m, 4H), 7.50 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 7.5 Hz, 1H), 2.57 (s, 3H). LCMS (ESI) 
409.2 [M+H]+, 407.2 [M-H]-; HPLC Purity at 254 nm, 97.2%. 
 
 2-(4-(2-Chloropyridin-3-yl)phenyl)-3-methyl-1,7-naphthyridine-
4-carboxylic acid (79): Intermediate 128 (32 mg, 0.12 mmol) intermediate 93 (28 mg, 0.12 
mmol), and KOH (60 mg, 1.07 mmol) were dissolved in 2 mL anhydrous EtOH. Following 
general protocol I, 2-(4-(2-chloropyridin-3-yl)phenyl)-3-methyl-1,7-naphthyridine-4-carboxylic 
acid (4 mg, 0.03 mmol, 8%) was recovered as a white solid. 1H NMR (300 MHz, CD3OD-d4) δ 
9.34 (s, 1H), 8.57 (d, J = 5.8 Hz, 1H), 8.48 – 8.42 (m, 1H), 8.02 – 7.91 (m, 2H), 7.80 – 7.65 (m, 
4H), 7.59 – 7.51 (m, 1H), 2.55 (s, 3H); LCMS (ESI) 376.1 [M+H]+, 374.1 [M-H]-; HPLC Purity 
at 254 nm, 96.0%. 
 
NN
O OH
F3C
NN
O OH
N
Cl
	 168	
 2-(4-(2-Chloro-6-methylpyridin-3-yl)phenyl)-3-methyl-1,7-
naphthyridine-4-carboxylic acid (80): Intermediate 128 (66 mg, 0.24 mmol), intermediate 94 
(62 mg, 0.24 mmol), and KOH (60 mg, 1.07 mmol) were dissolved in 3 mL anhydrous EtOH. 
Following general protocol I, 2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)-3-methyl-1,7-
naphthyridine-4-carboxylic acid (2 mg, 0.03 mmol, 4%). 1H NMR (300 MHz, CD3OD-d4) δ 9.88 
(s, 1H), 8.80 (d, J = 6.5 Hz, 1H), 8.57 (d, J = 6.6 Hz, 1H), 7.88 (dd, J = 10.8, 7.8 Hz, 3H), 7.72 
(d, J = 7.9 Hz, 2H), 7.45 (d, J = 7.8 Hz, 1H), 2.76 (s, 3H), 2.62 (s, 3H); LCMS (ESI) 390.1 
[M+H]+, 388.1 [M-H]-; HPLC Purity at 254 nm, 95.0%. 
 
 2-(4-(2-Chloropyridin-3-yl)phenyl)-3-methyl-6-
(trifluoromethyl)-1,7-naphthyridine-4-carboxylic acid (81): Intermediate 132 (8 mg, 1.9 x 10-
2  mmol) and NaOH (44 mg, 1.15 mmol) were dissolved in dioxane and water then heated to 60 
°C overnight. Upon completion, the mixture was concentrated to a residue and the corresponding 
carboxylic acid was used for the next step without purification. The residue was combined with 
(2-chloropyridin-3-yl)boronic acid (6 mg, 0.03 mmol), Na2CO3 (8 mg, 0.08 mmol), and 
Pd(PPh3)4 (1 mg) and dissolved in 0.5 mL dioxane and 0.5 mL H2O. The mixture was heated to 
110 °C for 3 hours. Upon completion, the mixture was concentrated, re-dissolved in 0.5 M NH3 
in MeOH, and purified via reverse-phase preparatory chromatography to yield 2-(4-(2-
chloropyridin-3-yl)phenyl)-3-methyl-6-(trifluoromethyl)-1,7-naphthyridine-4-carboxylic acid as 
a white film (2 mg, 4.5x10-2 mmol, 46% over 2 steps). 1H NMR (400 MHz, CD3OD-d4) δ 9.50 
(s, 1H), 8.47 – 8.43 (m, 1H), 8.30 (s, 1H), 8.01 – 7.94 (m, 1H), 7.81 (d, J = 8.3 Hz, 2H), 7.72 (d, 
NN
O OH
N
Cl
NN
O OH
N
Cl
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J = 8.2 Hz, 2H), 7.58 – 7.53 (m, 1H), 2.64 (s, 3H); LCMS (ESI) 444.2 [M+H]+, 442.2 [M-H]-; 
HPLC Purity at 254 nm, 98.9%.   
 
 Methyl 2-(4-bromophenyl)-3-methyl-6-(trifluoromethyl)-1,7-
naphthyridine-4-carboxylate (132): Intermediate 131 (1.38 g, 3.82 mmol) was dissolved in 10 
mL and 1 mL trifluoroacetic acid. The mixture was stirred at room temperature for 2 hours, 
before being concentrated to a residue. 1-(4-Bromophenyl)propan-1-one (813 mg, 3.82 mmol), 
and KOH (856 mg, 15.3 mmol) were added to the residue and the mixture was dissolved in 15 
mL anhydrous EtOH. In a sealed vial, the mixture was heated to 100 °C overnight. Upon 
completion, the mixture was concentration and the residue was re-dissolved in 1 M KOH, 
washed with EtOAc, and precipitated from aqueous layer by addition of HCl until the pH was 2-
3 and precipitant was collected. The dried precipitant was dissolved in 5 mL THF and 1 mL 
MeOH under an argon atmosphere and chilled to 0 °C. A 2.0 M solution of TMS-diazomethane 
in THF (0.4 mL, 0.8 mmol) was added to the mixture and the solution was allowed to warm to 
room temperature over 2 hours. The mixture was quenched by the addition of acetic acid, 
concentrated, re-dissolved in EtOAc and washed with brine (3x). The organic layer was dried 
with MgSO4, filtered, concentrated, and purified by silica chromatography to yield methyl 2-(4-
bromophenyl)-3-methyl-6-(trifluoromethyl)-1,7-naphthyridine-4-carboxylate (32 mg, 0.08 
mmol, 2% overall yield).1H NMR (300 MHz, CDCl3-d) δ 9.60 (s, 1H), 8.05 (s, 1H), 7.75 – 7.67 
(m, 2H), 7.56 – 7.47 (m, 2H), 4.17 (s, 3H), 2.54 (s, 3H); MS (ESI) 425.0, 427.0 [M+H]+.  
 
hDHODH expression and purification: hDHODH expression and purification followed the 
same protocol as described by Madak et al.44 The hDHODH construct was kindly provided by 
the De Brabander lab from UT Southwestern.1 Briefly, hDHODH was expressed in E. coli 
Rosetta 2 (DE3) in LB medium with ampicillin (100 µg/mL) and 0.1 mM FMN. Cells were 
grown at 37 °C to OD600 = 0.6, then induced with 1 mM IPTG for 3 hours. Cells were harvested 
by centrifugation at and the pellet was resuspended in lysis buffer (50 mM Tris-HCl, pH 8.5, 300 
NN
O O
Br
F3C
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mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 10 mM imidazole, 2% Triton X-100, 0.5 
mM FMN, 200 µM PMSF, 1 mg/mL lysozyme). The cell suspension was incubated on ice for 2 
hours, followed by sonication. The cleared supernatant was incubated with Ni-NTA resin for 1 h 
at 4 °C, and then loaded onto a column. The column was washed with wash buffer (50 mM Tris-
HCl, pH 8.5, 300 mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 25 mM imidazole, 0.1 mM 
FMN) and hDHODH was eluted with elution buffer (wash buffer containing 300 mM imidazole). 
Buffer exchange was carried out using an Amicon concentrator into storage buffer (100 mM 
HEPES, pH 8.0, 150 mM NaCl, 10% glycerol) and hDHODH was stored at -80 °C. 
 
DHODH Inhibition Assay: DHODH activity was monitored as previously described with some 
modifications.2 First, 1 µL of test compound (50X) or DMSO, 60 nM DHODH, 100 µM DCIP, 
and 20 µM CoQ10 (final concentrations for 50 µL) in the assay buffer (100 mM HEPES pH 8.0, 
150 mM NaCl, 10% glycerol, 0.1% Triton X-100) in a total of 40 µL were incubated together for 
30 min. The assay was started by the addition of 10 µL of dihydroorotate to a final concentration 
of 200 µM. The reduction of DCIP was measured by monitoring the absorbance at 600 nm over 
1 hr at room temperature using a microplate reader (BMG Labtech). Data were exported to 
Microsoft Excel for analysis and IC50 values were determined using GraphPad Prism6. 
 
General protocol for preparation of cells: HCT116 and MiaPaCa cells were grown in RPMI 
1640 supplemented with 10% fetal bovine serum (FBS) in the standard conditions of 37 ºC and 
5% CO2. Cancer cells were purchased from NCI Developmental Therapeutics Program and 
ATCC (Manassas, VA).   
 
Biological evaluation in cytotoxicity assay: Cells were seeded in a 96-well plate in 180 µL cell 
culture medium and incubated overnight. Compounds were added the following day and were 
incubated with the cells for 72 h. Post-treatment, thiazolyl blue tetrazolium bromide (MTT) 
(AMRESCO) was added to a final concentration of 300 µg/mL and incubated at 37 ºC for 3.5 h. 
The media containing compound and MTT was discarded and 100 µL DMSO was added to 
dissolve the insoluble formazan. The plates were shaken at room temperature for 15 min. A 
microplate reader (Molecular Devices) was then used to obtain the absorbance at 570 nm. Data 
were evaluated using GraphPad Prism 6 software. 
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Pharmacokinetic Studies: PK data was generated by the University of Michigan PK core. The 
study utilized (18) female CD-1 mice with a triple dose design. The drug at 2 mg/mL in PBS 
containing 20% DMSO and 50% PEG-400 was given by IV injection (10 mg/kg) and oral (PO) 
20 mg/kg. At the given time points (0.083 h, 0.167 h, 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 7 h, 16 h and 24 
h), blood samples were collected using heparinized calibrated pipettes. Samples were centrifuged 
at 15,000 rpm for 10 min. Subsequently, blood plasma was collected from the upper layer. The 
plasma was frozen at -80 ºC for later analysis.   
 
Thermodynamic solubility studies: Thermodynamic solubility was evaluated by Analiza 
(Cleveland, OH) using their standard protocol. In short, solubility was calculated using a CLND 
detector. Compounds were dissolved in 450 µL PBS pH 7.4 and shaken overnight at room 
temperature. The solution was filtered through a 0.45 µm filter and injected directly into the 
CLND. Concentrations were determined via calibration curves to assess thermodynamic 
solubility in solution.  
 
Crystallography: 
Cloning, Expression, Purification of DHODH; The gene for N-terminally truncated hDHODH 
(residues 33-396) was subcloned into pMCSG26 LIC site using pET22b-hDHODH (residues 30-
396) as the template with the following 3’ and 5’ primers 
(GTCTCTCCCATGGGAGATGAGCGTTTCTATGCTGAACAC and 
TGGTGGTGCCCAGCTTCCAGCCTCCGATGATCTGCTCCAATGG).   
The C-terminally tagged construct (hDHODH-His6) was transformed into E. coli Rosetta 2 
(DE3) cells.  Transformed cells were grown in Terrific Broth containing 100 µg/mL ampicillin at 
37 °C to an OD600 of 0.6.  Expression was induced by addition of 0.4 mM IPTG.  Cells were 
incubated at 25 °C overnight, harvested by centrifugation at 6,700 x g and the pellet stored at -80 
°C.  
Purification of hDHODH was performed as published with modifications.40  The thawed pellet 
was resuspended in 160 mL lysis buffer containing 50 mM HEPES pH 8.0, 300 mM NaCl, 10% 
glycerol, 10 mM imidazole, 0.05% (v/v) THESIT (Sigma Aldrich), 200 µM 
phenylmethylsulfoxide, supplemented with a protease inhibitor cocktail (complete EDTA-free, 
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Sigma Aldrich).  Resuspended cells were lysed by sonication and centrifuged at 34,000 x g. The 
resulting supernatant was added to 10 mL Ni NTA Superflow Resin (Qiagen) pre-equilibrated 
with lysis buffer.  After the lysate was incubated with Ni NTA resin for 1 hour at 4 °C, the resin 
was washed with lysis buffer containing 20 mM imidazole and the protein eluted with lysis 
buffer containing 400 mM imidazole.  Eluent was loaded onto a HiLoad 16/60 Superdex 75 
column (GE Healthcare) pre-equilibrated with 50 mM HEPES pH 7.8, 300 mM NaCl, 10% 
glycerol, 10 mM DTT, and 40 mM Anzergent 3-10 (Anatrace).  Fractions corresponding to 
hDHODH were pooled and 200 mM HEGA-8 (Anatrace) was added before concentrating 
protein to 18-22 mg/mL. 
 
Crystallization, Data Collection, and Structure Determination 
 hDHODH was incubated with 2 mM L-dihydroorotate and 1 mM inhibitor at 4 °C for two 
hours and crystallized by sitting drop vapor diffusion at 20 °C.  Protein was mixed in a 1:1 ratio 
with well solution containing 1.7-2.2 M ammonium sulfate, 1.4-1.5 M NaCl, 0.1 M sodium 
acetate pH 5.3, and 10 mM DTT.  Prior to data collection, crystals were cryoprotected in well 
solution supplemented with 20% ethylene glycol (hDHODH:73) or silica oil (hDHODH:76) and 
flash-cooled in liquid nitrogen.  Diffraction data were collected on the Advanced Photon Source 
LS-CAT beamline 21-ID-G.  All data were processed with HKL200045 and both structures were 
solved by molecular replacement in Phaser46 using a previous structure of hDHODH (PDB ID: 
4IGH) absent its ligands as the search model.  Iterative model building and refinement were 
performed using COOT47 and PHENIX48, respectively.  Ligand restraints were generated in 
eLBOW.49   
The structure of hDHODH with inhibitor 73 was solved to 1.46 Å in the space group of 
P1.  The structure contained two chains of protein in the asymmetric unit, with an RMSD of 
0.329 Å between chains based on SSM superpositioning in COOT.  In chain A, residues 33-396 
were modeled with the exception of two disordered loop regions corresponding to residues 69-73 
and 214-225.  Similarly, residues 36-396 of chain B were modeled with the exception of the 
same two disordered loop regions, which included residues 68-74 and 216-223.  In both chains, 
several peptide residues corresponding to the linker between the protein C-terminal histidine tag 
were also ordered.  
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The structure of hDHODH with inhibitor 76 was solved to 2.70 Å in the space group 
P3221, with one chain of protein in the asymmetric unit.  Residues 34-396 were modeled with the 
exception of two disordered loop regions 71-73 and 219-223.   
Upon comparison with the DHODH:73 structure (RMSD values of 0.734 for chain A and 
0.732 Å chain B), the only significant difference in the protein chains occurs in the residues 
preceding the first disordered loop region corresponding to residues 65-70. Near this solvent 
exposed loop in the DHODH:76 structure, there is electron density for the aliphatic chain in 
common to both detergents. The density is not ordered as to allow modeling of the full detergent 
molecule, so we have refined the chain from Anzergent 3-10, which was used during 
crystallization. The aliphatic chain forms van der Waals interactions with the side chains of F62 
and P69 as well as the backbone of residues 67-69. Additionally, the detergent makes contact 
with the benzyl group of 76. In the DHODH:73 structure, the aliphatic chain does not interact 
with the loop, but forms van der Waals interactions with the side chains of F62, L46, L42 and 
F37 along with the pyridine group of 73.  
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Chapter 4 
Design, Synthesis, and Characterization of Brequinar Conjugates as Probes to Study 
DHODH Inhibitiond 
 
4.1 Introduction 
Over 20 years ago, a potent dihydroorotate dehydrogenase (DHODH) inhibitor, 
brequinar, was evaluated in multiple cancer clinical trials.1, 2 In preclinical studies, brequinar 
inhibited rapid cellular growth by inducing pyrimidine depletion and suppressed >90% tumor 
growth in murine studies at 20-40 mg/kg/day.3, 4 However, its transition from bench to bedside 
was disappointing as few patients met their objective response despite the fact that analysis of 
patient-derived samples showed that DHODH was inhibited and pyrimidine depletion had 
occurred.5 As newer studies emerged suggesting that DHODH may be an effective target,6-10 we 
designed novel molecular probes to better understand its therapeutic relevance in cancer. In this 
work, we report our convergent syntheses of novel brequinar probes to induce DHODH 
degradation and improve brequinar’s accumulation in the mitochondria. Our approach was to 
incorporate late-stage functionalization of the brequinar scaffold with molecular “tags” to 
generate brequinar-based probes.  
 
4.2 Probe design 
To induce intracellular DHODH knockdown, we planned to develop a proteolysis-
targeting chimera (PROTAC) of brequinar. A bifunctional PROTAC probe can induce 
intracellular protein degradation by utilizing the cell’s ubiquitin proteasome system.11, 12 In short, 
a small molecule with a known target can be attached to an established E3 ligase ligand (tag) and 
when both moieties are simultaneously bound to their respective target, the E3 ligase may 
ubiquitinate lysine residues on the target protein.13, 14 This ubiquinated protein is then signaled 
																																																								d	Author contributions: Joseph Madak designed, synthesized, and characterized all compounds. Christine Cuthbertson and Wenmin Chen 
evaluated compounds in biochemical and cellular assays. Dr. Hollis Showalter and Dr. Nouri Neamati are corresponding authors. This work was 
previously published as: Chemistry. 2017, 23(56):13875-13878. DOI:10.1002/chem.201702999 	
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for degradation by cellular proteasomes. Many examples of this approach have been published.11, 
12, 15  
Our second probe was designed to direct subcellular localization to the mitochondria by 
incorporating a membrane permeable delocalized lipophilic cation onto a target compound. The 
electrochemical gradient required for mitochondrial respiration drives permeable cations across 
the membrane.16, 17 Our plan was to incorporate a large triphenylphosphonium  (TPP) cation, 
which should hinder water solvation and reduce unfavorable interactions with hydrophobic 
membranes. As a result, these cations are more membrane permeable leading to selective 
accumulation in the mitochondria. Because DHODH is located within the mitochondria, we 
propose that improving brequinar’s exposure to the target may improve potency in cells. 
We postulated that a properly designed PROTAC or TPP probe of brequinar would be 
more potent in cells than brequinar.  To evaluate this hypothesis, we designed probes to optimize 
the effectiveness of our functional tags without significantly decreasing inhibitory activity for 
DHODH. The design of the PROTAC probe focused on identifying linker attachment sites on 
brequinar that would allow for an E3 ligase to be recruited. The brequinar-analogue/DHODH co-
crystalized structure (1D3G) shows the presence of multiple lysine residues near the binding 
pocket (Figure 4.1 (A).18 Using this, we targeted probe 133, shown in Figure 4.1 (B), in which 
the para position of the terminal aromatic ring of brequinar incorporates a linker that should not 
significantly decrease DHODH potency and permit solvent exposure to the tag. Our second 
probe, which was aimed at improving mitochondrial accumulation, was designed to ensure an 
overall positive charge on the probe. Brequinar’s carboxylic acid functionality is mostly 
deprotonated at the pH (7.4) of cellular assays leaving the molecule with an overall negative 
charge, thus resulting in poor membrane permeability. To successfully transport a charged 
molecule to the mitochondria, it must possess an overall positive charge and have a high degree 
of lipophilicity. Toward this end, compound 134 (Figure 4.1, (C)) with the 
triphenylphosphonium head group became our target probe.  
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Figure 4.1 Brequinar binding pocket in DHODH and structures of probes. (A) Depiction of 
the brequinar binding pocket in DHODH and lysine residues with solvent exposure near the 
binding pocket. (PDB, 1D3G), (B) Structure of PROTAC Probe (133) and (C) structure of 
mitochondrial targeted probe (134).  
 
4.3 Synthesis 
Our synthetic approach for each probe focused on utilizing a convergent strategy with late-
stage incorporation of functional tags. The synthesis of a brequinar-PROTAC probe 
incorporating an ether attachment at the para position of the terminal aromatic ring is outlined in 
the following schemes. Scheme 4.1 described our initial synthesis of the brequinar moiety. The 
highly substituted quinoline ring was constructed using the Pfitizinger reaction to make 136, 
which was readily esterified to afford 137 in 89% yield upon generation of the cesium salt and 
exposure to iodomethane.19 Suzuki coupling of 137 with a suitable phenylboronic acid gave the 
TBS-protected phenol (138) in good yield (72%), which was then treated with TBAF to give 139 
in a 25% overall yield from 135.  
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Scheme 4.1: Synthesis of intermediate 139 
 
 Intermediate 142, the linker, was synthesized through 2-steps from triethylene glycol 
(140). A large excess of triethylene glycol in comparison to benzyl bromide was utilized to 
provide a mono-benzyled product (intermediate 141, Scheme 4.2). The terminal hydroxyl of 141 
was then activated as tosyl leaving group to yield 142. 
 
Scheme 4.2: Synthesis of intermediate 142 
 
 VHL ligand was synthesized following a previously published 6-step scheme (Scheme 
4.3).13, 14 Palladium catalyzed coupling of 4-methylthiazole with 4-bromobenzonitrile (143) 
yielded intermediate 144 in 94% yields. Nitrile reduction towards 145 was accomplished using 
NaBH4 but was low yielding (21%). Attempts to improve the yield of 145 utilized reductive 
silylation20 or LiAlH4 protocols but neither was higher yielding. Amide coupling of 145 to Boc-
Hyp-OH and subsequent Boc deprotection yielded 146 in suitable yields (66%). A second two-
step amidation/deprotection protocol was utilized to yield VHL ligand 147. 
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Scheme 4.3: Synthesis of VHL ligand 147.  
Condensation of the cesium phenolate salt of 139 with 14221 installed a PEG-linker to give 
148, which was positioned for a second-stage attachment of the VHL ligand (Scheme 4.4). 
Hydrogenolysis of the benzylated linker of 148 unveiled the terminal alcohol 149 (28% overall 
yield from 139), which was then activated with disuccimidyl carbonate. The activated 
intermediate was reacted under mildly basic conditions with the VHL E3 ligase ligand 147, to 
give carbamate 150. Mild ester hydrolysis of compound 150 was conducted with LiOH to 
minimize possible epimerization of the t-butyl chiral center (Scheme 4.5).  Thus, heating of 150 
at 40 °C for 5 days resulted in 50% conversion to desired product 133, which was separated from 
starting ester 150 by preparative reverse-phase chromatography in a 50% yield and a 1% overall 
yield from 135. 
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Scheme 4.4: Synthesis of probe 150.  
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Scheme 4.5: Synthesis of probe 133. 
 
The synthesis of our second probe, 134, is shown in Scheme 4.6.  Brequinar (2) was readily 
synthesized from ketone 151 under classic Pfitizinger conditions.19 The desired cationic fragment 
153 was generated through nucleophilic displacement of bromide 152 with triphenylphosphine. 
Amide coupling of 153 with 2 required extensive investigation to find conditions that allowed for 
easy purification of probe 134.  While standard-coupling conditions (HATU, HOBt/EDC) 
worked well, product purification was best facilitated by simple acid chloride generation of 2 
followed by reaction with amine 153. Probe 134 was generated in 26% overall yield from 151.    
O OOO
N
CO2Me
F
O
N
SN
HO
N
OH
O
N
H
150
LiOH
rt - 40 oC
4 days
O OOO
N
CO2H
F
O
N
SN
HO
N
OH
O
N
H
133
(50%)
	 185	
 
Scheme 4.6 Synthesis of mitochondria-directed probe 134.  
 
4.4 Biological evaluation of probes 
Probe 133 containing the crucial carboxylic acid maintained excellent potency (IC50 = 0.093 
± 0.04 µM) in the DHODH assay (Figure 4.2 (C)). However, in cells, 133 did not inhibit cell 
growth and showed an IC50 > 30 µM in HCT-116, a colon cancer cell line that is sensitive to 
DHODH inhibition, and > 50 µM in MiaPaca-2. Conversely, the methyl ester 150 was more 
potent in HCT-116 cells (IC50 = 6.8 ± 2.9 µM in HCT-116), which may be a result of superior 
cellular permeability in comparison to 133.  Ester 150 may be hydrolyzed to the carboxylic acid 
inside the cell, which may explain its cellular toxicity. This pro-drug approach would 
significantly improve target exposure and may also explain the difference between 150 and 133’s 
cellular activity. Interestingly, HCT-116 dosed with 150 completely blocked colony formation at 
2.5 µM and fewer colonies formed than were observed at a 4-fold higher dose of brequinar 
(Figure 4.2, (D)). The results of 150 in the clonogenic assay differed from the MTT, which may 
have occurred for a few reasons. In the clonogenic assay, cells were treated with 150 for twice as 
long as they were in the MTT assay, which may be more favorable towards ester hydrolysis to 
yield 133. However, 150 hindered new colony formation better than brequinar (2) and has 
inspired us pursue a more in-depth biological characterization of 150. Unfortunately, protein 
degradation was not observed with either 150 or 133 via western blot (Figure 4.3). There are 
several possible explanations for this lack of activity. First, there are currently no published 
PROTAC probes that induce protein degradation with mitochondrial targets. The protein 
ubiquitination system within the mitochondria may be significantly different than the cytosol or 
F
KOH, EtOH/H2O
reflux, 12 h
N
F
O OH
F
151
H2N Br
PPh3
n-BuOH, reflux
16 h152
H2N P(Ph)3
Br
153
(93%)
1: SOCl2 DMF (cat)
    1,2 DCE
    60 οC, 2 h
2: 153, DIPEA,
    1,2 DCE
    rt, 15 h
N
F
F
O
134
(48%)
N
H
P(Ph)3
2
(55%)
O
N
H
O
O
F
	 186	
utilize a different E3 ligase. Interestingly, Azzu and Brand established that the inner 
mitochondrial protein UCP2 can be degraded using cytosolic proteasomal machinery, but it is 
unclear which E3 ligase performs ubiquitination.22 It is possible that a ligand for an E3 ligase 
that targets mitochondrial proteins is necessary for degradation. Additionally, the linker between 
brequinar and the VHL ligand could require optimization. We incorporated an ethylene glycol 
linker to keep the ClogP low. Probe 133 has a predicted ClogP of 8.04 (free acid) with the 
ethylene glycol linker. If replaced with an aliphatic chain of similar length, the ClogP would be 
11.77 (free acid). Finally, other DHODH inhibitors may be better suited for PROTACs. An 
imatinib-based PROTAC probe did not induce degradation of BCR-ABL despite binding. 
However, dasatinib and bosutinib-based PROTACs probes did induce BCR-ABL degradation.23 
This suggests that other structurally distinct DHODH inhibitors could induce degradation. 
Despite this, probe 150 did possess excellent cytotoxicity in HCT-116 that was superior to 
brequinar in the colony formation assay.  
 
 
Figure 4.2 Biological evaluation of probes 133, 134, and 150. (A) Structures of brequinar and 
new probes. (B) Dose response curves from the DHODH assay. (C) IC50 values from brequinar 
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and new probes tested in DHODH and MTT assay. (D) HCT-116 colonies treated with varying 
doses of brequinar probes.  
 
 
Figure 4.3 Western blot analysis of cells with probes. HCT116 p53+/+ cells were treated with 
compounds and compared to control. No change of DHODH protein expression was observed in 
HCT116 p53+/+ cells after treatment of PROTAC compounds (133, 150), precursor compound 
139, VHL (147), or brequinar (2) for 12 h.  
 
 
Probe 134 was not observed to inhibit DHODH at high concentrations (IC50 > 50 µM), 
which was expected, but it did display an IC50 = 5.2 ± 0.3 µM in HCT-116 and was the most 
potent in MiaPaca-2 (IC50 = 3.7 ± 0.7 µM). Significant cytotoxicity of 134 in MiaPaca-2, 
suggested that better mitochondrial accumulation may improve the therapeutic relevance of 
DHODH inhibition in pancreatic cancer. Probe 134 must be hydrolyzed within the mitochondria 
to induce cytotoxicity through DHODH inhibition. A t1/2 of 277 min was observed for 134 in 
mouse-liver microsomes, which suggests that active metabolites may be generated during the 
dosing period. We found the TPP-amide linker 153 did not possess significant cytotoxicity (IC50 
> 100 µM) and that 134 followed similar trends to brequinar (lower IC50 value for continuous vs 
24 hr treatment). These data support the pro-drug mechanism of action and suggest that further 
pro-drug analogues are warranted. We acknowledge that an ester attachment may increase the 
chances of hydrolysis, however our initial efforts to generate an ester analogue of 134 were 
thwarted by poor compound stability. This proof of concept study has directed us to pursue SAR 
studies focusing on stable TPP pro-drugs that can be cleaved by mitochondrial esterases. 
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4.5 Conclusions 
In summary, we present the synthesis of two new brequinar-based probes to evaluate 
mechanistic details of DHODH inhibition. We have developed novel synthetic routes to 
brequinar probes with two different attachment sites off the quinoline scaffold, and have 
validated that the incorporation of targeting headpieces maintains cytotoxicity in cell lines. 
Future studies will focus on ligand/linker optimization and further evaluation of these probes.  
 
4.6 Experimental 
 
General methods. All reactions were performed under a nitrogen or argon atmosphere using 
standard inert gas techniques. Glassware for reactions were oven/flame dried in preparation for 
usage. All reagents and anhydrous solvents were purchased from commercial sources and used 
without further purification. Microwave catalyzed reactions were performed on a Biotage 
Initiator+ and sealed vials were purged with argon gas. The progresses of reactions were 
monitored using analytical thin-layer chromatography (TLC) on aluminum-backed pre-coated 
silica plates (Silicycle, SiliaPlate 200 µM thickness, F254) and visualized by UV absorbance. 
Flash chromatography purifications were performed using a Biotage® Isolera Chromatography 
system with 10g and 25g Ultra-SNAP Cartridge columns (25 µm spherical silica).  1H NMR 
spectra were obtained using a Bruker (300 or 400 MHz) or a Varian (400 or 500 MHz).  
Chemicals shifts are reported in ppm and calibrated based on known solvent peaks (1H using 
CDCl3 = 7.26 ppm, MeOD = 3.31 ppm, DMSO, 2.50 ppm; 13C using CDCl3 = 77.16 ppm, 
MeOD = 49.00 ppm, DMSO, 39.52 ppm).24 Spectral data was reported using the following 
abbreviations: (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of 
doublets), coupling constants are reported in Hz, followed by integration. 13C NMR spectra were 
obtained at 126 MHz on a Varian 500 MHz instrument with a proton decoupled probe. 13C 
spectra are reported with observed carbon-fluorine splitting and couplings constants are reported 
with relation to CF bond (JCF1 = CF bond, JCF2 = ortho to CF bond, JCF3 = meta to CF bond).  
Data from MS spectrometry and HPLC traces were obtained using a Shimadzu LCMS 20-20 
system, which was equipped with photo diode UV detector and a Kinetex® 2.6 µm, XB-C18 100 
Å, 75 x 4.6 mm column. HPLC traces were obtained at room temperature using a gradient 
method from 1% to 90% MeCN in H2O with 0.01% formic acid over 20 minutes. The flow rate 
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was 0.50 mL/min. Semi-preparative purifications were performed at room temperature on a 
Shimadzu LC-20 modular HPLC system, which was equipped with a photo diode UV detector 
and a Kinetex® 5 µm XB-C18 100 Å, 150 x 21.2 mm column. Semi-preparative purification was 
performed using a gradient method from 10% to 90% MeCN in H2O with 0.01% trifluoroacetic 
acid over 30 minutes.  
 
2-(4-Bromophenyl)-6-fluoro-3-methylquinoline-4-carboxylic acid 
(136): 5-Fluoroindoline-2,3-dione (1.90 g, 11.5 mmol) and KOH (3.89 g, 69.6 mmol) were 
dissolved in 19 mL EtOH and the solution was stirred at room temperature. After 15 min, 1-(4-
bromophenyl)propan-1-one (2.45 g, 11.5 mmol) was added and the mixture was heated at reflux 
for 18 h. Upon completion, the mixture was cooled to room temperature and EtOH was removed 
in vacuo. The solution was washed with ethyl acetate (3x) and then acidified with aqueous HCl 
until pH 2-3 was reached. Product precipitation was observed and the solid was collected over a 
frit. 2-(4-Bromophenyl)-6-fluoro-3-methylquinoline-4-carboxylic acid was isolated as a tan solid 
and used without further purification (3.70 g, 10.3 mmol, 89%). 1H NMR (500 MHz, DMSO-d6) 
δ = 8.14 – 8.10 (m, 1H), 7.73 – 7.67 (m, 3H), 7.57 (d, J = 8.1 Hz, 2H), 7.51 – 7.47 (m, 1H), 2.39 
(s, 3H). 13C NMR (126 MHz, DMSO-d6) δ = 168.70, 160.82 (d, J CF1= 247.0 Hz)., 159.03, 
143.31, 140.91, 139.38, 132.75 (d, JCF3= 9.6 Hz), 131.67 (2C), 131.57 (2C), 125.76, 123.70 (d, 
JCF3 = 10.2 Hz), 122.53, 120.15 (d, JCF2 = 25.7 Hz), 108.15 (d, JCF2 = 23.1 Hz), 18.11. MS 
(ESI+) 360.00, 361.95 [M+H] 358.10, 360.15 [M-H].  
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Methyl 2-(4-bromophenyl)-6-fluoro-3-methylquinoline-4-
carboxylate (137): 2-(4-Bromophenyl)-6-fluoro-3-methylquinoline-4-carboxylic acid (6.50 g, 
18.1 mmol) and Cs2CO3 (7.06 g, 21.7 mmol) were dissolved in 90 mL anhydrous DMF and the 
solution was stirred for 15 min at room temperature under an argon atmosphere. Methyl iodide 
(2.27 mL, 36.5 mmol) was added drop-wise to the solution and the reaction was stirred at room 
temperature for an additional 12 hours. The mixture was diluted with brine and product was 
extracted with EtOAc (3x). The combined EtOAc was washed with brine (6x), dried with 
magnesium sulfate, and concentrated in vacuo. Purification via flash chromatography (2:1 
hexane/EtOAc) yielded methyl 2-(4-bromophenyl)-6-fluoro-3-methylquinoline-4-carboxylate as 
white powder (6.02 g, 16.1 mmol, 89%). 1H NMR (500 MHz, Chloroform-d) δ = 8.11 (dd, J = 
9.2, 5.4 Hz, 1H), 7.64 (d, J = 8.3 Hz, 2H), 7.50 – 7.41 (m, 3H), 7.37 (d, J = 9.5, 2.7 Hz, 1H), 
4.09 (s, 3H), 2.40 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 168.01, 161.27 (d, JCF1= 249.5 
Hz), 158.94, 143.53, 139.07, 139.04, 132.44 (d, JCF3= 9.4 Hz), 131.76 (2C), 130.73 (2C), 126.64, 
124.31 (d, JCF3= 10.3 Hz), 123.13, 119.91 (d, JCF2= 25.8 Hz), 108.00 (d, JCF2= 23.4 Hz), 52.95, 
18.18. MS (ESI+) 373.95, 375.95 [M+H] 
 
Methyl 2-(4'-((tert-butyldimethylsilyl)oxy)-[1,1'-
biphenyl]-4-yl)-6-fluoro-3-methylquinoline-4-carboxylate (138): Methyl 2-(4-bromophenyl)-
6-fluoro-3-methylquinoline-4-carboxylate (652 mg, 1.75 mmol) and (4-((tert-
butyldimethylsilyl)oxy)phenyl)boronic acid (661 mg, 2.62 mmol) were dissolved in a degassed 
mixture of 10 mL toluene/5 mL H2O in a microwave vial. Pd(PPh3)4 (202 mg, 0.17 mmol) and 
Na2CO3 (1.06 g, 10.0 mmol) were added to the mixture, the vial was sealed, and then heated at 
130 °C for 2 h. Toluene was removed under reduced pressure and the mixture was extracted with 
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EtOAc (3x), dried with magnesium sulfate, filtered, and concentrated. The residue was loaded 
onto a silica column and eluted in a gradient of 9:1 hexane/EtOAc to yield methyl 2-(4'-((tert-
butyldimethylsilyl)oxy)-[1,1'-biphenyl]-4-yl)-6-fluoro-3-methylquinoline-4-carboxylate as a 
yellow oil (627 mg, 1.25 mmol, 72%). 1H NMR (500 MHz, Chloroform-d) δ 8.16 (dd, J = 3.8, 
1.1 Hz, 1H), 7.72 – 7.67 (m, 2H), 7.64 – 7.60 (m, 2H), 7.57 – 7.52 (m, 2H), 7.50 – 7.45 (m, 1H), 
7.42 – 7.37 (m, 1H), 6.95 (d, J = 7.4 Hz, 2H), 4.11 (s, 3H), 2.48 (s, 3H), 1.03 (s, 9H), 0.26 (s, 
6H). 13C NMR (126 MHz, Chloroform-d) δ 168.20, 161.15 (d, J	CF1= 248.9 Hz)., 159.94, 155.70, 
143.59, 141.26, 138.87, 138.82, 138.44, 133.76, 132.46 (d, JCF3 = 9.2 Hz), 129.44 (2C), 128.25 
(2C), 126.95, 126.85 (2C), 124.18 (d, JCF3 = 10.2 Hz), 120.55 (2C), 119.65 (d, JCF2 = 25.7 Hz), 
107.93 (d, JCF2 = 23.4 Hz), 52.87, 25.82 (3C), 18.36, -4.24 (2C). MS (ESI) 502.25 [M+H]  
 
Methyl 6-fluoro-2-(4'-hydroxy-[1,1'-biphenyl]-4-yl)-3-
methylquinoline-4-carboxylate (139): Methyl 2-(4'-((tert-butyldimethylsilyl)oxy)-[1,1'-
biphenyl]-4-yl)-6-fluoro-3-methylquinoline-4-carboxylate (627 mg, 1.25 mmol) was dissolved in 
12 mL THF. TBAF (392 mg, 1.50 mmol) was slowly added to the solution and the mixture was 
stirred at room temperature for 2 hour. Upon completion, the reaction mixture was concentrated, 
the residue was washed with a saturated solution of aqueous NH4Cl, and the product was 
extracted with EtOAc. The organic layer was dried with sodium sulfate, filtered, concentrated, 
and purified via flash chromatography using 1:1 EtOAc/Hexane to yield methyl 6-fluoro-2-(4'-
hydroxy-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylate (209 mg, 0.54 mmol, 43%). 1H 
NMR (500 MHz, DMSO-d6) δ 9.63 (s, 1H), 8.16 – 8.12 (m, 1H), 7.75 – 7.68 (m, 2H), 7.68 – 
7.64 (m, 2H), 7.61 – 7.53 (m, 3H), 6.89 (d, J = 8.5, 1.5 Hz, 2H), 4.07 (s, 3H), 2.41 (s, 3H). 13C 
NMR (126 MHz, DMSO-d6) δ 167.25, 160.44 (d, JCF1 = 246.5 Hz), 159.39, 157.43, 142.92, 
140.30, 138.64, 138.60, 137.52, 132.27 (d, JCF3 = 9.5 Hz), 129.64 (2C), 127.85 (2C), 126.45, 
125.58 (2C), 123.27 (d, JCF3 = 11.0 Hz), 119.77 (d, JCF2 = 25.9 Hz), 115.82 (2C), 107.82 (d, JCF2 
= 23.2 Hz), 53.14, 17.84. MS (ESI) 388.10 [M+H]  
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2-(2-(2-(Benzyloxy)ethoxy)ethoxy)ethan-1-ol (141): Compound 
141 was prepared following a modified protocol described by Jiang & Yu.21 Triethylene glycol 
(140) (3.97 mL, 29.8 mmol) was dissolved in THF (46 mL) and the solution was chilled to 0 °C. 
After 15 min, NaH (1.20 g, 30.1 mmol) was added and the mixture was stirred for an additional 
15 min before adding benzyl bromide (2.10 mL, 17.5 mmol). The reaction mixture was warmed 
to room temperature overnight. Upon quenching with water, the mixture was concentrated and 
then extracted with EtOAc. The dried extracts were concentrated to a residue that was purified 
via flash chromatography eluting with 1:1 hexane/EtOAc to yield 2-(2-(2-
(benzyloxy)ethoxy)ethoxy)ethan-1-ol as a clear oil (2.09 g, 8.74 mmol, 50%). 1H NMR (500 
MHz, Chloroform-d) δ 7.37 – 7.31 (m, 4H), 7.28 – 7.20 (m, 1H), 4.54 (s, 2H), 3.76 – 3.51 (m, 
12H). 13C NMR (126 MHz, Chloroform-d) δ 138.06, 128.41 (2C), 127.83 (2C), 127.70, 73.28, 
72.60, 70.63, 70.57, 70.32, 69.36, 61.67. MS (ESI) 241.70 [M+H]  
 
2-(2-(2-(Benzyloxy)ethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate (142): 2-(2-(2-(Benzyloxy)ethoxy)ethoxy)ethan-1-ol (141) (2.09 g, 
8.74 mmol)) was dissolved in 60 mL of THF and 20 mL of H2O. KOH (1.71 g, 30.5 mmol) was 
added to the mixture, which was stirred at room temperature for 15 min before TsCl (2.00 g, 10.5 
mmol) was added and the mixture for stirred overnight. Upon completion, the mixture was 
poured into a saturated solution of ammonium hydroxide and extracted with dichloromethane 
(3x). The extract was pooled, dried with magnesium sulfate, filtered, and concentrated to yield 2-
(2-(2-(benzyloxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate as a orange oil (2.50 g, 6.33 
mmol, 72%), which was used without further purification. 1H NMR (500 MHz, Chloroform-d) δ 
7.79 (d, J = 8.3 Hz, 2H), 7.38 – 7.21 (m, 7H), 4.55 (s, 2H), 3.71 – 3.57 (m, 12H), 2.43 (s, 3H). 
13C NMR (126 MHz, Chloroform-d)) δ 144.91, 138.36, 129.94 (2C), 128.51 (2C), 128.13 (2C), 
127.89 (2C), 127.76 (2C), 73.39, 70.93, 70.83, 70.73, 69.55, 69.38, 68.85, 21.78. MS (ESI) 
395.15 [M+H].  
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4-(4-Methylthiazol-5-yl)benzonitrile (144): Compound 144 was prepared 
following a protocol that was reported by Buckley14 and Galdeno13. A mixture containing 4-
bromobenzonitrile (5.00 g, 27.5 mmol), 4-methylthiazole (4.98 mL, 54.7 mmol), KOAc (5.40 g, 
55.0 mmol), and palladium acetate (62.0 mg, 0.27 mmol) were dissolved in 16 mL DMAc. The 
mixture was heated to 140 °C overnight, cooled, and then poured into EtOAc. The solution was 
washed with H2O (6x), dried with magnesium sulfate, filtered, and concentrated. The resulting 
oil was crystallized by the addition of hexanes and used without further purification. 4-(4-
Methylthiazol-5-yl)benzonitrile was isolated as a yellow solid (5.15 g,  25.8 mmol, 94%) and 
matched the reported spectral data.13 1H NMR (400 MHz, Chloroform-d) δ 8.76 (s, 1H), 7.75 – 
7.71 (m, 2H), 7.60 – 7.55 (m, 2H), 2.59 – 2.56 (m, 3H). MS (ESI) 200.90 [M+H].  
 
 (4-(4-Methylthiazol-5-yl)phenyl)methanamine (145): Compound 145 was 
prepared following a protocol reported by Buckley14 and Galdeno.13 Compound 144 (5.15 g, 
25.8 mmol) was dissolved in 280 mL anhydrous MeOH. Cobalt chloride hexahydrate (9.90 g, 
41.7 mmol) was added and the solution was placed on an ice bath for 30 min. NaBH4 (5.22 g, 
138 mmol) was slowly added over 20 min, bubbling was observed, and the solution turned black. 
The mixture was stirred for 90 min and quenched with cold H2O. The quenched solution was 
poured over a frit to remove insoluble by-products and the filtrate was washed with H2O then 
extracted with EtOAc.  The organic layer was dried with sodium sulfate, filtered, concentrated, 
and purified via flash chromatography using a gradient of 1-10% 0.5 M methanolic ammonia in 
DCM. Compound 13 was isolated (1.12 g, 5.49 mmol, 21%) and matched the reported spectral 
data.14 1H NMR (400 MHz, Chloroform-d) δ 8.65 (s, 1H), 7.41 – 7.35 (m, 4H), 3.90 (s, 2H), 
2.50 (s, 3H). MS (ESI) 204.90, 187.80 (fragmentation product reported by Galdeno also 
observed)13, 14 [M+H].  
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 (4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (146): Compound 146 was prepared following a protocol 
reported by Galdeno13. Anhydrous DMF (55 ml) was added to a round-bottom flask containing 
compound 145 (1.12 g, 5.49 mmol), Boc-Hyp-OH (1.27 g, 5.49 mmol), DIPEA (3.85 mL, 22.0 
mmol), and HATU (2.30 g, 6.05 mmol).  The mixture was stirred at room temperature overnight. 
The solution was diluted with H2O and extracted with EtOAc. The EtOAc layer was washed with 
brine (6x), dried with magnesium sulfate, and concentrated. The residue was purified via flash 
chromatography using a gradient from 1-10% 0.5 M methanolic ammonia in DCM. (MS (ESI) 
418.15 [M+H]). The isolated oil was re-dissolved in 10 mL of 4.0 N HCl in dioxane and stirred 
at room temperature for 1 h. The solvent was concentrated and used without further purification. 
Compound 14 was isolated as an oil (1.16 g, 3.66 mmol, 66% two steps) and matched the 
reported spectral data.14 1H NMR (300 MHz, Chloroform-d) δ 8.69 (s, 1H), 8.28 – 8.04 (m, 1H), 
7.45 – 7.32 (m, 4H), 4.52 – 4.44 (m, 3H), 4.10 (t, J = 8.4 Hz, 1H), 3.10 – 3.00 (m, 1H), 2.88 – 
2.77 (m, 1H), 2.54 (s, 3H), 2.41 – 2.32 (m, 1H), 2.07 – 1.93 (m, 1H). MS (ESI) 317.90 [M+H]  
 
 (4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-
(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (147): A mixture containing 
compound 146 (1.16 g, 3.29 mmol), Boc-L-tert-leucine (847 mg, 3.67 mmol), HATU (1.67 g, 
4.40 mmol), and DIPEA (2.56 mL, 14.7 mmol) was dissolved in 55 mL DMF. The mixture was 
stirred at room temperature overnight, diluted with H2O, and extracted with EtOAc.. The EtOAc 
layer was washed with a saturated NaHCO3 solution (2x), brine (6x), dried with magnesium 
sulfate, filtered, and concentrated. (MS (ESI) 531.10 [M+H]) Residue containing the 
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intermediate was dissolved in 10 mL of 4.0 N HCl in dioxane, stirred at room temperature for 1 
hour, and followed the workup described by Buckner.14 The solution was concentrated to an 
orange oil and matched the reported spectra of  (4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-
hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (970 mg, 2.25 mmol, 
68% yield two steps) and used without further purification. 1H NMR (300 MHz, Methanol-d4) δ 
8.90 (s, 1H), 7.50 – 7.41 (m, 4H), 4.66 – 4.34 (m, 4H), 3.82 – 3.65 (m, 1H), 3.49 (s, 1H), 2.50 (s, 
3H), 2.30 – 2.17 (m, 1H), 2.16 – 2.07 (m, 1H), 1.04 (s, 9H). MS (ESI) 431.15 [M+H].  
 
Methyl 2-(4'-(2-(2-(2-
(benzyloxy)ethoxy)ethoxy)ethoxy)-[1,1'-biphenyl]-4-yl)-6-fluoro-3-methylquinoline-4-
carboxylate (148): Compound 139 (209 mg, 0.54 mmol) was dissolved in 11 mL DMF. Cs2CO3 
(790 mg, 2.42 mmol) was added to the solution and the mixture was stirred at room temperature 
for 5 min. 2-(2-(2-(Benzyloxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (142) (255 mg, 
0.65 mmol), was slowly added and the mixture was heated at 75 °C for 2 h. The solution was 
concentrated to an oil, re-dissolved in DCM, washed with brine (6x), dried with magnesium 
sulfate, and re-concentrated to an oil. The crude was purified by silica chromatography eluting 
with a gradient from 10% to 40% EtOAc in hexane. Methyl 2-(4'-(2-(2-(2-
(benzyloxy)ethoxy)ethoxy)ethoxy)-[1,1'-biphenyl]-4-yl)-6-fluoro-3-methylquinoline-4-
carboxylate was isolated (173 mg, 0.28 mmol, 52%) and used without further purification. 1H 
NMR (500 MHz, Chloroform-d) δ 8.20 – 8.15 (m, 1H), 7.71 – 7.66 (m, 2H), 7.61 (d, J = 8.3 Hz, 
2H), 7.60 – 7.56 (m, 2H), 7.51 – 7.46 (m, 1H), 7.41 – 7.25 (m, 6H), 7.04 – 7.00 (m, 2H), 4.58 (s, 
2H), 4.22 – 4.17 (m, 2H), 4.11 (s, 3H), 3.93 – 3.88 (m, 2H), 3.80 – 3.63 (m, 8H), 2.48 (s, 3H). 
13C NMR (126 MHz, Chloroform-d) δ 168.23, 162.20, 161.21 (d, JCF1 = 249.1 Hz). 159.93, 
158.79, 143.53, 141.23, 138.42, 133.39, 132.43 (d, JCF3 = 9.7 Hz), 129.49 (2C), 128.50 (2C), 
128.30 (2C), 127.87 (2C), 127.72, 127.00, 126.88 (2C), 124.23 (d, JCF3 = 10.1 Hz), 119.76 (d, 
JCF2 = 25.7 Hz), 115.17 (2C), 110.14, 107.97 (d, JCF2 = 23.4 Hz)., 73.39, 71.04, 70.87 (2C), 69.91, 
69.60, 67.70, 52.94, 18.34. MS (ESI) 610.45 [M+H].  
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Methyl 6-fluoro-2-(4'-(2-(2-(2-
hydroxyethoxy)ethoxy)ethoxy)-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylate (149): 
Compound 148 (173 mg, 0.28 mmol) was dissolved in 30 mL anhydrous EtOH and the solution 
was purged with argon for 30 min. Activated Pd on charcoal (10%) (60 mg) was added to the 
solution, (excess EtOH was used to submerge all Pd/C) and the mixture was stirred under an H2 
environment overnight. The mixture was filtered over EtOAc washed celite and eluted with 
EtOAc. Filtrate was concentrated and loaded onto silica column eluting with a gradient of 20 – 
66% EtOAc in hexane. Compound 149 was isolated (79 mg, 0.15 mmol, 54%).  1H NMR (500 
MHz, Chloroform-d) δ 8.21 (s, 1H), 7.69 (d, J = 8.3 Hz, 2H), 7.64 – 7.56 (m, 4H), 7.52 – 7.45 
(m, 1H), 7.38 (dd, J = 9.5, 2.7 Hz, 1H), 7.07 – 6.99 (m, 2H), 4.24 – 4.18 (m, 2H), 4.11 (s, 3H), 
3.94 – 3.88 (m, 2H), 3.79 – 3.69 (m, 6H), 3.69 – 3.61 (m, 2H), 2.48 (s, 3H). 13C NMR (126 
MHz, Chloroform-d) δ 168.16, 161.25 (d, JCF1 = 249.2 Hz), 159.85, 158.71, 143.29, 141.31, 
138.16, 133.47 (2C, overlap), 132.26 (d, J	CF3	 =	 10.1	 Hz), 129.54 (2C), 128.35 (2C), 127.08, 
126.90 (2C), 124.28 (d, JCF3 = 9.9 Hz), 119.90 (d, JCF2 = 25.5 Hz), 115.17 (2C), 108.00 (d, JCF2	= 
23.7 Hz), 72.64, 71.02, 70.55, 69.91, 67.64, 61.94, 52.98, 18.33. MS (ESI) 520.30 [M+H].   
 
Methyl 6-fluoro-2-(4'-(((12S)-12-((4R)-4-hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-13,13-dimethyl-10-oxo-3,6,9-trioxa-11-
azatetradecyl)oxy)-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylate (150): Compound 
149 (40 mg, 0.08 mmol) was dissolved in 3 mL anhydrous MeCN. DIPEA (0.07 mL, 0.39 mmol) 
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was added and the mixture was stirred at room temperature for 15 min. N,N’-disuccinimidyl 
carbonate (102 mg, 0.40 mmol) was added and the mixture was stirred at room temperature for 
12 hours before being concentrated. The residue was dissolved in DCM and washed with H2O 
(3x). The organic layer was dried with magnesium sulfate, filtered, concentrated, and used 
without further purification. In a separate round-bottom flask, compound 147 (34 mg, 0.08 
mmol) was dissolved in DMF (2.0 mL) and DIPEA (0.07 mL, 0.39 mmol). The organic residue 
containing the succimidyl intermediate was dissolved in 1.5 mL DMF and the mixture was 
slowly added to the basic solution containing 147. The combined solution was stirred at room 
temperature for 12 hours. Upon completion, the mixture was concentrated to an oil, re-dissolved 
in EtOAc, and washed with brine (6x). The organic layer was dried with magnesium sulfate, 
filtered, concentrated, and loaded onto silica column, eluting in a slow gradient towards 90/10 
DCM/MeOH with 0.5 M NH4. Compound 150 was isolated as a clear oil (16 mg, 0.02 mmol, 
25% yield, two-steps). 1H NMR (500 MHz, Methanol-d4) δ 8.83 (s, 1H), 8.10 (dd, J = 9.3, 5.4 
Hz, 1H), 7.72 (d, J = 8.3 Hz, 2H), 7.64 – 7.57 (m, 5H), 7.47 – 7.36 (m, 5H), 7.04 (d, J = 8.7 Hz, 
2H), 4.58 (t, J = 8.3 Hz, 1H), 4.54 – 4.47 (m, 2H), 4.36 – 4.31 (m, 2H), 4.23 – 4.13 (m, 4H), 4.10 
(s, 3H), 3.91 – 3.83 (m, 3H), 3.78 (dd, J = 10.9, 3.9 Hz, 1H), 3.74 – 3.65 (m, 6H), 2.44 (s, 3H), 
2.41 (s, 3H), 2.25  – 2.17 (m, 1H), 2.13 – 2.04 (m, 1H), 1.01 (s, 9H). 13C NMR (126 MHz, 
Methanol-d4) δ 174.40, 172.65, 169.00, 162.55 (d JCF1 = 244.4 Hz), 161.55, 160.25, 158.57, 
152.77, 149.00, 144.32, 142.56, 140.91, 140.21, 139.20, 134.16, 133.38, 132.58 (d, J CF3 = 9.6 
Hz), 131.48, 130.61 (2C), 130.35 (2C), 129.15 (2C), 128.93, 128.46 (2C), 127.47 (2C), 125.51 
(d, J CF3 = 10.1 Hz), 120.94 (d, J CF2 = 26.2 Hz), 116.16 (2C), 108.98 (d, J CF2 = 23.9 Hz), 71.78, 
71.59, 71.09, 70.90, 70.51, 68.72, 65.44, 60.95, 60.81, 57.99, 53.43, 43.70, 38.90, 36.68, 26.95 
(3C), 18.32, 15.83. LCMS (ESI) 976.45 [M+H], 95% purity based on HPLC chromatograph at 
254 nm.  
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6-Fluoro-2-(4'-(((12S)-12-((4R)-4-hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-13,13-dimethyl-10-oxo-3,6,9-trioxa-11-
azatetradecyl)oxy)-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid (133): 
Compound 150 (10 mg, 0.01 mmol) was dissolved in a 1 mL solution of 1:1 THF/H2O. LiOH (5 
mg, 0.21 mmol) was added to the solution and the mixture was stirred at room temperature 
overnight. LCMS indicated pre-dominantly starting material remained. Additional LiOH (20 mg, 
0.83 mmol) was added and the solution was heated to 40 °C for three additional days (reaction 
progress monitored by LCMS). The mixture was concentrated and purified via reverse phase 
chromatography eluting with a gradient from 0 to 100 MeCN in H2O. Compound 1 was isolated 
as a clear oil (5 mg, 0.01 mmol, 50%). 1H NMR (300 MHz, Methanol-d4) δ 8.87 (s, 1H), 8.08 – 
8.00 (m, 1H), 7.76 (d, J = 7.9 Hz, 2H), 7.70 – 7.56 (m, 5H), 7.57 – 7.39 (m, 5H), 7.09 (d, J = 8.3 
Hz, 2H), 4.65 – 4.49 (m, 3H), 4.41 – 4.33 (m, 2H), 4.26 – 4.13 (m, 4H), 3.96 – 3.84 (m, 3H), 
3.84 – 3.62 (m, 7H), 2.52 – 2.38 (m, 6H), 2.30 – 2.06 (m, 1H), 2.06 – 2.02 (m, 1H), 1.04 (s, 9H). 
13C NMR (126 MHz, Methanol-d4) δ 174.43, 172.66, 161.92 (d, JCF1 = 247.0 Hz), 161.76, 
160.94, 160.16, 158.58, 152.82, 149.02, 144.26, 142.25, 140.23, 140.05, 135.47 (d, JCF2 = 12.6 
Hz), 134.39, 133.41, 131.57, 131.49, 130.50 (2C), 130.37 (2C), 129.15 (2C), 128.94 (2C), 
127.39 (2C), 125.78 (d,  JCF3 = 10.0 Hz), 124.87, 120.16 (d, JCF2 = 26.2 Hz), 116.13 (2C), 110.22 
(d, JCF2 = 22.8 Hz)., 71.78, 71.59, 71.10, 70.91, 70.53, 68.71, 65.44, 60.97, 60.82, 57.98, 43.70, 
38.92, 36.68, 26.94 (3C), 18.14, 15.81. LCMS (ESI) 962.45. [M+H], 960.35 [M-H], 96% purity 
based on HPLC chromatograph at 254 nm. 
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1-(2'-Fluoro-[1,1'-biphenyl]-4-yl)propan-1-one: (151) 1-(4-
Bromophenyl)propan-1-one (2.00 g, 9.39 mmol), (2-fluorophenyl)boronic acid (1.95 g, 14.1 
mmol), K2HPO4 (3.89 g, 28.2 mmol), and Pd(PPh3)4 (0.54 g, 0.47 mmol) were added to a 
microwave vial. 12 mL of dioxane and 2 mL of H2O were added and the vial was sealed. The 
reaction was stirred at 130 °C for 1.5 hour and the mixture was concentrated upon completion. 
The product was purified from the residue via flash chromatography with a gradient of 1% to 
60% EtOAc in hexane to yield compound 12 (679 mg, 2.98 mmol, 32% yield). 1H NMR (500 
MHz, Chloroform-d) δ 8.02 (d, J = 8.4 Hz, 2H), 7.62 (dd, J = 8.4, 1.7 Hz, 2H), 7.43 (td, J = 7.8, 
1.8 Hz, 1H), 7.36 – 7.30 (m, 1H), 7.21 (td, J = 7.6, 1.2 Hz, 1H), 7.18 – 7.12 (m, 1H), 3.00 (q, J = 
7.2 Hz, 2H), 1.24 (t, J = 7.2 Hz, 3H). MS (ESI) 229.05 [M+H].  
 
6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-
4-carboxylic acid (Brequinar) (2): 5-fluoroisatin (2.17 g, 13.2 mmol) was dissolved in a 35 mL 
solution of EtOH/H2O (2:1 ratio). KOH (2.95 g, 52.6 mmol) were added and the solution was 
stirred at room temperature for 15 min (solution turns dark when KOH is added). Compound 151 
(2.0 g, 8.77 mmol) was added and the mixture was heated at reflux overnight. Upon completion, 
the mixture was cooled to room temperature, dioxane/EtOH were concentrated in vacuo, and the 
solution was diluted with 1 M KOH. The basic solution was washed with EtOAc (3x) and then 
acidified to pH 2-3 with HCl (precipitant formation observed). Precipitant was poured over a 
fritted funnel then triturated with EtOAc and Et2O, before collection. Compound 20 isolated as a 
tan solid (1.81 g, 4.82 mmol, 55%). 1H NMR (400 MHz, DMSO-d6) δ 8.15 (dd, J = 9.2, 5.6 Hz, 
1H), 7.79 – 7.69 (m, 5H), 7.65 (t, J = 7.8, 1.7 Hz, 1H), 7.54 – 7.45 (m, 2H), 7.41 – 7.32 (m, 2H), 
2.47 (s, 3H).  13C NMR (126 MHz, DMSO-d6) δ 168.38, 160.34 (d, JCF1 = 245.7 Hz), 160.16, 
159.35, 159.28, 158.20, 142.94, 139.26, 135.17, 132.32 (d, JCF3 = 10.0 Hz), 130.82 (d, JCF4 = 3.3 
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Hz), 129.87 (d, JCF3 = 10.1 Hz), 129.38 (2C), 128.59 (d, JCF4 = 2.9 Hz), 127.73 (d, JCF3 = 13.9 
Hz), 125.34, 125.07 (d, JCF4 = 3.6 Hz), 119.67 (d, JCF2 = 25.7 Hz), 116.21 (d, JCF2 = 22.5 Hz), 
107.72 (d, JCF2 = 23.4 Hz), 17.77. MS (ESI) 375.70 [M+H], 373.65 [M-H].  
 
 (3-Aminopropyl)triphenylphosphonium (153);  Compound 153 was 
prepared following a modified protocol from Zeng et al.25 3-Bromopropan-1-amine (152) (1.0 g 
4.56 mmol) was dissolved in 20 mL of n-BuOH. Triphenylphosphine (1.19 g, 4.56 mmol) was 
added and the mixture was heated at reflux overnight.  The reaction mixture was cooled to RT 
for 15 min before the addition of 12 mL of hexanes. The mixture was then stirred for 30 min and 
filtered over a frit. The white solid was washed with another 12 mL hexane (2x) before 
triturating with a 50/50 solution of t-butyl methyl ether and hexane (3x). (3-
Aminopropyl)triphenylphosphonium was isolated (1.69 g, 4.24 mmol, 93%) and used without 
further purification. 1H NMR (500 MHz, DMSO-d6) δ 7.94 – 7.73 (m, 15H), 3.98 – 3.86 (m, 
2H), 3.10 – 3.02 (m, 2H), 1.97 – 1.82 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 135.56 (d, 
JCP4 = 3.1 Hz) (3C), 134.06 (d, JCP3 = 10.2 Hz) (6C), 130.83 (d, JCP2 = 12.5 Hz) (6C), 118.47 (d, 
JCP1 = 86.0 Hz) (3C), 39.24, 20.53, 18.88 (d, JCP1 = 52.8 Hz). MS (ESI) 320.15 [M+H].  	
 
 (3-(6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-
methylquinoline-4-carboxamido)propyl)triphenylphosphonium (134): Compound 2 (102 
mg, 0.27 mmol) was dissolved in 3 mL of anhydrous 1,2 DCE. SOCl2 (0.11 mL, 1.51 mmol) and 
1 drop of DMF were added slowly then the mixture was heated at 60 °C for 2 h.  (Acid chloride 
formation was monitored via TLC; 1 drop of reaction mixture was added to a vial containing 
TEA and MeOH, then the mixture was checked for the presence of methyl ester). The reaction 
mixture was cooled to room temperature, concentrated, re-dissolved in 1,2 DCE, and re-
concentrated. The acid chloride was re-dissolved in 3 mL 1,2 DCE and slowly added to a 
separate round bottom flask, which contained a stirring solution of compound 153 (130 mg, 0.33 
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mmol), DIPEA (0.30 mL, 1.72 mmol), and 2.00 mL of anhydrous 1,2 DCE chilled over an ice 
bath. (Gas release was observed when the acid chloride was added to the solution). The mixture 
was stirred overnight. Upon completion, the mixture was concentrated, loaded onto silica column 
and eluted in a 1-30 % MeOH gradient in DCM with 0.5 M NH3. Fractions containing desired 
compound was concentrated, re-dissolved in MeCN and crystallized by the addition of 
Et2O/Hexane. The precipitant was poured over a frit and triturated with cold EtOAc, Et2O, t-
Butyl methyl ether, and hexane. Compound 134 was isolated as a tan solid with a red tint (89 
mg, 0.13 mmol, 48%). 1H NMR (500 MHz, DMSO-d6) δ 8.88 (t, J = 5.6 Hz, 1H), 8.12 (dd, J = 
9.2, 5.5 Hz, 1H), 7.95 – 7.74 (m, 15H), 7.74 – 7.66 (m, 4H), 7.63 (t, J = 8.0 Hz, 1H), 7.50 – 7.42 
(m, 1H), 7.40 – 7.33 (m, 3H), 3.72 – 3.54 (m, 4H), 2.32 (s, 3H), 1.94 – 1.81 (m, 2H). 13C NMR 
(126 MHz, DMSO-d6) δ 166.72, 160.67 (d, JCF1 = 248.2 Hz), 159.62 (d, JCF1 = 247.0 Hz), 
159.57, 143.45, 143.41, 139.79, 135.63, 135.51 (d, JCP4 = 3.1 Hz) (3C), 134.03 (d, JCP3 = 10.3 
Hz) (6C), 132.62 (d, JCF3 = 10.0 Hz), 131.25 (d, JCF4 = 3.3 Hz), 130.81, 130.76 (d, JCP2 = 12.4 
Hz) (6C), 130.35 (d, J = 8.1 Hz), 129.74, 129.09 (d, J = 3.0 Hz), 128.14 (d, JCF3 = 13.0 Hz), 
125.91, 125.54 (d, JCF4 = 3.4 Hz), 124.54 (d, JCF3 = 10.1 Hz), 119.99 (d, JCF2 = 25.5 Hz), 118.70 
(d, JCP1 = 86.0 Hz) (3C), 116.68 (d, JCF2 = 22.5 Hz), 108.43, 108.25, 25.94, 22.56, 19.00 (d, 
JCP1 = 51.6 Hz), 17.86. LCMS (ESI) 678.15 [M+H], 98% purity based on HPLC chromatograph 
at 254 nm 
 
hDHODH expression and purification. The hDHODH construct was provided by the De 
Brabander lab at UT Southwestern.26 hDHODH was expressed in E. coli Rosetta 2 (DE3) in LB 
medium with ampicillin (100 µg/mL) and 0.1 mM FMN. Cells were grown at 37 °C to OD600 = 
0.6, then induced with 1 mM IPTG for 3 hours. Cells were harvested by centrifugation at 4,000 x 
g for 15 min at 4 °C. The pellet was re-suspended in lysis buffer (50 mM Tris-HCl, pH 8.5, 300 
mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 10 mM imidazole, 2% Triton X-100, 0.5 
mM FMN, 200 µM PMSF, 1 mg/mL lysozyme). The cell suspension was incubated on ice for 2 
hours, followed by sonication. The lysate was clarified by centrifugation at 35,000 x g for 20 min 
at 4 °C. After the supernatant was incubated with Ni-NTA resin for 1 h at 4 °C, the resin was 
loaded onto a column. The column was washed with wash buffer (50 mM Tris-HCl, pH 8.5, 300 
mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 25 mM imidazole, 0.1 mM FMN) and 
hDHODH was eluted with elution buffer (wash buffer containing 300 mM imidazole). Buffer 
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exchange was carried out using an Amicon concentrator into storage buffer (100 mM HEPES, 
pH 8.0, 150 mM NaCl, 10% glycerol) and hDHODH was stored at -80 °C. 
 
DHODH activity assay. DHODH activity was monitored as previously described with 
modifications.27 First, 1 µL of test compound (50x) or DMSO, 60 nM DHODH, 100 µM DCIP, 
and 20 µM CoQ10 (final concentrations for 50 µL) in the assay buffer (100 mM HEPES pH 8.0, 
150 mM NaCl, 10% glycerol, 0.1% Triton X-100) in a total of 40 µL were incubated together for 
30 min. The assay began with the addition of 10 µL of dihydroorotate to a final concentration of 
200 µM. The reduction of DCIP was measured by monitoring the absorbance at 600 nm over 1 
hr at room temperature using a microplate reader (BMG Labtech). Data were exported to 
Microsoft Excel for analysis and IC50 values were determined using Prism 6 software.  
 
Microsomal stability studies to determine t1/2. Assays to determine microsomal stability and 
t1/2 were performed by the University of Michigan Pharmacokinetics Core. A microsome 
solution was created, which contained 10 μL of mouse liver microsome (20 mg/mL) in 330 μL 
0.1 M phosphate buffer (3.3 mM MgCl2). Aliquots (40 μL) from stock solutions of test 
compounds (10 μM) were added and the mixture was incubated at 37 ℃ for 3 min. The 
enzymatic reactions were initiated by addition of 20 μL NADPH solution (freshly prepared 
containing 4 mg NADPH in 240 μL of 0.1M phosphate buffer (3.3 mM MgCl2)). Aliquots of 40 
μL were removed from reaction solutions and stopped by the addition of chilled acetonitrile, 
which contained 50 ng/mL of CE302, an internal standard, at the designated time points (0, 5, 10, 
15, 30, 45, and 60 min). Verapamil was used as positive control with the same method. The 
incubated solution was centrifuged at 3500 g for 15 minutes and the supernatant was used for 
LC/MS/MS analysis. A ratio of the natural log peak area (compound peak area/ internal standard 
peak area) was plotted against time and used for data extrapolation.  Chromatographic conditions 
utilized a 5 cm x 2.1 mm I.D. 3.5 µm XBridge column from Waters and utilized a gradient 
method of 5-95% MeCN in H2O containing 0.1% formic acid.  
 
Cell culture. HCT116 P53 +/+ and MiaPaca-2 cells were maintained in RPMI-1640 (Gibco) 
supplemented with 10% heat-inactivated FBS (Gibco). Cells were grown at 37 °C in a 
humidified atmosphere of 5% CO2. For subculture and counting, cells were washed with DPBS 
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(Gibco) without calcium or magnesium, incubated with 0.25% trypsin-EDTA solution (Gibco) 
for 5 min, neutralized with full medium, centrifuged, re-suspended with culture medium and 
counted by Countess II FL. All experiments were performed using cells in exponential growth. 
Cells were routinely checked for Mycoplasma contamination. 
 
Western blot. HCT116 p53+/+ cells were seeded into 6-well microtiter plates for 4 x 105 cells 
per well, and allowed to attach overnight before the addition of the dilution of compound (10X). 
After 12h treatment, the cells are lysated with RIPA buffer with the presence of protease 
inhibitors and phosphatase inhibitors. The cells are collected and centrifuged. The pellet was 
discarded. Protein concentration of whole-cell lysate in the supernatant was determined by BCA 
protein assay kit (Thermo Scientific). Proteins were resolved in 10% SDS/PAGE and 
electrotransferred to transfer membrane (Immobilon®-FL). After blocking with TBS blocking 
buffer (Thermo Scientific), membranes were probed with DHODH primary antibody (Santa Cruz 
Biotechnology; rabbit; 1:1000) and GAPDH primary antibody (Signaling; rabbit; 1:4000 ) in 5% 
BSA (EMD Millipore corporation) in TBST (Tris-buffered saline, 0.1% Tween 20) and then 
washed and incubated with goat anti-rabit IgG (H&L) secondary antibody (Dylight 800 4x PEG 
conjugated; Thermo Scientific; 1:4000). The membrane was imaged by Odyssey® CLx Imaging 
System. 
 
Clonogenic assay. HCT116 p53+/+ cells were seeded 500 cells per well into 24-well plates for 
or 200 cells per well into 96-well plates, and allowed to attach overnight before the addition of 
compounds. After 7-day contentious treatment, the medium was removed and crystal violet 
solution was added to fix and stain the colonies for 20 min. Crystal violet was removed and the 
colonies were washed with ddH2O for three times. The colonies were imaged by Odyssey® CLx 
Imaging System. 
 
Growth inhibition assay. HCT116 p53+/+ cells or MiaPaCa-2 cells were seeded 2500-3000 
cells per well in 96-well microtiter plates, and allowed to attach overnight before the addition of 
the serial dilution of compounds (10X). After 72h, cells were incubated with 0.3 mg/mL 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (VWR) for an additional 3h at 37 °C. 
After removal of the supernatant, DMSO was added to the wells, and the absorbance was read at 
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570 nm. All assays were performed in triplicate. Percentage of cell growth inhibition was 
expressed as (1 − A/C) × 100% (A and C were the absorbance values from experimental and 
control cells, respectively). IC50 values were determined for each drug from nonlinear regression 
analysis of log (drug concentration) vs. percentage of cell growth inhibition using Prism 7.0. SD 
or SEM was calculated based on the IC50 values obtained from at least three independent 
experiment. 
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Chapter 5 
Summary and Future Directions 
 
5.1 Summary  
 Dihydroorotate dehydrogenase (DHODH) remains a viable target for cancer 
chemotherapy. Inhibition of DHODH is known to induce pyrimidine depletion and halt cell cycle 
progression at the S phase.1-3 In cells and murine studies, DHODH inhibitors are able to abrogate 
tumor growth. However, the anticancer properties of DHODH inhibitors, such as brequinar, did 
not translate well from the bench to bedside. Despite promising preclinical data, brequinar failed 
to induce an objective response in multiple cancer clinical trials for patients with solid tumors.4-10 
In fact, no DHODH inhibitor has been FDA approved to date for cancer therapy. Therefore, 
single agent usage of DHODH inhibitors may not work well for the treatment of solid tumors. 
However, many studies highlight a promising future for DHODH inhibitors. Multiple studies 
have demonstrated the ability of DHODH inhibitors to overcome resistance to standard 
chemotherapy.11-14 For instance, DHODH inhibition has been demonstrated to sensitize triple 
negative breast cancer cells to genotoxic agents by limiting the supply of nucleotides available 
for DNA repair.14 As triple negative breast cancer presents a major public health problem, any 
enzyme capable of inducing pyrimidine depletion and thus slowing growth is an important 
target.15  
 Beyond sensitizing resistance cell lines, DHODH is vital for cellular differentiation. 
Inhibition of DHODH has been observed to induce differentiation in acute myeloid leukemia 
cells (AML).16 This is not isolated to one study, as DHODH inhibitors have been demonstrated 
to decrease self-renewal capacities of neural crest cells in zebrafish.17 These results may have a 
significant impact on potential therapies in AML or in evaluating the cancer stem cell theory.18 If 
the cancer stem cell theory is correct, inducing differentiation may decrease the percentage of 
pluripotent stem cells and increase the population of differentiated cells that are susceptible to 
conventional chemotherapy. While the exact mechanism is unknown, this empirical observation 
strengthens interest in DHODH inhibitors.  
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 Within this dissertation, Chapter 1 (Figure 5.1) highlights the importance of DHODH for 
cancer. Discussed are the many induced effects by DHODH inhibition and a summary of key 
studies that will certainly guide the future of DHODH targeted therapy in cancer. In short, 
shRNA protein knockdown studies demonstrate that DHODH is necessary for cancer cell 
growth.  
 
Figure 5.1: Summary of anticancer effects induced by DHODH inhibition. 
 
 The enzymatic target of our lead compound was disclosed as DHODH in Chapter 2. This 
dissertation’s focus has always been on anticancer drug discovery. Using a phenotypic cell-based 
screening approach, a novel inhibitor with an unknown enzymatic target was discovered. 
Through initial pharmacophore studies, the lead compound presented a remarkably similar 
structure activity relationship with brequinar, a potent DHODH inhibitor. Cells overexpressing 
DHODH were found to be most sensitive to lead compound 1 and brequinar. Furthermore, the 
lead compound was unable to induce greater than 50% cell growth inhibition when treated to 
uridine-supplemented cells. Uridine-monophosphate is a downstream end product of DHODH’s 
pathway and DHODH inhibition induces cell growth inhibition by halting its production. Finally, 
when evaluated in the DHODH inhibition assay, lead compound possessed an IC50 = 0.347 ± 
0.072 µM. These results indicated that DHODH was the target our lead compound and new 
DHODH inhibitors can be pursued using the DHODH assay.   
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Figure 5.2: Lead compound 1 inhibits DHODH.  
 
 In Chapter 3, we pursued a structure-guided approach toward the development of 
improved dihydroorotate dehydrogenase (DHODH) inhibitors with the goal of forming new 
interactions between DHODH and the brequinar class of inhibitors. Two potential residues, T63 
and Y356, suitable for novel H-bonding interactions were identified in the brequinar-binding 
pocket. Analogues were designed to maintain the essential pharmacophore and form new 
electrostatic interactions through strategically positioned H-bond accepting groups. This effort 
led to the discovery of potent quinoline based analogues 71 (DHODH IC50 = 10.6 ± 1.1 nM) and 
73 (DHODH IC50 = 32.9 ± 4.6 nM). A co-crystal structure between 73 and DHODH depicts a 
novel water mediated H-bond interaction with T63. Additional optimization led to the 1,7-
naphthyridine 76 (DHODH IC50 = 53.9 ± 1.7 nM) that forms a novel H-bond with Y356. 
Importantly, compound 71 possesses significant oral bioavailability (F = 56%) and an 
elimination t1/2 = 2.78 hours (PO dosing). In conclusion, the data supports further preclinical 
studies of our lead compounds toward selection of a candidate for early stage clinical 
development. 
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Figure 5.3: Lead optimization of DHODH inhibitors forming new electrostatic interactions  
 
 Chapter 4 focuses on the development of brequinar-based probes of DHODH (Figure 
5.4). To further understand brequinar-based DHODH inhibition and DHODH’s therapeutic 
relevance in cancer, we have developed novel brequinar-based probes. We disclose a 16-step 
convergent synthesis of the first brequinar-PROTAC and a 4-step approach towards the first 
mitochondrial-directed brequinar probe. A PROTAC and mitochondria-directed probe of 
brequinar both possesses cytotoxicity that is superior to brequinar in a colony formation assay. 
 
Figure 5.4: Novel probes designed to study DHODH inhibition 
 
5.2 Significance of the study 
 The work highlights a successful drug discovery project that began with an unknown 
target and resulted with one of the most potent inhibitors of the DHODH enzyme ever reported. 
Through rational based drug design and a myriad of medicinal chemistry techniques, an inhibitor 
with improved water solubility and an IC50 = 0.011 ± 0.001 µM for DHODH was discovered.  
Additionally, the following contributions to DHODH and cancer have been made: 
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• First potent inhibitors to incorporate pyridine analogues in lipophilic pocket 
• Developed novel synthetic route for generation of napthyridine analogues and 
demonstrated a new potential interaction with 1,7 napthyridines.  
• First reported synthesis of a novel C6 substituted 1,7 napthyridine using ortho-lithiation 
protocol.  
• A total of over 150 final and intermediate compounds were synthesized and chacterized 
• A 16-step total synthesis was reported for the generation of the first ever brequinar-
PROTAC molecule.  
• First reported synthesis of novel triphenylphosphonium-brequinar analogue 
 
These findings are of interest to all readers focusing on antimetabolic cancer therapy. 
Furthermore, this dissertation contributes to the overall understanding of DHODH targeted 
therapy in cancer. Data that highlights the limitations of DHODH targeted therapy, primarily 
lack of cellular efficacy and nucleotide salvage pathways are presented. Additionally, the 
effectiveness of DHODH targeted therapy is discussed; namely the potential for overcoming 
drug resistance and inducing differentiation. Collectively, this work further elucidates DHODH 
validity as an enzymatic target for cancer.  
 
5.3 Future directions 
5.3.1 Crystallography studies 
 Next generation DHODH inhibitors for this project will depend upon crystallography 
studies with a C6 substituted 1,7 napthyridine.  Co-crystal structures with these inhibitors will 
provide insight into the importance of the C6 position. This task is attainable, as multiple labs 
have generated co-crystals with human DHODH and this has already been done with two of our 
compounds.19, 20 The results from this co-crystal may highlight pockets for additional interactions 
or sites of solvent exposure that may be utilized to develop additional PROTAC probes.  
 
5.3.2 Non-solid tumor and differentiation assays 
 The limitations of DHODH-targeted therapy for solid tumors are well known and 
depicted in this thesis. However, it is possible that DHODH inhibition may be therapeutically 
relevant for cancers of leukocytes or lymphocytes. During the brequinar clinical trials, 
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myleosuppression was a commonly observed side effect.7, 8, 10, 21-23 In fact, brequinar was briefly 
pursued as an immunosuppressant for transplantation patients.24, 25 Other DHODH inhibitors, 
e.g., leflunomide/teriflunomide, are FDA approved for autoimmune diseases such as 
rheumatoid/psoriatic arthritis and multiple sclerosis.26, 27 The potential of these inhibitors to 
suppress the immune system is well documented.27 In cancer chemotherapy studies, DHODH 
inhibitors were not observed to induce objective responses in solid tumors. However, DHODH 
inhibitors have never been evaluated in clinical trials for leukemia. The surprising ability of 
brequinar to induce differentiation in AML may soon signal a change in direction for use of this 
class. For our inhibitors, cellular activity should be evaluated in leukemia and lymphoma models. 
Additionally, differentiation assays should be pursued to assess if our DHODH inhibitors possess 
similar results as brequinar. Furthermore, the combination of brequinar and dipyridamole should 
be evaluated in differentiation assays.  
 
5.3.3 Combination studies 
 The future of DHODH inhibitors appears to be in combination therapy. Therefore, studies 
to identify synergistic pairings should be pursued. Our lab is currently evaluating a combination 
of DHODH inhibitors with an inhibitor of the nucleotide salvage pathway, dipyridamole.28 For 
the brequinar clinical trials, the nucleotide salvage pathway was a proposed compensatory 
mechanism for cells to survive DHODH inhibition. While the combination was previously 
evaluated in vitro, the results were not further pursued in vivo.29 However, the in vitro results 
were promising, with brequinar and dipyridamole able to halt cell growth in the presence of 5- 
10 µM of uridine. The combination was unsuccessful at high concentrations of uridine >50 µM  
but those concentrations may not be physiologically relevant. Nonetheless, DHODH inhibitors in 
combination with dipyridamole should be evaluated in vivo to assess if intracellular uridine 
levels may be reached to fuel rapid cellular growth. This represents one of many combinations 
that should be pursued with a DHODH inhibitor.  
 
Altogether, the work described in this thesis makes a significant contribution to DHODH 
targeted cancer therapy. Our work discloses a potent human DHODH inhibitor with improved 
aqueous solubility, the first ever brequinar-PROTAC, and first brequinar-TPP compounds. These 
inhibitors and probes will significantly advance the understandings of DHODH in cancer. Future 
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studies with these inhibitors will seek to identify synthetic lethal targets for combination studies. 
One combination with dipyridamole is already under evaluation in vivo.  
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